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Introduction
The perfect baby-a wide grin, ten fingers, ten toes, and the po
tential to become a doctor, Olympic athlete, or President of the
United States. Prospective parents share this dream. The dream
often becomes an expectation as prospective parents mentally attend
their children's graduation ceremonies, weddings, and hundreds of
similar events during the first and second trimesters of their existence.
But, for many prospective parents, these hopes and expectations will
not survive the birth of their children: genetic diseases and congenital
malformations-and the physical and mental disabilities accompany
ing them-occur in approximately three- to five-percent of all live
births.1 The increasing availability of prenatal genetic screening and
advances in screening technology, coupled with the identification of
more gene malfunctions responsible for diseases, now offer prospec
tive parents the possibility of knowing that their children may suffer
from serious physical and mental impairments at a time when abor1.

Benjamin P. Sachs & Bruce Korf, The Human Genome Project: Implications for
Os. & GYN. 458, 459 (1993).

the Practicing Obstetrician, 81
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tion is still an option. Even when abortion is not an option because of
legal or personal concerns, prenatal genetic screening offers an oppor
tunity to prepare. In other words, although prenatal genetic screening
may present an opportunity in the future to treat the unborn through
genetic therapy ,2 prenatal genetic screening is presently a tool for pro
spective parents, not their fe tuses. The opportunity now associated
with that technology is enhanced parental choice. The role of doctors
and genetic counselors is to give prospective parents the information
about their unborn they seek so that they can make an informed
choice.
The objectives of this Article are to present an accurate portrayal
of the practice of prenatal genetic screening; to analyze the opportuni
ties it presents in the context of, and in contrast with, procreative lib
erty and abortion law; and to propose suggestions to ensure that the
technology is welcomed, but with caution. Part I discusses how the
international effort to map the human genome, the Human Genome
Project, is making extensive prenatal genetic screening possible. It
also discusses the practice of prenatal genetic counseling and how,
perhaps as a result of the surge in technological capability arising from
the Human Genome Project, the medical profession is offering genetic
screening technology to prospective parents without first seriously
questioning its social implications.
Part II approaches the practice of prenatal g enetic screening from
four different perspectives: a genetic counselor, a researcher working
on the Human Genome Project, a woman who went through genetic
counseling and terminated her pregnancy, and a family that includes a
child with spina bifida. These perspectives are presented through a
series of personal accounts, the purposes of which are to enable us to
approach and analyze the practice of prenatal genetic counseling from
the perspective of reality as well as from theory and to identify impor
tant issues that are presently being overlooked or ignored.
Part III analyzes the practice of prenatal genetic counseling in the
context o f abortion law and parental choice. Specifically, it addresses
how the decision to terminate a pregnancy based upon the results of
prenatal g enetic screening is-because of the nature of the decision
and its social implications-distinguishable from a basic exercise of
procreative liberty.

2. See infra notes 95 (addressing the enhanced obligations to the fetus that may ac
company gene therapy capabilities), 110 (addressing advances in gene therapy).
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Part IV offers an �ssessment of the practice of prenatal genetic
screening within the United States and identifies dependency on re
search laboratories for diagnostic purposes and a profound lack of
scrutiny and conscious public policy decision making regarding this
issue. It also discusses legislation proposed in France-expected to be
enacted into law before the end of 1994-which will ensure that im
portant public policy decision making surrounding prenatal genetic
screening will be made by publicly accountable policy makers, rather
than by France's medical profession.
Part IV sets forth a proposal for applying regulations that pres
ently exist in the United States to research-stage genetic testing and
for erecting other regulations to establish boundaries around the prac
tice of prenatal genetic screening in this country. The rationale under
girding this proposal is to ensure that the policy issues presented by
prenatal genetic screening are addressed and subjected to public scru
tiny. The proposal draws upon the legislation introduced in France; a
report issued recently by the Committee on Assessing Genetic Risks,
which operates within the Division of Health Sciences Policy of the
Institute of Medicine; and the social implications of prenatal genetic
screening identified throughout this Article.

I.

The Technology to Know

Each of us has twenty-three pairs of chromosomes, which consist·
of strands of DNA (deoxyribonucleic acid).3 Our chromosomes con
tain 50,000 to 100,000 genes encoded in some three billion base pairs
of DNA.4 Each of these genes is located along strands of DNA in an
arrangement that resembles a ladder twisted into a spiral (a formation
officially known as a "double helix"). Genes consist of a variable
number of DNA base pairs known as nucleotides (the rungs on this
ladder-like arrangement), and each gene provides the information to
produce proteins responsible for the development of a single human
trait-whether that trait be the color of our eyes, our tendency to be
depressed or elated, our height, or our susceptibility to a specific dis
ease.5 The human genome represents the complete pattern of human
DNA, which means the entire nucleotide (base pair) composition.
3.

See generally ALAN E.H. EMERY & RO BERT F. MUELLER, ELEMENTS

4.

Sachs & Korf, supra note 1, at 458.

CAL GENETICS 108-09 (7th ed. 1988) (basic text on human genetics).

OF

MEDI

Allan Bruckheim, Genetic Engineering Helping to Resolve Inherited Diseases,
Hous. PosT, May 5, 1993; see generally R.C. 0LBY, ORIGINS OF MENDELISM ( 1966) (trac5.
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A gene with an altered or deficient nucleotide composition will
fail to produce the proteins needed for normal development of the
trait it controls, thereby resulting in a genetic abnormality.6 Just as
the development of specific traits may be traced to specific genes, the
development of diseases with a genetic component-such as cystic fi
brosis or Down's Syndrome·may be traced to specific genetic abnor
malities. The possibilities arising from the identification of the genetic
abnormalities (aberrations in nucleotide composition) responsible for
specific diseases are nothing less than miraculous. Consider, for ex
ample, that between three and four thousand medical disorders have
been linked to altered genes,7 and that a single defect in a single gene
is the cause of the most severe form of cystic fibrosis.8
However, linking genetic abnormalities to specific diseases does
not necessarily mean that a person with the specific genetic abnormal
ity will suffer the physical and/or mental symptoms of the disease as
sociated with that abnormality.9 The relationship between a person's
genotype (or the genetic makeup and the production of the proteins
for which those genes are responsible) and a person's phenotype (or
observable physical and mental traits) is influenced by a number of
factors.10 For example, many physical traits-some obvious, such as
weight-are influenced by one or more environmental factors. Moreing the growth of ideas about inheritance and variation that eventually led to the Mende
lian solution).
6. See WALTER GILBERT, A V1s10N OF THE GRAIL IN THE CODE OF CODES 83-97
(Daniel J. Kevles & L. Hood eds., 1992); see also Sonia M. Suter, Note, Whose Genes Are
These Anyway?: Familial Conflicts over Access to Genetic Information, 91 MICH. L. REV.
1854 (1993). As explained in this Note, "[i]f parts of a gene are missing, rearranged, substi
tuted, or even supplemented with extra DNA, the body will make an altered or deficient
'
protein or sometimes will produce no protein at all. When that protein is crucial to biologi
cal function, disease results." Id. at 1857. See Donald R. Helinski & Charles Yanovsky,
Correspondence Between Genetic Data and the Position of Amino Acid Alteration in a Pro
tein, 48 PROC. NAT. ACAD. 173-90 (1964).
7. Sachs & Korf, supra note 1, at 459; see also Kimberly Nobles, Birthright or Life
Sentence: Controlling the Threat of Genetic Testing, 65 S. CAL. L. REV. 2081, 2086 (1992).
8. Reuters, Gene Defect Related to Mild Cystic Fibrosis, Hous. PosT, Mar. 11, 1993,
at AlO ("The severe form of cystic fibrosis, which affects some 70 percent of sufferers,
results from a single defect in the gene that carries the code for a protein known as cystic
fibrosis transmembrane regulator, which regulates the flow of salt ions in and out of
cells."); see also A. MACLEOD & K. SIKORA, MOLECULAR BIOLOGY AND HUMAN DISEASE
(Blackwell Scientific Publications 1984). It is important to note, however, that many genet
icists feel as though the degree of severity of a disease cannot be accurately correlated with
a type of mutation. See infra note 15 and accompanying text.
•

9. See AssEsSING GENETIC RisKs: IMPLICATIONS FOR HEALTH AND SocIAL POLICY
ch. 2, at 1-5, (Lori B. Andrews et al. eds., 1995) (prepublication copy dated Nov. 4, 1993);
Suter, supra note 6, at 1856-59.
10.

See Suter, supra note 6, at 1857.
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over, because our chromosomes are paired, we all carry two sets of
genes. It is possible, therefore, for a person to have both a normally
functioning gene and an abnormally functioning gene for a given trait.
If the a bnormal gene is recessive, 11 the normal gene compensates for
it so that the person's phenotype includes the normal trait that the
gene controls.12 Such a person will be a carrier for the genetic abnor
mality but will not suffer its physical or mental symptoms.13 In addi
tion, some diseases are "polygenic" or "multifac torial," meaning that
they are caused by some combination of genetic abnormalities.14 Fi
nally, even if a dominant, abnormally functioning gene is conclusively
identified and it is certain that the physical or mental symptoms of the
disease linked to that genetic abnormality will be present, the symp
toms may not always be severe. The severity of symptoms depends
upon what protein the abnormally functioning gene is producing and
the exact role of that protein.15
An expanding body of knowledge about the normal gene content
(or genome) of the forty-six human chromosomes is being obtained
through the use of molecular techniques such as genomic mapping.16
This knowledge offers the possibility of identifying the specific genetic
abnormalities responsible for countless medical disorders. Whenever
such an identification is made, tests can be developed to determine

11. However, when genetic abnormalities are dominant, they will affect the pheno
type despite being paired with a normally functioning gene. Rosalind Skinner, Unifactorial
Inheritance, in 1 PRINCIPLES AND PRACTICE OF MEDICAL GENETICS 53, 97 (Alan E.H.
Emery & David L. Rimoin eds., 2d ed. 1990).
12. The sex distinction between males and females is attributable to an XX chromo
some pairing in females as compared to an XY chromosome pairing in males. With sex
linked (monogenic) diseases, even though a male carries a recessive gene on his X chromo
some, he has no complementing gene on his Y chromosome to offset it. In contrast, a
female carrying the same gene on her respective X chromosome has another X chromo
some, which may have a normally functioning gene to offset the abnormally functioning,
recessive one.
13. See generally Friedrich Vogel, Mutation in Man, in 1 PRINCIPLES AND PRACTICE,
supra note 11, at 53; Suter, supra note 6, at 1857-58.
14. See EMERY & MUELLER, supra note 3, at 199. As explained by the Committee on
Assessing Genetic Risks in its recent report,
Disorders resulting from changes in one gene alone are called monogenic (e.g.,
cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy). Disorders re
sulting from changes in several genes are called multifactorial. Multifactorial dis
orders (e.g., common types of coronary heart disease and most forms of diabetes)
tend to affect far more individuals than do monogenic disorders.
AssESSING GENETIC RISKS, supra note 9, ch. 2, at 2.
15. See John A. Philips III & Haig H. Kazazian, Jr., Hemoglobinopathies and Thalas
saemias, in 2 PRINCIPLES AND P RACTICE, supra note 11, at 1315, 1324-25.
16. See generally M. INOUYE, EXP ERIMENTAL MANIPULATION OF GENE EXPRESSION
(1983).
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whether fetuses carry the specific genetic abnormalities and the likeli
hood of their developing the associated medical disorder.
The following is a discussion of the efforts of the scientific com
munity to map the human genome and how this technology presently
is being made available to the public through the practice of prenatal
genetic counseling.
A.

The Human Genome Project

The Human Genome Project, an effort to map all forty-six chro
mosomes that was initiated by Congress in 1989, will receive an esti
mated two hundred million dollars in federal funds per year for the
next ten to fifteen years17-that is, unless the Project is completed
sooner.18 The overall mapping initiative is being funded domestically
by three major institutions: the National Institutes of Health (NIH),19
the Department of Energy {DOE), and the Howard Hughes Medical
17. See generally Victor A. McKusick, The Human Genome Project: Plans, Status,
and Applications in Biology and Medicine, in GENE MAPPING: USING LAW AND ETHICS AS
GumES 18, 22-26 (George J. Annas & Sherman Elias eds., 1992); James D. Watson, The
Human Genome Project: Past, Present, and Future, 248 SCIENCE 44 (1990). Federal fund
ing of the project began in 1988:
In 1988, the first Congressional appropriation for this project amounted to $17.2
million. In fiscal year 1991, approximately $87 million was made available. It
now is estimated that the project will require $200 million per year for the next
.10-15 years. Similar research is being funded by other United States agencies,
including the Department of Energy.
Sachs & Korf, supra note 1, at 45 (footnotes omitted). A significant portion of this funding
(four percent according to AssESSING GENETIC RISKS, supra note 9, at 460) is being re
served for the Ethical, Legal, and Social Issues Joint Working Group [ELSI] to research
the ethical implications of the resulting technology:
NIH's National Center for Human Genome Research, for example, has pledged
to spend as much as one to three percent of its research budget on the study of
the "ethical, social and legal issues that may arise from the application of knowl
edge gained from the Human Genome Initiative." The Center has also formed an
"Ethics Committee" and hired a philosopher to help formulate and deal with eth
ical issues. Likewise, the international Human Genome Organization (HUGO),
made up of forty-two scientists from around the world, has formed an ethics com
mittee and "intends to provide a forum for the discussion of ethical, social, com
mercial, and legal considerations relating to the genome project."
George J. Annas, Mapping the Human Genome and the Meaning of Monster Mythology, 39
EMORY L.J. 629, 650 (1990) (footnote omitted) [hereinafter Annas, Monster Mythology].
HUGO now has more than 42 members, and the organization may be contacted at: 7986
D. Old Georgetown Road, Bethesda, MD 20814; (301) 654-1477.
18. See generally U.S. Human Genome Project Updates Goals, HUMAN GENOME
NEws, Nov. 1993, at 1 (discussing how progress made over the last three years has put the
overall project goals well within reach).
19. To take advantage of the opportunity presented by federal support and rapid ad
vances in chromosome and DNA mapping techniques, the NIH established the National
Center for Human Genome Research on October 1, 1989.
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Institute. 20 Work on deciphering the human genome also is being
conducted by institutions in other countries. For example,European
efforts are being coordinated by the Human Genome Organization
(HUGO), a private organization.21
In addition to identifying genes, the traits they control,and their
locations on chromosomes, scientists are breaking genes down into
their fundamental chemical components-the DNA base pairs that
form them-in order to identify the composition of healthy genes and
their abnormal counterparts responsible for specific diseases. Because
identifying (or "sequencing") the DNA base pairs (nucleotides) re
sponsible for health impairments is the key to genetic screening,
"[a]dvances in genetic research are occurring simultaneously with the
development of new techniques for prenatal genetic testing ... ."22
Since 1983, more than two thousand genes have been mapped to par
ticular chromosomes. 23 W hile this number is expected to soon rise
sharply due to the recent completion of a map covering ninety percent
of human DNA,present mapping capability is still not precise enough
to pinpoint the location of all genes in DNA, and certainly not the
DNA base pairs making up those genes.24
At the present time, prenatal screening can be used to detect 600
of the 3,000 to 4,000 known genetic defects,25 and scientists have iden
tified the genetic abnormalities responsible for 122 different genetic
diseases.26 Advances in mapping technology are causing these num
bers to grow exponentially. For example, "[t]he gene for cystic fibro
sis was mapped in about four years with a jumping technique, instead
of the approximately eighteen years that 'walking' would have
taken."27 The result is that mapping efforts are bringing about almost
20.

Annas, Monster Mythology, supra note 17, at 637.

21.

Id. See also Sachs & Korf, supra note 1, at 458-59.

22.

Sachs & Korf, supra note 1, at 458.

23.

K ate Thomas, Marriage in the Works for Biology, Electronics, H o us. PosT, Apr.

14, 1993, at Bl; John C. Fletcher & Dorothy C. Wertz, Ethics, Law, and Medical Genetics:
After the Human Genome is Mapped, 39 EMORY L.J. 747, 755 (1990).
24.

Scientists Draw Human DNA, BosToN GLOBE, Dec. 16, 1993, at A17 ("Research

ers said the map will also help the Human Genome Project, an effort to reveal the se
quence of DNA's 3 billion building blocks.").
25. See supra note 7.
26.
27.

Thomas, supra note 23; see generally ASSESSING GENETIC RISKS, supra note 9.
Fletcher & Wer tz supra note 23, at 754. The common method for identifying
,

D r�A base pairs is called "shot gunning," and the present cost for identifying DNA base
.
pam is $1 to $1.50 per base pair. Earl Lane, Faster Deciphering of Genes Developed,
H ol'.s. CHRON., Dec. 13, 1992, at Cl3. That cost may be reduced to less than 50 cents
.
three years through a less repetitive and time consuming sequencing method known
w1thm
as "primer walking." Id.
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daily discoveries of the genetic mutations responsible for common
health impairments.28 Recent discoveries include the ·identification of
a defective gene that may cause nearly one-third of all human brain
tumors,29 a genetic abnormality responsible for breast cancer,3° a ge-

28.

For example, from the summer of 1992 through the summer of 1993, Houston

area genetic researchers identified genetic abnormalities linked to the onset of: myotonic
dystrophy (a muscular disorder), Lowe syndrome (a brain, eye, and kidney disorder), X
linked hyper IgM syndrome (an immunological disorder), X-linked agammaglobulinemia
(an immunological disorder), retinitis pigmentosa (an eye disease), Marfan syndrome (a
joint and heart disorder), spinocerebellar ataxia type 1 (a neurological disease that affects
an estimated 1 in 25,000 people, the symptoms of which usually do not appear until people
are in their 30s and 40s, and that results in death 10-15 years after onset), lung cancer
(determining that the P53 gene is missing), bladder cancer (researchers have determined
that a tumor-suppressor gene is missing), esophageal cancer (determining that the P53
gene is missing), and acute myelogenous leukemia (determining that a tumor-suppressor
gene is missing). Leslie Loddeke, Geneticists on 'Threshold' of Discoveries, Rous. PosT,
June 13, 1993, at A33, A34 [hereinafter Loddeke, Geneticists]; Leslie Loddeke, Baylor Re
searcher Discovers Disease-Causing Gene, Rous. PosT, July 1, 1993 [hereinafter Loddeke,
Baylor] (reporting on July 1, 1993 findings appearing in NATURE GENETICS journal). The
Baylor Human Genome Center, one of ten in the nation, is credited with making and/or
substantially contributing to the following disease-gene discoveries: fragile X syndrome
(mental retardation), myotonic dystrophy (a muscular disorder), Duchenne dystrophy (a
muscular disorder), Charcot-Marie-Tooth syndrome (peripheral neuropathy), Lowe syn
drome (a brain, eye, and kidney d�sorder), Kallman's syndrome (a sensory disorder), two
immune-system disorders, and spinocerebellar ataxia type 1 (a neurological disease dis
cussed above in more detail). Loddeke, Geneticists, supra, at A34; Loddeke, Baylor, supra.
29.

See generally W.K. Cavenee, Accumulation of Genetic Defects During Astro

cycoma Progression, 70(b) CANCER 1788-93 (1992) ("Scientists have tracked down a defec
tive gene that may cause nearly a third of all human brain tumors, opening the way for new
strategies to stop these cancers."); Scientists Find Gene that Causes Brain Tumors, Rous.
PosT, Mar. 12, 1993, at A18. As for the significance of such a discovery, consider that
about 15,600 Americans are diagnosed with brain tumors each year, and 11,500 die from
them. Id.
30.

Richard Saltus, Mutated Gene Tied to Early Breast Cancer Is Located, BosTON

GLOBE, Sept. 15, 1994, at 1, 30 (discussing the discovery of a mutated gene that puts some
women at an enormously high risk of contracting breast and ovarian cancer, and recogniz
ing that this discovery will make prenatal diagnosis an option for prospective parents); see
S.R. Wolman, Genetic Markers as Prognostic Indicators in Breast Cancer, 70(b) CANCER
1765-76 (1992); see also Damaged Gene Linked to Cancers in Women, BOSTON GLOBE,
Apr. 14, 1994 (addressing the identification of genetic links to inherited breast cancer, non
inherited breast and ovarian cancer, and cervical cancer). Women who inherit this gene
have a 59 percent chance of developing breast cancer before they reach the age of 50, and
an 80 percent chance of developing the disease by the age of 65. DNA Test Early Warning
for Breast Cancer, Rous. PosT, Apr. 21, 1993, at AS (discussing reports presented in the
Journal of the American Medical Association). In comparison, women in general have only
a 2 percent chance of developing breast cancer before the age of 50, and a 6 percent chance
of becoming afflicted by the age of 65. Id. As a result of this discovery, g�netic screening
to detect the gene may make . a life-and-death difference to the 600,000 women in the
United States with inherited susceptibilities to breast cancer. Id.
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netic link to colon and rectal cancer,31 a genetic cause of hereditary
melanoma,32 the genetic cause of Huntington's disease,33 a genetic
link to Alzheimer's disease,34 and approximately ninety percent of the
mutations responsible for cystic fibrosis.35 Within�several years, pre
natal tests may be widely available to identify predispositions for alco
holism, Alzheimer's disease, arthritis, various cancers, dementia,
diabetes, dyslexia, glaucoma, heart disease, hypertension, manic de
pression, schizophrenia, and fundamental personality characteristics
such as sexual orientation.36
31.

"[S]cientists say they have tracked down a flawed gene, inherited by as many as

one in 200 people, that dramatically raises a person's risk of colon and rectal cancer."
Richard Saltus, Flawed Gene Called Link to Colon Cancer, BosTON GLOBE, Dec. 3, 1993,
at Al, A18; see also K.R. Cho & B. Vogelstein, Genetic Alterations in the Aderoma-Carci
noma Sequence, 70(b) CANCER 1727-31 (1992) (addressing identification of a genetic de
fect linked to one in seven colon cancers); Genetic Marker for Cancer Precursor, BosToN
GLOBE, Dec. 30, 1993, at A3. It is expected that a blood test capable of detecting high-risk
individuals will be available some time in 1994. Id. Some 600,000 cases of colon cancer,
one of the most common inherited diseases identified in humans, are diagnosed each year,
and the disease causes 300,000 deaths annually. Scientists Find Basis for Colon Cancer,
Hous. PosT, May 6, 1993, at A16. This discovery makes early diagnosis-a factor crucially
important for treating the disease-possible through genetic screening. See Richard Saltus,
Finding Seen Bringing Test to Pinpoint Those at Risk, BosTON GLOBE, Dec. 3, 1993, at
A19.
32.

See Associated Press, Gene May be Linked to Deadly Skin Cancer, L.A. TIMES,

Sept. 1, 1994, at A27 (stating that a mutated gene called p.16 is linked to inherited mela
noma and may be involved in noninherited cases as well).
33.

"After 10 backbreaking years in a research purgatory of false leads, failed experi

ments and long stretches of mordant despair, an international team of scientists says it has
discovered the most coveted treasure in molecular biology, the gene behind Huntington's
disease." Huntington's Disease Gene Is Found at Last, Hous. CHRON., Mar. 24, 1993, at
Al2. "Huntington's disease afflicts about 30,000 Americans, and as many as 150,000 are at
risk of developing it." Id.
34.

See generally E.H. Corder, Gene Dose of Apolipoprotein E Type 4 Allele and Risk

of Alzheimer's Disease in Late Onset Families, 261 SCIENCE 801-956 (1993); see also Anas
tasia Toufexis, Alzheimer's Clue, TIME, June 21, 1993, at 59 (discussing the possibility of a
blood test to identify people likely to develop Alzheimer's and a drug capable of prevent
ing the proteins responsible for the onset of the disease from "doing their deadly work");
Associated Press, FDA OKs New Drug for Alzheimer's Patients, WOR CESTER TELEGRAM
& GAZETTE, Sept. 10, 1993, at A7; Mike Snider, Alzheimer's Research Pace Could Mean
Drug by 2000, Hous. PosT, June 21, 1993, at A4 (tracing Alzheimer's to the production of
a protein called beta-amyloid); Richard Saltus, Researchers Close in on Genetic Factor in
Alzheimer's, BosTON GLOBE, Nov. 8, 1993, at 3; Michael Waldholz, Alzheimer's Is Linked
to the Way the Blood Transports Cholesterol, WALL ST. J., June 7, 1993 ("People born with
a certain fairly common gene are at high risk of developing Alzheimer's late in life.").
35.

As a result of this discovery, "it is possible to identify approximately 80% of

couples at risk of having an affected child and to offer prenatal diagnosis when both mem
bers of the couple are carriers." Sachs & Korf, supra note 1, at 459.
36.

See infra note 152 and accompanying text. See generally Philip Elmer-Dewitt, The

Genetic Revolution, TIME, Jan. 17, 1994, at 46-53 (this issue is a special report entitled
Genetics: The Future Is Now). The development of genetic tests for a wide range of condi-
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The Practice of Prenatal Genetic Counseling

Although its use has been widespread in the United States since
the advent of amniocentesis in 1966,37 the practice of prenatal genetic
screening is undergoing tremendous change as it assimilates the tech
nology generated by the Human Genome Project.38 Thus, "[w]e stand
at the brink of a virtual explosion of knowledge about human genetics
that may change how we think about and what we do about dis
ease. "39 Specifically, with each success in identifying a genetic abnor
mality associated with the onset of a specific health impairment comes
the potential to test fetuses for the presence of that genetic abnormal
ity. The practice of prenatal genetic counseling involves making this
technology available to prospective parents. It also involves using lim
ited information-perhaps nothing more than a probability resulting
from a research-stage test-under severe time constraints to help pro-

tions and diseases that manifest themselves in middle and late life and the implications of
the availability of "predispositional tests" is fully addressed in the recent report issued by
the Committee on Assessing Genetic Risks, Division of Health Sciences Policy, Institute of
Medicine. AssESSING GENETIC R1sKs, supra note 9, exec. summ. at 2, 7-8; ch. 2, at 22-51;
Louis J. Elsas II, A Clinical Approach to Legal and Ethical Problems in Human Genetics,
39 EMORY L.J. 811, 813 (1990); see also Natalie Angier, Report Suggests Homosexuality Is
Linked to Genes, N.Y. TIMES, July 16, 1993, at Al, C81 (researchers report linking male
homosexuality to a small region of one human chromosome in a study conducted on ge
netic material collected from 40 pairs of gay brothers; "in 33 of the pairs, the brothers had
identical pieces of the end tip of the X chromosome"); William A. Henry Ill, Born Gay?,
TIME, July 26, 1993, at 36-39 (addressing how studies of family trees and DNA make the
case that homosexuality is in the genes); John A. Robertson, Procreative Liberty and
Human Genetics, 39 EMORY L.J. 697, 711 (1990) ("As genes that predispose for cancer,

heart disease, alcoholism, depression, diabetes and other conditions are identified, these
dilemmas will be repeated."); Depression Link to Genetics Sought, BosTON GLOBE, Oct.
13, 1993; Ruth Sorelle, Gene Linked to Seizures, Retardation Is Discovered, Hous. CHRON.,
Aug. 19, 1993 at A18; Judy Foreman, Genes Are Stressed in Heart Disease Study, BosToN
GLOBE, Apr. 14, 1994 (discovering a Swedish study which found that genetic factors play a

strong role in triggering death from heart disease relatively early in life); Tim Friend, Scien
tists Closing in on Dyslexia Gene, USA TODAY, Oct. 14, 1994, at Al.
37. See infra note 48 (discussing amniocentesis and other prenatal diagnostic
techniques).
38. See generally ASSESSING GENETIC RISKS, supra note 9, ch. 2, at 13-51; ch. 4, at 121; ANGE.LA RODDEY HOLDER, LEGAL ISSUES IN PEDIATRICS AND ADOLESCENT
MEDICINE 25-46 (2d ed. 1985) (discussing amniocentesis, genetic counseling, and genetic
screening).
39. Peter Conrad, Genetic Counseling as Work, HASTINGS CENTER REP., July/Aug.
1993, at 41 (reviewing CHARLES L. BosK, ALL Goo's MISTAKES: GENETIC COUNSELING
IN A PEDIATRIC HOSPITAL (1992) (based upon genetic counseling fieldwork conducted
over a decade ago)).
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spective parents make what might be the most traumatic decision of
their lives.40
There are approximately·450 certified genetic counselors and 500
clinical geneticists in the United States today.41 gven if these num
bers increase dramatically, there will be competition for limited access
to counselors and geneticists as genetic tests are made more available
and less expensive, and as more prospective parents are referred to
and seek out the services of genetic counselors. For example, consider
that, based upon the current number of counselors, just making cystic
fibrosis counseling available to the entire population would occupy
approximately seventeen weeks per counselor, per year.42
The availability of genetic screening services in the United States
fluctuates dramatically depending upon geographic location.

The

availability of basic testing and access to the full range of commercial
and research-stage testing is maximized in cities such as Boston, Mas
sachusetts and Houston, Texas, where there are internationally recog
nized medical facilities, research institutions participating in the
Human Genome Project, and a highly educated population that ex
pects and seeks out state-of-the-art medical treatment. Also, because
medicine is a service profession, the availability of screening services
is likely to be maximized in states that have recognized wrongful life
and wrongful birth actions against doctors.43 In New York, for exam40. See Fletcher & Wertz, supra note 23, at 748 ("Medical geneticists are mediators
between other fields in medicine with experience in dealing with ethical problems in
human genetics."). For a thorough discussion of the practice of genetic screening and the
emotional impact of fetal abnormality on parents, see M. Neil Macintyre et al., The Impact
of an Abnormal Fetus or Child on the Choice for Prenatal Diagnosis and Selective Abortion,
in ABORTION, MEDICINE, AND THE LAW 524-44 (J. Douglas Butler & David F. Walbert

. eds., 1992); see also THADDEUS E. KELLY, CLINICAL GENETICS AND GENETIC COUNSELING
365-93 {2d ed. 1986) (summarizing how clinical diagnoses are made based upon prenatal
genetic testing). For discussion of how genetic screening can be utilized to confirm or
replace clinical diagnosis for many genetic diseases, see C. Thomas Caskey, Genetic Predis
position and the Human Genome Project: Case Illustrations of Clinical Problems;
Presymptomatic Genetic Diagnosis-A Worry for the United States, in GENE MAPPING,
supra note 17, at 178; Edward R.B. McCabe, Genetic Screening for the Next Decade: Appli
cation of Present and New Technologies, 64 YALE J. BIOLOGY & M ED . 9, 9 (1991); McK
usick, supra note 17, at 36-39.
41. Sachs & Korf, supra note 1, at 459; Peacock Presentation, infra note 79. There are

1,888 persons generally certified by the American Board of Medical Genetics and an addi
tional 180 certified by the newly established American Board of Genetic Counseling (fo r
master's-level persons). The practice and profession of genetic counseling, including the
certification and educational backgrounds of counselors, is described in detail infra Part
II.A.
42. Sachs & Korf, supra note 1, at 459.
43. See Belinda L. Kimble, Wrongful Birth: A Practioner's Guide tua New Arrival, 55
ALA . L. REv. 84 (1994); see also Keel v. Banach, 624 So.2d 10�2 {Ala. 1993) (recognizing a
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ple, the fear of liability has helped to inspire obstetricians to refer vir
tually all patients who are at any risk44 to genetic counselors. The
result is that twenty-five-thousand women. in the state of New York
are screened for fetal genetic abnormalities each year.45
As discussed above in Part I.A., as a consequence of the Human
Genome Project, we will experience a period of tremendous expan
sion in genetic screening capability during the next several years.46

At

the present time, although " [p] renatal diagnosis is now available for
hundreds of conditions, ranging from profound mental retardation
and early death ... to disorders that affect daily living and shorten

[one's ]

life span but do not cause serious mental incapacity [, ] ... and

include [s] disorders that cause·serious mental and physical deteriora

tion but do not begin until middle age [, ] "47 the prenatal diagnosis of

cause of action for wrongful birth). These actions, and the impact of liability in general,
are discussed infra Part IV.A.(3).
44.

The list of factors indicating a risk for bearing a child with a genetic disorder

includes:
[A]dvanced maternal, age; previous offspring with a chromosomal aberration;
chromosomal abnormality in either parent; family history of sex-linked condition;
inborn errors or metabolism; neural tube defects; hemoglobinopathies; amni
ocentesis . . . .

Inquiries should be made about the outcome of previous

pregnancies, mental retardation, or other known or suspected inherited or meta
bolic disease.
George J. Annas & Sherman Elias, Legql and Ethical Implications of Fetal Diagnosis and
Gene Therapy, 35 AM. J. MED. GENET. 215, 215-16 (1990). Moreover, because they share a
greater percentage of genetic material, some ethnic groups are more prone to carry partic
ular genetic abnormalities. See generally KENNETH

1.,,

GARVER & SANDRA G. MARCHESE,

GENETIC COUNSELING FOR CLINICIANS 60-68 (1986) ; Suter, supra note 6, n.47 (identifying
a number of genetic diseases that have been identified as occurring at higher rates in par
ticular ethnic groups); Reuters, Gene Tied to Blacks Health Risk, BosTON GLO B E, Sept. 7,
1994, at 17. See also RICHARD J. HERRNSTEIN & CHARLES MURRAY, THE BELL CURVE:
INTELLIGENCE AND CLASS STRUCTURE IN AMERICAN LIFE 105 ( 1994) (concluding that 40
to 80 percent o f one's intelligence is controlled by one's genes, and drawing a correlation
between intelligence and race). But see E.D. Hirsch, Jr., Good Genes, Bad Schools, N.Y.
TIMES, Oct. 29, 1994, at 19 (citing studies which refute the finding that race and intelligence
are genetically linked).
45.

See Nobles, supra note 7, at 2086.

46.

Specifically,

[t]he prospect of dozens or even hundreds of relatively inexpensive new genetic
diagnostic tests emerging rapidly from the genome project has been held out as
likely by both the project's advocates and its opponents. Many of these new
markers will identify genes related to common illnesses and other traits and con
ditions that were previously well outside prenatal health professionals' routine
range of concerns.
Kathleen Nolan, First Fruits: Genetic Screening, HASTINGS CENTER REP ., July/Aug. 1992,
(Special Supplement), at S2.
47.
23.

AssESSING GENETIC RISKS, supra note 9, ch. 2, at 13; seep/so Thomas, supra note
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fetuses is restricted by a number of technology limitations. These lim
itations include the analytical/diagnostic techniques available ; the in
vasiveness

of

commonly

used

testing

procedures,

namely

· amniocentesis and chorionic villus sampling (CVS ) ; and the risks that
these testing procedures pose to fetuses.48 In the past, testing has
48. The "accepted" prenatal diagnostic technologies are: (1) amniocentesis; (2) CVS;
{3) PUBS; and (4) ultrasound.
Amniocentesis: Amniocentesis, generally performed at 14 to 16 weeks gestation, involves
entering the amniotic sac, removing some of the fluid that surrounds the fetus, and analyz
ing cells suspended in that fluid which have been shed by the fetus. AssEsSING GENETIC
RISKS, supra note 9, ch. 2, at 15 (Box 2-2); Annas, Monster Mythology, supra note 17, at
641. Until 1986 this analysis consisted of little more than counting chromosomes-for ex
ample, to determine the sex of the child ("sexing") so as to eliminate the possibility of sex
contingent diseases such as hemophilia, which .occurs almost exclusively in boys. Since the
advent of DNA-based diagnostics, the number of testings that can be done has increased
immensely. However, given the limited applicability of these additional tests to a wide
audience, determining number and structure of chromosomes and fetal sex is the extent of
testing in most cases at the present time. See generally id. "The Council of Regional Net
works for Genetic Services (CORN) has estimated, on a very limited sample of reporting
centers, that over 1 million amniocenteses were performed in the United States in 1990[,]"
which implies that twenty-five percent of all pregnancies in the United States undergo the
procedure. AssEsSING GENETIC RISKS, supra note 9, ch. 2, at 15. "Limitations of amni
ocentesis are the relatively advanced gestational age at which it is performed and the wait
ing period associated with the culture of the amniotic cells before test results are
available." Id.
Chorionic villus sampling (CVS): CVS is now performed between nine and twelve weeks
of gestation but may be performed as early as eight weeks, although not all conditions can
be diagnosed with reliability at eight weeks. The procedure involves placing a fine plastic
catheter or needle into the placenta and taking a small biopsy of placental tissue. AssEss
ING GENETIC RISKS, supra note 9, ch. 2, at 15; Interview with Michael Mennuti, M.D.,
Chairman, Obstetrics & Gynecology, University of Pennsylvania, Good Morning America:
CVS Prenatal Test (ABC television broadcast, Sept. 18, 1992). The amniotic cavity-the
sac of fluid-is not entered. Id. "Rapid reporting of results in twenty-four hours is also an
advantage compared to the ten to fourteen days required to grow cells from traditional
second trimester amniocenteses." AssESSING GENETIC RISKS, supra note 9, at 15. How
ever, CVS may carry an increased risk to the fetus. Specifically, "[w]hen the prenatal
screening test commonly known as CVS [chorionic villus sampling,] was introduced in the
mid-1980s, it was hailed as a major medical advance. . . . But now there's fear that CVS
may be causing birth defects in some babies." Mennuti Interview, supra. According to Dr.
Mennuti:
There have been a few children born after CVS who had defects of the hands and
feet, missing fingers and toes, and several children who also had underdevelop
ment of the lower jaw and tongue. These are very rare defects, and so there was
concern immediately that there might be a problem here . . . . Well, the theory is
that these defects may occur because when the small pieces of placenta are re
moved, there may be bleeding or blood loss from the placenta, and that may
cause decreased blood flow to the areas where we're seeing the defects in the
'
fetus. That decreased blood flow then may result in the defects.
Mennuti Interview, supra. See Sachs & Korf, supra note 1, at 460; Elsas, supra note 36, at
832 ("New techniques, such as transcervical and transabdominal chorionic villus biopsy
(CVS), with unknown maternal or fetal risks, now enable diagnosis earlier in pregnancy. Is
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been used generally only to detect the most common and devastating
the risk of having a chromosomally unbalanced liveborn greater than these procedural
risks of prenatal monitoring?" (footnote omitted)).

Percutaneous umbilical blood sampling (PUBS): Fetal blood is obtained at approximately
eighteen weeks gestation with a needle inserted-while being observed through ultra
sound-into the umbilical cord. AssEsSING GENETIC RisKs, supra note 9, ch. 2, at 15. The
procedure is most often used to clarify ambiguous chromosomal analysis resulting from
amniocentesis or CVS, but because it has been associated with a five percent rate of fetal
loss, it is being reserved for situations in which rapid diagnosis is essential and in which
diagnostic information cannot be obtained by safer methods. Id.

Ultrasound: Ultrasound, a noninvasive procedure that involves viewing the fetus on a
monitor, can only be relied upon to detect observable, physical abnormalities. Although
ultrasound is becoming-or has become-,-a routine part of obstetrical practice in the
United States, standards for ultrasound equipment and training and certification of person
nel have not been developed. AssESSING GENETIC RISKS, supra note 9, ch. 2, at 16. The
importance of this is reflected by the observation that, although low sensitivity, specificity,
and predictive value of examinations make ultrasound a generally crude and unreliable
indicator of fetal abnormalities, "[w]hen ultrasound is performed by highly skilled opera
tors, the sensitivity of this screening device in detecting congenital malformations can be as
high as 90 percent." Id.
"New" techniques in prenatal diagnosis include:

Early amniocentesis: Amniocentesis is now being used as early as week nine of gestation.
The safety and accuracy of this procedure has not been evaluated adequately. AssESSING
GENETIC RISKS, supra note 9, ch. 2, at 19.

Fluorescence in situ hybridization (FISH): Originally, a DNA research tool that relies
upon DNA probes visualized by fluorescence methods, FISH is now being relied upon for
prenatal diagnosis. Id. "This technique has also been the source of recent controversy
about 'a rapid (but wrong) prenatal diagnosis' in which a prenatal diagnostic error resulted
from a test whose accuracy is said to exceed 99 percent." Id.

Diagnosis using fetal cells isolated from maternal blood: Fetal cells have been detected in
maternal blood as early as nine weeks of gestation, and first-trimester prenatal diagnosis of
Down's Syndrome as a result of this technique has been reported. Id. However, this tech
nique is only at the research stage and it is highly subject to error because the slightest
contamination-for example, from a previous pregnancy-can result in both false-positive
and false-negative results. Id.

Preimplantation diagnosis and In-vitro fertilization (/VF): This technique involves remov
ing ova (eggs) from a woman's ovaries, fertilizing them outside of the womb, removing
some cells when the eggs have divided, analyzing those cells, and then implanting the
healthy zygotes. See Andrea Bonnicksen, Genetic Diagnosis of Human Embryos, HAS
TINGS CENTER REP., July/Aug. 1992, (Special Supplement), at S5; Barbara Katz Rothman,
Not all that Glitters Is Gold, HASTINGS CENTER REP., July/Aug. 1992, (Special Supple
ment), at Sll-S15; see also Philip Elmer-Dewitt, Catching a Bad Gene in the Tiniest of
Embryos, TIME, Oct. 5, 1992, at 81 (noting that days-old embryos are being tested for
genetic abnormalities outside the womb and discussing how this technique has been used
to detect several inherited ailments, including hemophilia, Duchenne muscular dystrophy,
and Tay-Sachs disease). Dr. Mark Hughes, Director of Baylor's Prenatal Genetics Center,
has developed a procedure for rapidly spotting the cystic fibrosis defect in a single strand of
DNA using a gene cloning technique called "polymerase chain reaction." Elmer-Dewitt,

Catching a Bad Gene, supra at 82. As stated by Dr. Hughes, "It's like finding one typo
graphical error in a book 180 times the size of the Encyclopedia Britannica in about six
hours . . . . " Id.; see also Good Morning America: Genetic Disease Test (ABC television
broadcast, Sept. 25, 1992). "The advantage of preimplantation testing is that it avoids the
'
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disorders on women who are at an increased risk for having offspring
with these disorders.49 But times are changing: As more of the ge
netic abnormalities responsible for health impairments are identified,
tests to detect these abnormalities become available, testing tech
niques improve, and common knowledge about testing options ex
pands, more prospective parents will be encouraged to undergo and
seek out prenatal genetic screening. Perhaps within the not-too-dis
tant future, rather than some prospective parents being asked whether
they want prenatal genetic tests performed, all prospective parents
will be asked which test or tests they want to be run. Moreover, as the
gap between the deluge of laboratory information generated by the
Human Genome Project and physicians and geneticists working with
need for screening and abortion after pregnancy has occurred. In addition, it opens the
door eventually to gene therapy on the embryo . . . ." Robertson, supra note 36, at 706.
However, there are some major limitations to this kind of testing. First, the procedure
subjects the pregnant woman to some risk. Second, because there is limited genetic mate
rial with which to work, only a limited number of tests can be run. Third, there is a limited
time frame within which to work; all testing must be done within seventy-two hours. More
over, IVF costs more than $15,000 per cycle and "only 14 percent of women deliver a live
born infant after one cycle of invitro fertilization, and the rate of live births is no better
than 1 for every 10 embryos transferred at the centers with the best records." AssEss1No
GENETIC R1sKs, supra note 9, ch. 2, at 20.
Embryoscopy: This technique, which involves penetrating the abdomen and outer layers
of the amniotic sac with a scope smaller than a straw, is reported to carry the same level of
danger as amniocentesis. See F. Albert Reece & Carol J. Homke, Embryoscopy, Fetal
Therapy, and Ethical Implications, 57 ALB. L. REV. 709 (1994) (discussing background in
formation on embryoscopy, its applications, and ethical implications); Interview with Al
bert Reece, M.D., Chairman, Dep't of Obstetrics, Temple University School of Medicine,
Today Show (NBC television broadcast, July 1 1 , 1993). Although highly experimental, em
bryoscopy may be used to diagnosis physical abnormalities in fetuses well within the first
trimester of pregnancy and with certainty. See generally Reece & Homke, supra (address
ing the potential applications of embryoscopy, including gene therapy); see also Gina Ko
lata, Miniature Scope Gives the Earliest Pictures of a Developing Embryo, N.Y. TIMES, July
6, 1993, at B6.
49. See Robertson, supra note 36, at 710. Specifically,
[p]renatal diagnosis of fetuses can at present detect only a limited number of ge
netic disorders. Down's syndrome, Tay-Sachs disease, spina bifida, sickle cell
anemia, and cystic fibrosis are among the diseases that can be detected through
prenatal screening of fetuses. Because the tests are invasive and pose some risk
to the fetus, they are performed only on women who are at increased risk for
having offspring with those disorders. Women over thirty-five, those with a prior
handicapped birth, or those who are carriers of genetic disorders now choose
these tests. If a maternal blood test became available, the demand for prenatal
screening of fetuses would increase dramatically, even though it should not be
come a substitute for carrier screening.
Id. ; see also Nobles, supra note 7. at 2087 ("Because of the inherent invasiveness and risk
to the fetus of present screening techniques, prenatal screening is performed only on wo
men with a genetic predisposition to conceive children with inherited diseases.").
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pati �nts narrows, testing te �hnique� will improve, thereby making it
possible to do �ore extensive testmg and to test more efficiently.so
.
Thus, an expans10n of the practice of prenatal genetic ,screening is
imminent.
C.

Our Failure to Question
As discussed above, prenatal genetic screening involves the appli

cation of technology that, because of work on the Human Genome
Project and related technological discoveries, is advancing exponen
tially. If one considers the research-stage tests available on a world
wide scale , even our present screening capability is nothing less than
awesome.

With such a surge in technology comes new ethical

problems, problems for which established ethical principles may not
be easily applied.s1 Without public policy foresight and resulting regu
lation, there is some danger that society will not discover violations of
its ethical principles until the technology and practices responsible for
these violations have already been introduced and widely applied.s2
The confrontation over legalized abortion in the early 1970s di
vided our society and brought about a legal and ethical civil war that
continues to rage.s3 In contrast, we have warmly embraced the tech
nological capability to test for genetic abnormalities, almost without

50. For example, consider that "[i)n a marriage of biology and electronics, members
of the Genosensor Consortium are developing a microchip-driven DNA probe that holds
the possibility of diagnosing diseases in a single second." Thomas, supra note 23.
51. See Eric J. Cassell, The Sorcerer's Broom: Medicine's Rampant Technology, HAS
TINGS CENTER RE P ., Nov./Dec. 1993, at 32 ("Like the broom in The Sorcerer's Apprentice,
technologies come to have a life of their own, not only because of their own properties but
also because of certain universal human traits. "); Jody W. Zylke, Examining Life's (Geno
mic) Code Means Reexamining Society's Long-Held Codes, 267 JAMA 1715 (1992); see
also Future Directions of Human Genome Project Considered,

HUMAN GENOME NEws,

July 1993, at 6 ("Participants [in a meeting held by the NIH National Center for Human
Genome Research in April of 1993] observed that anticipating and addressing ethical,
legal, and social implications (ELSI) of genome research will become more important as
disease-gene mapping expands and improved sequencing technology makes available
more-refined molecular diagnostics."); Genetic Grammar, HASTINGS CENTER REP July/
Aug. 1992, (Special Supplement), at Sl. Cf Albert R. Jansen, The Birth of Bioethics, HAS
TINGS CENTER RE P., Nov./Dec. 1993, (Special Supplement), at SL For a contrary opinion,
see John Maddox, New Genetics Means No New Ethics, 364 NATURE 97 (1993) (asserting
that genome sequencing will not create novel problems, for the techniques are "hardly
novel" and unlikely to be more troublesome than those involving the genetic manipulation
of bacteria twenty years ago).
52. See generally HASTINGS CENTER REP., July/Aug. 1992, (Special Supplement) (ad
dressing genetic screening capability and its implications).
53. For a general discussion of this conflict, the competing social values that continue
to generate it, and an issue-by-issue discussion of the dozens of difficult questions it encom
passes, see LAURENCE H. TRIBE, ABORTION: THE CLASH OF ABSOLUTES (1990).
.,
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question.54 This is true despite the fact that late-term (for the pur
poses of this Article, generally meaning week twenty and thereafter)55
abortion is the only real option available, besides carrying and deliver
ing the fetus, if a defect or disease is revealed by prenatal genetic
screening.56

As recently recognized by the National Institutes of

Health,
54. According to a survey conducted by the March of Dimes, "[m]ost Americans sup
port gene therapy, genetic testing and genetic research, even though they have scant
knowledge of the procedures" Ruth SoRelle, Survey Finds Americans Back Gene Therapy
Research, Hous. CHRON., Sept. 29, 1992, at Al. But see infra note 179 and accompanying
text (public reaction to fetal cloning). For a general treatment of various issues surround
ing genetic screening technologies, see THE CooE OF CODES: SCIENTIFIC AND SocIAL
IssuEs IN THE HuMAN GENOME PROJECT (Daniel J. Kevles & Leroy Hood eds., 1992).
55. Genetic screening presently depends upon amniocentesis, which, because of the
danger it can pose to the fetus, generally is not performed before the fourteenth week of
pregnancy. See supra note 47 and accompanying text; see also Curt S. Rush, Note, Genetic
Screening, Eugenic Abortion, and Roe v. Wade: How Viable is Roe's Viability Standard?, 50
BROOK L. REv. 113, 127 (1983). But see Kolata, infra note 1 18, at 1 (discussing how visible
deformities may be detected as early as week six through embryoscopy).
56. Abby Lippman, Prenatal Genetic Testing and Screening: Constructing Needs and
Reinforcing Inequities, 17 AM. J.L. & MED. 15, 34 & n.90 (1991) (addressing fetal abnor
m ality as one grounds for abortion). "Prenatal genetic diagnosis today only permits us to
offer the patient termination of pregnancy. . . . Gene therapy, or gene supplementation,
has not become a reality." Sachs & Korf, supra note 1 , at 460. In addition to technological
limitations, gene therapy indisputably is treatment and, as such, it is subject to FDA
approval.
Nevertheless, recently there have been some major gene therapy successes. See Ge
raldine A. Collier, Attacking a Killer: New Center to Study, Treat Gaucher Disease,
WORCESTER TELEGRAM & GAZETTE, Sept. 13, 1993, at Cl; Elmer-Dewitt, Genetic Revolu
tion, supra note 36, at 46; Judy Foreman, Scientists Study Steps in Death of Cells, BosTON
GLOBE, Nov. 19, 1993, at 12; Daniel Golden, Elation, Tinged by Frustration, BosTON
GLOBE, Oct. 17, 1993, at 33 (addressing how the discovery of a cure for cystic fibrosis is
accompanied by a delay in making it available to the public); Stephen C. Hyde, Correction
of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy, 362 NA
TURE 250 (1993); Leon Jaroff, Battler for Gene Therapy, TIME Jan. 17, 1994, at 56-57;
S h oushu Jiao, Long-Term Correction of Rat Model of Parkinson's Disease by Gene Ther
,

apy, 362 NATURE 450 (1993); Richard A. Knox, Cystic Fibrosis Is Reported Corrected by
Gene Therapy, BosTON GLOBE, Oct. 15, 1993, at 1 , 22; A. Dusty Miller, Human Gene
Therapy Comes of Age, 357 NATURE 455 (1992); Richard Saltus, Blocking the Signals that
Make Cells Sick, BosroN GLOBE, Nov. 1 , 1993, at 29, 31 (identifying this technology as a
possible means to prevent cancer, arthritis, allergies and some mental disorders); Richard

Saltus, Key Immune Component Reported Found, BosToN GLOBE, Nov. 5, 1993, at 17; Earl
Ubell, Is Mending Sick Genes a Miracle Cure?, PARADE MAG., Jan. 16, 1994, at 8; Benja
min S. Wilfond & Norman Forst, The Introduction of Cystic Fibrosis Carrier Screening into
Clinical Practice: Policy Considerations, 70 MILBANK Q. 629-59 (1 992) (issue number 4).
For example, researchers in Los Angeles injected a five-day-old baby with gene-altered
blood cells from his mother's placenta to correct an immunological disorder. Similarly,
two Ohio girls have undergone three years of gene therapy to fight an immunological dis
order known as severe combined immunodeficiency (SCID). Miller, supra. Moreover, re
cent advances enabling scientists to cut and splice genes are being used to modify the bone
m arrow cells of patients with ovarian cancer to enable them to withstand the toxic side
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[t)he ultimate goals of [Genome Project-related] advances are the
treatment, cure, and eventual prevention of genetic disorders, but
effective interventions Jag behind the ability to detect disease or in
creased susceptibility to disease. Thus, many genetic services today
consist of diagnosis and counseling; effective treatment is rare. Nev
ertheless, as more genes are identified, there is growing pressure to
broaden existing screening programs, and otherwise increase both
the number of available genetic tests and the volume of genetic in
formation they generate.57

One reason for our acceptance of extensive prenatal genetic
screening is that it is being introduced to us through the health profes
sion rather than through a social movement. Prenatal genetic screen
ing is perceived, at least on the surface, as being about medical
diagnosis rather than about rights-about the decision to abort

a

wanted child made by parents who will mourn the loss of its life. It i s
also a reflection o f o u r increased acceptance of abortion whe n a fetus
is physically or mentally impaired and, therefore, the premium w e
place on " normalcy. " Polls consistently show that seventy to eighty
percent of people approve of abortion being legally available when
the fetus has a serious abnormality, even if they may not be willing t o
have an abortion themselves under those circumstances.58
Nevertheless, however gentle its delivery, this new technology
carrie s cutting ethical problems.59 Along with wonderful possibilities
effects of medications. Id. Also, researchers have reported success with treating cystic
fibrosis by introducing a corrective gene into the patient's system through an inhaler. This
effort is already considered a working-level project by the FDA. Id.
57. ASSESSING G ENETIC RISKS, supra note 9, ch. 2, at 1. See Mitchell Zuckoff, Words
of Hope Usher in Drug for Cystis Fibrosis, BosTON GLOBE, Dec. 31, 1993, at 1 , 15.
58. Robertson, supra note 36, at 713. Our society's acceptance of abortion unde r
these circumstances may even give rise to social pressure to abort:
Society does not truly accept children with disabilities or provide assistance for
their nurturance. Thus, a woman may see no realistic alternative to diagnosing
and aborting a fetus likely to be affected. . . . Regardless of the driving forces for
dependency on this technology, the result is the construction of a particular
"need": the basic "need" to know the gestational age of the fetus; the additional
"need" to demonstrate that the pregnancy is progressing "normally." And the
"needs" grow.
Lippma n, supra note 56, at 32-33.
59. Some of these ethical problems are identified through the objections being raised
to prenatal genetic screening:
Right-to-life groups oppose the practice as a search and destroy mission. Handi
capped groups are afraid that it devalues the lives of existing handicapped per
sons. Others are concerned that these techniques are available only to the middle
class and not to those without health insurance. Despite the freedom it offers,
some feminists object to prenatal testing because it becomes implicitly obliga
tory-women are then expected to be tested and do not effectively have the right
to say no. Still, prenatal diagnosis is now firmly established and is likely to ex
pand as screening techniques move to earlier stages of pregnancy. For example,
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such as the realization of a great expansion of parental choice, genetic
screening gives rise to ethical problems at least as complex as the most
difficult problems arising from the abortion issue. 60 Moreover, espe
cially in the absence of regulation through reliance on research labo
ratories rather than commercial testing and conscious choice at the
public policy level, genetic screening soon will be the more common
procedure. As discussed more fully in Parts II and III of this Article,
genetic screening testing capability is expanding and that capability is
being used for diagnostic purposes more readily than it is being
questioned.
U.

Law, Ethics, and Legal Storytelling

Law is a social instrument-something we share and, at least at a
societal level, agree to. Individual laws are societal obligations we
tort law has recognized the obligation of physicians to offer prenatal testing to
women in at-risk categories.
Robertson, supra note 36, at 710 (footnotes omitted). Many of these issues are explored in
Stuart Taylor, Jr., Blame-the-Moms-Defense, AM. LAW., Mar. 1994, at 3, 27-29, a fictional
account of a court case arising from a genetic therapy treatment to enhance intelligence.
60. For example, consider that the presence of a genetic abnormality does not neces
sarily mean that the disease it has been linked to will be present because "[m]any of these
diseases probably result from the interaction of genes and the environment." Sachs &
Korf, supra note 1 , at 459; see also supra Part I. Therefore, parents may be aborting
wanted children based upon the presence of genetic abnormalities that will either never
cause medical or physical impairments, or the emergence of which may be avoided through
the manipulation of environmental factors. See Sachs & Korf, supra note 1 , at 459. In sum,
when the decision to abort a pregnancy arises from the result of genetic screening, there is
often added conflict. The factors contributing to this conflict have been summarized as
follows:
a) Beliefs about the higher moral status of the fetus at midtrimester when abor
tion decisions must be made following amniocentesis;
b) The wide spectrum of severity in some disorders (for example, sickle cell
disease);
c) The treatability of some disorders (for example, phenylketonuria) which can
now be diagnosed prenatally using DNA techniques;
d) The guilt that parents, who have a living child with a disorder, feel towards
that child when considering abortion of a newly diagnosed fetus;
e) Concerns that the moral reasoning that justifies a practice of selective abortion
may create a precedent for neglect of persons with genetic disorders who are born
and survive (some critics compare the reasoning for abortion with arguments for
active euthanasia in severely handicapped newborns);
f) Decisions about abortion in twin pregnancies where one twin is healthy and
the other affected; and
g) The fact that a decision not to abort after a positive genetic finding can also be
an ethical problem if the woman or couple involved are pressured to abort or
threatened with loss of medical care.
Fletcher & Wertz, supra note 23, at 762-63.
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codify and enforce. They are obligations we can fulfill, and can expect
others to fulfill, on a daily basis.61 In other words, they are expres
sions of " a basic minimum standard of human behavior considered
acceptable in society."62 Ethical principles, on the other hand, are the
ideal. They are what we strive to be, but cannot realize necessarily ort
a daily basis and cannot expect others to realize. 63 "Ethics and law
converge on morality, the practical guidance that communities of per
sons create and recreate to use in everyday life to resolve conflicts
among desires, goods, principles, and rules. "64
Because laws codify what we can expect of ourselves and others,
while ethics are aspirations of what we would like and would like
others to be, it is natural and necessary that generally we maintain a
gap between these two levels of behavior. To some extent, this gap is
protected by the recognition of individual rights under the Constitu
tion;65 it is a recognition that ethical standards are not always shared
61. See generally MARTIN P. GOLDING, PHILOSOPHY OF LAW 52-53 (1975) ("This is
the very basic issue of authority and freedom. What does a society have the right to de
mand of its members in the way of affirmative action or restraint? And what ought to be
reserved to the individual as subject to his own choice and decision?"); SAMUEL MERMIN,
LAw AND THE LEGAL SYSTEM: AN INTRODUCTION 5 (2d ed. 1982) (addressing the func
tions and limits of law). As stated by Mermin,
[t]he legal system constitutes a framework within which certain common expecta
tions about the transactions, relationships, planned happenings, and accidents of
daily life can be met (and this force for predictability and regularity can itself be
viewed as a species of maintenance of order). We expect that our customary ways
of behavior will be facilitated and not disrupted by law without strong reason; we
expect that those who have suffered personal injuries-particularly those who
were without fault-will be compensated for their injuries under the Jaws of tort;
that those who have made promises will be held to their promises (or, if not, be
required to make recompense) under the Jaws of contract; that those who own
property can get the law to enforce their expectations that they have exclusive
rights in it and are free to dispose of it as they wish.
Id. at 6 (emphasis in original) (footnote omitted).
62. Fletcher & Wertz, supra note 23, at 750.
63. Id. at 750 ("[E]thics aspires to an ideal of optimum behavior and conduct.").
64. Id. at 749; see also Alexander Morgan Capron, Why Law and the Life Sciences?,
HASTINGS CENTER REP., May/June 1 994, at 42-43. The extent to which morality may be
codified through Jaws has been phrased as the following question: "What are the spheres
of morality that are in fact essential to society?" GOLDING, supra note 61, at 66 (address
ing the concept of "public morality"). As explained by Professor Capron, "In a society in
which ethical standards were clear, extensive, and strong, there would be no need for the
law at all. Thus. might it be that we have turned to the law to tell people what they must do
because ethics has failed to convince them of what they should do?" Capron, supra at 42;
see also JosEPH CAMPBELL, THE PowER OF MYTH 3 (1988).
65. See MERMIN, supra note 61, at 7 ("In the Constitution can be seen another vital
function of our law: protection of the citizen against excessive or unfair government power.
I refer mainly to the Bill of Rights-to such basic rights as freedom of speech, press, and
religion, the right to privacy and against unreasonable searches and seizure, the privilege
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and should not be imposed. A large part of legal training is learning
to understand, and even to protect, this gap.66 Consider that many of
us trained in law grow uncomfortable when this gap is narrowed-for
example, when legal scholarship takes a highly deontological form, de
fining and approaching problems from the perspective of the individ
ual, as is true with critical race theory and feminist theory.67 This
discomfort arises from the understanding, whether conscious or sub
conscious, that law can no longer work as an enforceable standard if
the behavior it prescribes engulfs morality and rises to the level of
pure ethics. 68
The objective methods and tools of the law (formality in expres
sion and interaction, the codification and enforcement of elaborate
rules and procedures, reliance on precedent that has arisen out of fact
patterns at least once removed from the case at issue) enable us to
b elieve that law is neutral and fairly applied among us. Ethical stan
dards, on the other hand, touch upon personal values and become
subjective-a matter of one's own morality. Therefore, even though

against self-incrimination, the right of jury trial for crime.") (emphasis in original). For
example, it is well settled that the Constitution places limits on a state's right to interfere
with the most basic decisions regarding family and parenthood; such decisions are left to
the individual. See, e.g., Planned Parenthood v. Casey, 505 U.S. _, 112 S. Ct. 2791 (1992)
(the right to choose abortion prior to the point of viability); Carey v. Population Servs.
lnt'l, 431 U.S. 678, 684-86 (1977) (contraception); Moore v. East Cleveland, 431 U.S. 494
(1977) (family living arrangements); Eisenstadt v. Baird, 405 U.S. 438 (1972) (contracep
tion); Loving v. Virginia, 388 U.S. 1 (1967) (interracial marriage); Griswold v. Connecticut,
381 U.S. 479 (1965) (procreative liberty); Skinner v. Oklahoma ex rel. Williamson, 316 U.S.
535 (1942) (the procreative liberty of habitual criminals); Pierce v. Society of Sisters, 268
U.S. 510 (1925) (the right to send children to private school); Meyer v. Nebraska, 262 U.S.
390 (1923) (the right of children to be taught a foreign language). But see Bowers v. Hard
wick, 478 U.S. 186 (1986) (refusing to recognize a right to privacy in sexual relationships
between consenting homosexual adults).
66. Consider the experience of a first-year Jaw school student being taught that "the
law" is a set of constructs often at least once removed from what is "fair." Students are
taught that rules are simply "the rules," and fairness is provided through notice that they
exist and the understanding that all people are subjected to them equally and without ex
ception. See generally Golding, supra note 61, at 1 1 8-25 (addressing "procedural justice"
and "justice and equality," and noting that "[t]he prevailing tradition in philosophy relates
the core sense of 'justice' to the idea of equality.").
67. See infra note 73 and accompanying text.
68. The distinction between law and ethics is reflected by the fact that, because they
are the "highest truths," ethics remain steady while laws change: "Ethical principles and
relationships, such as respect for persons and the physician-patient relationship, are fairly
stable and uniform over time, even for centuries, and across cultures. Laws, on the other
hand, may differ from state to state in this country. Laws change rapidly on specific is
sues." Fletcher & Wertz, supra note 23, at 750.
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ethics may be respected and generally aspired to by all, their enforce
ment is better left to the individual. 69
Nevertheless, society is often confronted with problems that do
not lend themselves to solutions distanced from ethics.70

Abortion,

capital punishment, the right to refuse medical treatment71-these are
problems for which we, at least at the present time and on the national
level, do not have a shared understanding.72 We often approach such
issues from our personal ethical stances, and we question or cling to
the governing law, depending upon whether it supports or challenges
our own positions.
The technique of legal storytelling is a means to deal with the
interaction of law and ethics.

A highly personal, human approach to

problems and a means to identify problems that have not been recog

nized by society, " [t] he technique of legal storytelling is an effort to
communicate insight gained through personal experience to those
who have not shared in that experience. "73 Through legal storytelling,
69.

As explained by Fletcher and Wertz:

Ethics inspires human potential and development to higher ideals of service,
human betterment and fulfillment. . . . The authority to punish or to coerce gives
law greater influence in society than morality, which has only the power of praise
or blame . . . . Law maintains the stability of the social order, rather than making
people into "better" human beings, although it may claim to accomplish this indi
rectly. . . . Law, despite its frequent association with the concept of justice, does
not necessarily seek, nor achieve, justice; rather, law seeks to allocate power and
claims to distribute the cost of risks and losses (compensation for injuries). Ethics
on the other hand, is consciously concerned with seeking justice and bringing
about social change to enhance the search for justice.
Id. at 751.
70.

As is discussed in more detail in Parts III and IV, many life-and-death decisions

regarding medical treatment fall into this category. For example, decisions such as whether
seriously impaired newborns should be treated are left to parents, doctors, and perhaps
ethics committees. See REN�E R. ANSPACH, DECIDING WHo L1vEs: FATAL CHOICES IN
THE INTENSIVE-CARE NURSERY (1993); DAVID W. MEYERS, THE HUMAN BODY AND THE
LA W 83 (2d ed. 1990); see also HOLDER, supra note 38, at 82-122.
71.

See Cruzan v. Director, Missouri Dept. of Health, 497 U.S. 261 (1991). For a

discussion of the doctrine of substituted judgment and the state's struggle to involve itself
in decisions embodying difficult ethical questions through that doctrine, see Louise Har
mon, Falling Off the Vine: Legal Fictions and the Doctrine of Substituted Judgment, 100
YALE L.J. 1 (1990). For discussions of ethical and legal implications surrounding euthana
sia, see Dying Well?: A Colloquy on Euthanasia & Assisted Suicide, HASTINGS CENTER
REP., March/April 1992.
72.

Nevertheless, Fletcher and Wertz have summarized six ethical principles com

monly found in the literature of biomedical ethics: autonomy, •nonmaleficence, benefi
cence, justice, strict monetary utilitarianism, and non-moral reasons. Fletcher & Wertz,
supra note 23, at 775.
73.

Michael J. Malinowski, "Hello, Dad.

•

This is your daughter.

Can I get an abor

tion? ": An Essay on the Minor's Right to Confidential Abortion, in ABORTION, MEDICINE,
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one is able to analyze the effects of law and the absence of law on an
extremely practical and real level. Our own personal morality, which
is shaped by our own perspectives and experiences,is tested and tem
pered by the experiences of others.
The following are such personal experiences: the insight of a ge
netic counselor, the p erspective of a researcher working o n the
Human Genome Project, the experience of a woman who underwent
genetic counseling and chose abortion, and the experience of a family
that includes a child with spina bifida. These stories are offered as a
way to understand7 4 the practice of genetic screening and its impact
on families. They are also offered as a means to evaluate the need for
enforcing existing legal restraints on, and erecting others around, the
practice of prenatal genetic screening.
A Counselor's Story75

A.

The background needed to be a genetic counselor varies,depend
ing on whether you want board certification. Most genetic counselors,
AND

THE LAW 201 (J. Douglas Butler & David F. Walbert eds., 1992). This technique is

associated with a group of creative and often poetic scholars-such as D errick Bell,
Kimberle Crenshaw, Richard Delgado, Mari Matsuda, and Patricia Williams-who are
now enlightening us with the victim's story told through a body of legal scholarship known
as "outsider j urisprudence." Id. See, e.g., Richard Delgado, Storytelling for Oppositionists
and Others: A Plea for Narrative, 87 Mrctt. L. REV. 2411 (1989); Richard Delgado, When a
Story ls Just a Story: Does Voice Really Matter?, 76 VA. L. REV. 95 ( 1 990); Mari J. Mat
suda, Looking to the Bottom: Critical Legal Studies and Reparations, 22 HARV. C.R.-C.L.
L. REv. 323 (1987); Mari J. Matsuda, Public Response to Racist Speech: Considering the
Victim 's Story , 87 MICH. L. REV. 2320 ( 1989); Mari J. Matsuda, Voices of America: Accent,
A ntidiscrimination Law, and a Jurisprudence for the Last Reconstruction, 100 YALE L.J.
1329 (1991); Patricia Williams, The Obliging Shell: An Informal Essay on Formal Equal
Opportunity, 87 MICH. L. REv. 2128 (1989).
74.

Understanding is a matter of perspective, and legal storytelling is about approach

ing difficult legal topics from the perspective of reality rather than from pure theory. It is
also about acknowledging perspectives that have been overlooked, such as that of the
patient:
[P]hysicians publish articles in highly prestigious and relatively accessible j ournals
such as the New England Journal of Medicine and the Journal of the American
Medical Association.

Nurses and other ancillary health care providers publish

their experiences, if at all, in less well-known journals. Patients' experiences al
most never get into print. Correspondingly, law professors and practitioners pub
lish in law reviews, a forum to which the objects of the discussion-nurses,
doctors, psychologists, and certainly patients-generally do not have access in the
ordinary course of their activities.
Ellen Wright Clayton, Screening and Treatment of Newborns, 29 Hous. L. REV. 85, 90
( 1 992) (discussing the importance of the individual, subjective experience in the context o f
genetic screening o f newborns).
75.

The following is neither the story of one counselor nor of one facility; it is a

narrative compiled from several discussions with a genetic counselor and other sources.
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including myself, are master's level ( meaning that we have a master' s

graduate degree in this field ) and board-certified

(meaning

that we

have a wide general knowledge of all aspects of genetics and genetic
counseling ) . Master's level counselors have undergraduate degrees in
the fields of science or psychology; our master' s counselors are from
genetic counseling programs. Numerous nurse-counselors and social
workers do certain types of counseling. Non-master's level counselors
used to be eligible for board certification, but in the mid-1980s, the
qualification of graduation from a master's level training program in
genetic counseling was added, limiting the ability of nurses and social
workers to get board certification as general counselors.
Until this year, certification for master's level genetic counselors
was done exclusively by the American Board of Medical Genetics,
which also certifies M.D. and Ph.D. geneticists. Now it is done by the
newly formed American Board of Genetic Counselors. This came
about because medical genetics recently received formal recognition
as a medical specialty76 by the American Board of Medical Specialties

( ABMS) .

But, by ABMS guidelines, if the M.D. geneticists wish to

maintain that recognition, their specialty board cannot also be certify
ing non-M.D ./Ph.D . 's. So the counselors have formed a separate cer
tification board.77 Several other divisions were also needed, which is
sad because historically the M.D.'s, Ph.D.'s, and M.S.'s have all
worked pretty closely with each other. But, to avoid losing coopera
tion, communicating boards have been set up.
Personally, I do primarily prenatal genetics. I see about 700 pa
tients per year. According to the statistics of the National Society of
Genetic Counselors

(NSGC) ,

the average counselor sees about 450

These discussions took place during the spring of 1993. Much of the text was transcribed
from audiotape, then edited by the author and transformed into the narrative presented.
That tape , although confidential, is on file with the author.
The counselor responsible for most of the information presented asked me to note at
the outset that terms such as "mother," "parent," and "couple" should be taken to mean
the pregnant woman and her primary supporters, if she has any. The counselor also asked
me to stipulate that this discussion is presented with the understanding that not all
pregnant women are members of "couples," and that the father of a pregnancy should be
as involved in prenatal counseling and decision making as possi?Ie.
.
76. See infra note 286 (discussing how who provides genetic counselmg may have a
tremendous impact on the counseling received by patients).
.
.
77. See Business Meeting Minutes, The American Society of H�man G�net1cs C!"lov
y,
ial
spe
1cal
me
official
� �
�
12, 1992) (addressing the recognition of medical genetics as an
ies
and stating that "to remain in compliance with the [American Board of Medical Specialt
re
be
must
)]
(ABMG
cs
Geneti
l
Medica
(ABMS)] requirements the (American Board of
by a new
structured so that in th� future masters level genetic counselors will be certified
Board , the American Board of Genetic Counseling (ABGC)" ).
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patients per year, with the range being from

200

to one thousand. I

see most patients only once, but I have seen some several times and
h a d extensive telephone contact with others; it depends on what they
need.
When I meet with a patient, I do a full pregnancy history:

Have

you been ill during the pregnancy so far? What's your ethnic back
ground? How much alcohol have you consumed? Is there any family
history you are worried about? Sometimes patients have family his
tory they are worried about, and we'll talk about that. Sometimes it
turns out that the mother is most worried about the fact that her sis
ter's child has cerebral palsy and the father is most worried about the
fact that the mother hasn't quit smoking. We 'll cover all those issues.
We work through everything and pull it all together as best we can to
find the most appropriate tests.

We end up saying something like,

"Based upon what you've told me, here is the testing we can offer.
This one will tell you this, that one will tell you that. They cost
amount. It takes

"Y"

"

X"

long to get the results. No test can guarantee a

'perfect' baby."
We also discuss accuracy, ambiguity, potential risk of miscarriage,
aftercare, and other things they have to know to make an informed
decision, including anything else they want to talk about. I will ask
them if they have thought about what they will do if the results indi
cate that there is a problem, and if they would like to hear more about
particular disorders. A lot of people do not want to hear too many
d etails; it's too overwhelming. But there are things that need to be
i ncluded to reach an informed decision.
After the decisions are made, I arrange for the procedures they
have decided to undergo, make sure that whatever testing that is to be
done is lined up, and then I follow through with the results. If every
thing is fine and the lab does not see any signs of an abnormality,
great. I'll call the parents and their OB ( obstetrician) with the results,
and they continue with their regular prenatal care. If an abnormality
is detected, we will talk about it, and I work with them to help them
make whatever decision is comfortable for them.

If they decide to

continue with the pregnancy, I let them know whether there are any
pediatricians we recommend, the names of specialists they might
need, parents groups, and things they will need to help get ready. For
those who terminate, we make arrangement for this if their own OB
isn't comfortable doing so. We work with the parents so they'll know
what to expect during that procedure, and afterwards. I personally
don't do long-term e xtended grief and family counseling, but other
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counselors have chosen to get additional training in those areas.
Many centers coordinate support groups for those who have ended a
pregnancy for genetic reasons, and a family therapist is often part o f
that team.
*

*

*

Biostatisticians figure that, on the forty-six chromosomes, there
are between fifty and one hundred thousand different genes. We have
identified about

4,000, but

testing is only available for about 100. Not

all testing is done at my center.

We routinely send samples off to

other facilities. Once you get past the basics, different labs have dif
ferent areas of specialization and expertise. Research labs get very
specialized and particular about what they will and will not take for
analysis .78
People will come in and say, "Test for everything that you can."
I 'll explain that we can't do this. First, it's not feasible and second, the
cost would be astronomical.79 Average amnio fees are currently about
one thousand to twelve thousand dollars, including OB charges, so
nogram, and basic lab fees.

Of course, adding on extra testing in

creases that cost. Insurance coverage is a big factor for most people,
given the cost. Most insurance companies will only pick up what's
medically indicated.80 Medicaid isn't accepted by all laboratories,
which is a reflection of the poor rate of payment. HMOs in particular
get very touchy about adding anything on without proof of medical

78. See infra note 84 (addressing dependency on and the discretion of research
laboratories).
79. According to one genetic testing facility, most testing beyond standard chromo
some analysis will run approximately $250 for each test. It is important to note that the
costs, availability, and utilization of tests may be greatly influenced by market forces:
A test [for cystic fibrosis, carrier screening] is available for about $200 from sev
eral testing companies that have strong financial incentives to market their prod
uct aggressively. Many physicians are likely to offer the test to their patients-to
meet patient demand, to minimize the risk of later malpractice claims, or to profit
from providing an additional service.
Robertson, supra note 36, at 699-700 (footnotes omitted).
There is talk in the scientific community about bringing down the cost of genetic
screening through panel tests-one test that screens for several genetic abnormalities. For
example, in the spring of 1 993, Baylor's Institute for Molecular Genetics in Houston, Texas
came out with a panel test that screens for cystic fibrosis, Tay Sachs, and Gaucher's. The
panel is run on one blood sample for $150, and it carries a greater than 95 percent accuracy
rate as to whether the subject carries any of the three diseases. See Sandra Grilliot Pea
cock, M.S., Baylor College of Medicine, Class Presentation, Abortion, Law, and Social
Choice, University of Houston Law Center (Apr. 19, 1993).
80. See infr� note 218 (�ddressing re�usal of health maintenance organizati ons
(HMOs) to provide care for children born with prenatally diagnosed ailments).
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necessity. And then, if you want to do it at a lab outside of the
HMO's network, you really better be able to back up your request.
Even though most insurance companies do not like to pay for the
expensive treatment of an abnormality after birth, I tell patients up
front not to expect insurance to cover termination. Some insurance
companies will come through, though-especially on appeal. But you
cannot count on that up front. Besides, termination clinics don't ac
cept insurance, and terminations done in hospitals are more
expensive.81
We always try to get results back while termination is still a legal
option.82 Termination is legal until the twenty-fourth week of gesta
tion in most states. Assuming it takes two to three weeks for results,
twenty-one weeks is about the latest you want to send a sample to a
lab for routine testing. If special testing is required and results are
going to take longer, the testing obviously must be done sooner. Oc
casionally, a woman will request testing after the point of having ter
mination as an option ; she may have just raised the money for testing
or just discovered a risk factor. Lots of people are surprised to learn
that the law doesn't allow termination for fetal anomaly at all stages
of pregnancy; others are surprised that termination is an option past
the first trimester.
Many people would like the information from the testing as early
as they can get it. That is why first-trimester testing like CVS was
developed.83 You can have it done between weeks ten and twelve of
gestation and have the results back by week fifteen. Earlier options,
earlier reassurance-these are the benefits, especially when compared
with amnio, which is generally not done until week fifteen. Of course,
with the recent controversy regarding allegations that CVS may cause
limb defects, some patients are opting to wait for amnio. Amnio has
been attempted earlier than week fifteen, but detailed studies on do
ing amnio at that stage have not been completed. There are tech
niques that can be done prior to conception for certain conditions, but
they involve in-vitro fertilization (IVF) and they are primarily in the
81. In 1991, first-trimester terminations at a nonhospital-based clinic in the Houston
area ranged from approximately $200 to $900. Second-trimester terminations ranged from
$750 to $2,200 if done at a nonhospital-based clinic. Second-trimester, in-hospital termina
tions generally ranged from $1,200 to $5,000 depending on charges for use of hospital facil
ities and personnel, anesthesiology, medications, and doctor's fees. Post-termination
options such as autopsy add more costs.
82. Abortion is a legal option in Colorado, Florida, and Kansas well into the third
trimester. See infra note 140.
83. See supra note 48 (discussing CVS and other prenatal diagnostic techniques).
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research stage. Another promising technique that is still in research is
based on the premise that fetal cells will cross into maternal circula
tion. At some point during pregnancy, it should be feasible to draw
blood from the mother, sort the fetal cells from the mother's cells, and
analyze the fetal cells for genetic diseases without assuming any of the
risks associated with amnio or CVS. Finally, it now may be possible to
detect visible deformities in fetuses as early as week six.
We keep track of research advancements, but generally we only
contact research labs directly if they are the best ones working on a
disease for which a family needs testing. Research labs are definitely
churning out testing advances faster than commercial labs can accept
them . 84 Certain research labs simply dominate the field with the qual
ity of their work on specific diseases, and they will make their tests
available for this reason. We'll occasionally find that the best place
for a test to be run is in Canada, Europe, or Japan. We'll then coordi
nate with that researcher and take care of the test the same way we
would if the test were done in the United States-except for we'll
have to cope with international requirements for shipping medical
specimens. If a researcher says that a test isn't ready for clinical appli
cation, we'll let the patient know that also.85 Sometimes patients will
want to do testing even if the test is just in the beginning stages of
research. They may feel that any information is better than none.
Some tests will always stay "research" under current technology sim
ply because the disease is so rare that no commercial lab is interested
in doing the testing for it.
The labs with which I've worked have all been very much aware
of the legal and medical liability of testing. If, for any reason, a lab is
not satisfied with the quality of the sample or of the analysis, it will
often recommend repeat testing. Most of the times repeat testing will
show everything is fine, but I do know of families who opted not to do
repeat testing and the baby was born with the suspected problem. It's

84. According to several sources, facilities providing genetic screening and counseling
services are more involved with research laboratories because they are pushing far ahead
of the commercial laboratories. A related issue is whether research laboratories-which
are often fully funded by grants and driven by different incentives than commercial labora
tories-are even willing to run their tests on prenatal samples. For example, there are
laboratories on the cutting edge of testing for certain diseases that discoura�e prenatal
samples because the people running the laboratories do not believe in termination for the
specific genetic diseases.
85. The direct contact between researchers and the public is discussed in more detail,
infra Part II.B.
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one of the reasons I raise the issues of accuracy and possible ambigu
ity during the initial session. 86
This is the one thing I'll hear over and over again from patients
who didn't have full pre-procedural counseling-that they weren't
told of certain risks like ambiguity in the test results. Of course , you'll
also have patients who don't recall being told about these issues even
when you

know that you

covered them. There is also the chance that,

because so much is raised during a session, the patient cannot remem
ber clearly whether something was said or not. Some centers require
that counseling be on a separate day from the procedure to give pa
tients time to think fully about everything. It's a good idea, but the
reality is that many patients have difficulty getting off work, arranging
day care, or just traveling to the center if it's far away.
We strongly recommend that patients who have abnormal results
indicating a fetus with a genetic condition return in person for further
counseling.

Again, logistics don't always make this possible, but a

good number do return-especially if the result is for a condition with
which they may not be fully familiar, like a sex chromosome anomaly.
We prefer to have both members of the couple come in, assuming the
father is involved, and minors should come with a parent but, again,
the world isn't perfect and, logistically, this can't always happen. For
those who decide to continue pregnancies knowing that their baby has
a genetic condition, we can put them in touch with support groups and
specialists and give them ideas of how to work with their insurance
companies-practical help in addition to trying to answer the ques
tions of why did it happen and will it happen again.
If the patient decides to end her pregnancy, and her own OB has
no recommendations to make, we put her in touch with a clinic or
gynecologist who we feel is safe. We don' t generally get involved with
ethics committees or such, as long as the pregnancy is under twenty86. See supra Part I.A. As for the general accuracy of tests, with some diseases, such
as Down's Syndrome, genetic testing can conclusively detect whether the disease is pres
ent. With other diseases that are caused by multiple mutations, geneticists are less specific
because to give a 100 percent assurance that the disease is not present would require test
ing for the presence of all causative mutations. Consider that more than 230 mutations
have been documented as causing cystic fibrosis, AssESSING GENETIC RISKS, supra note 9,
ch. 2, at 3, and no lab in the world is currently set up to test for all of them. According to a
confidential source in the Houston area, at least with the most common commercial test
ing, market competition between Houston facilities has pushed genetic screening providers
to the point of offering the highest degree of certainty at a fair price. For example, the
reason that one Houston lab does a cystic fibrosis test for 24 mutations (the highest in the
industry as of July 1993) is that other laboratories in Houston had already reached the
point of testing for 12, then 14, and then 17.
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four weeks and the hospital has no policies about doing so. Generally,
termination is either by induction of labor or by dilation and evacua
tion of the uterus (D&E),87 depending on what the fetus's gestational
age is, insurance coverage, whether an autopsy is needed, whether
parents wish to view the baby, and other factors. If the parents do a
labor induction, viewing the baby is encouraged because psychological
literature shows that creating memories helps in resolving the grief by
making the baby and diagnosis real . Basically, it says to the patient,
"You really were pregnant; there really was a baby; there really was a
disease; and here's physical proof."
We are more likely to involve hospital ethics committees if the
couple is continuing a pregnancy but does not desire "heroic" care
after delivery-for instance, if the baby is known to have a lethal con
dition like anencephaly (the baby will be born without a developed
brain due to a failure of the neural tube-the precursor to the spinal
cord and central nervous system-to close). It helps in these cases to
make sure in advance that both the neonatologists and the mother
(and father, if involved) are in agreement as to what constitutes "rea
sonable and humane care." I know of more than one woman who
decided not to deliver at the tertiary care center because the ne
onatologists and she could not come to agreement on the care of the
baby after delivery. In my view, the OB is the mother's doctor, not
the baby's, so the OB cannot really influence these decisions.
Sometimes a hospital policy may be such that the baby doesn't
have to be given to a neo's care immediately after delivery, but, still,
calling the neo or the ethics team is hard to resist-especially if the
baby's diagnosis is tentative. A variety of factors play in here: (1) an
unprepared staff may not be aware that the specific diagnosis isn't
needed if the possibilities are all fatal; (2) staff tend not to use cost as
an immediate decision-making factor, even if they are aware of the
potential financial burden since, in the United States, staff are trained
to make full attempts at saving all lives regardless of costs; and (3) the
potential legal liability of not calling in other specialists can be devas
tating if the patient were to sue later.
*

*

*

A few couples have inquired about putting a baby with a genetic
condition up for adoption. National organizations for conditions like
Down's Syndrome and spina bifida state that they have lists of couples

87. The techniques used for performing a late-term abortion are summarized infra
note 117.
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wanting to adopt children with these conditions.88 I haven't worked
with any couples who have pursued this option prenatally. Even those
who have investigated it seriously have ended up not doing it. I get
different answers as to why. Some say it would be completely against
their morals to knowingly bring a child with a genetic disease into the
world and then not be willing to care for the child. One girl said that
she was going to adopt out the baby if it were healthy but not if it had
a genetic disease. Her reason was that she would always wonder if her
child was getting enough love and support, and to know that her child
needed that much more love and support because of its condition
would make her worry even more. The few parents I've met who
have pursued the adoption option have done it when the b aby was
born with an unexpected genetic disease and, after trying to take care
of the child within their own family, they found that they just couldn't.
The only family I've ever encountered personally who had adopted a
child with a known genetic disease first got involved with children
with genetic diseases through foster care and then moved to adoption.
A lot of the saddest cases seem to occur when the anomaly is not
discovered until after twenty-four weeks and the patient is left with no
legal option other than to deliver, or when the patient would like to
terminate but doesn't have the financial resources-for instance, if the
mother is on Medicaid and state funds aren't available for termination
(federal funds can't be used for this currently).89 Some of the diagno
ses that are made late could have been made earlier if more aggressive
care had been sought. But sometimes OB care isn't started before
twenty-four weeks, or sometimes the OB doesn't scan for physical
anomalies until after twenty-four weeks. The most frustrating cases
are when an OB scans early, thinks he sees something, but then waits
to see what happens rather than directly referring the patient for a full
evaluation. For some really severe conditions, like anencephaly, the
doctors can end the pregnancy at any point so long as they can pro
vide proof of the diagnosis, but there is some controversy over the
conditions that justify this and the proof needed.90 If there is any
88. See infra note 147 (addressing the availability of families willing to adopt children
with health impairments).
89. Subsequent to the time the author transcribed this narrative, the Clinton Adminis
tration changed the policy regarding federal funding of abortions. Under the present pol
icy, states must now pay for the abortions of poor women impregnated through rape and
incest. See Medicaid Abortion Rule Seen as Peril, BosTON G LO BE Jan. 6, 1994.
90. According to one confidential source, another option for these patients is to refer
them to states such as Kansas where one can legally terminate a pregnancy for genetic
abnormalities up to 30 weeks. The cost j ust for the abortion procedure, based upon 1 993
,
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doubt about the diagnosis or the patient's agreement with the decision
to end the pregnancy, doctors tend not to offer this option.
Any couple who has a pregnancy with a genetic disease, whether
they terminate or not, has to go through a mourning process. Tuey
mourn the loss of the normal child they hoped to have.91 No matter
how glad they are that they terminated the pregnancy or how much
they love the health-impaired child they decided to have, they still will
be saddened for the loss of the child or the things their child cannot
do. Both men and women grieve this loss, though they often do it
differently. As part of the grief counseling, we try to make couples
aware that they may grieve differently, but that they both will grieve.
*

*

*

"What would you do in my situation?" People are always asking
that of counselors. Although we are supposed to be nondirective,92
many people have no idea what to base their decision on. How direc
tive is it to talk patients through the decision-making process? By
"talking through" I mean discussing the things I would consider and I
see others considering, such as: How stable is my marriage? Am I
financially capable of raising this child? Is my job flexible enough to
handle this? Should I stay at home instead? Will I psychologically
and physically be able to handle the special needs of this child? What
would it be like to raise this child? How would having the child affect
my other children? What am I prepared to do and not do for the
special needs, both physical and psychological, of this child?
data, is $4,000, and, according to the facility I contacted, there are no general emergency
funds available to cover this cost. See generally Frank A. Chervenak & Laurence B. Mc
Cullough, An Ethically Justified, Clinically Comprehensive Management Strategy for Third
Trimester Pregnancies Complicated by Fetal Anomalies, 75(3) Os. & GYN. 3 1 1 (1990). Like
doctors in Kansas, doctors in Colorado and Florida are responsible only to their profes
sional colleagues, and abortions may be performed well into the third trimester. See also
infra note 140 and accompanying text.
91. The psychological impact of having a child with a health impairment is discussed
infra note 144 and accompanying text.
92. Nondirective counseling has been defined as follows:
"Nondirective" genetic counseling means that counselors refrain from giving
moral advice, even if asked, out of respect for the moral autonomy of patients.
Counselors encourage the patient or parental couple to make moral choices in
light of [the patient's or parents'] own values. This stance is the prevailing ethical
approach to genetic counseling in many nations.
Fletcher & Wertz, supra note 23, at 765; see Annas & Elias, supra note 44, at 216-17 (quot
ing conclusions of the Judicial Council of the American Medical Association, and stressing
that counselors should avoid the imposition of their personal moral values); see also infra
note 286 (comparing natural science training to social science training in the context of
counseling skills).
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There has been a fair amount of controversy on non directiveness
within the field. Some of the OBs and medical geneticists with whom
I have worked with will get directive, especially if they feel the diagno
sis is extremely severe or extremely mild. The concept of non direc
tiveness gets undefined when you realize that it's considered "sad but
okay" to terminate for sex chromosome anomalies that might have
nothing to do with IQ or general functional physical health, but it's
considered "bad and not okay" to terminate simply on the basis of the
fetus's sex-no matter how poorly that child might be treated because
of its sex. Telling someone that you consider his or her moral and
ethical judgment to be okay for one situation but not for another is
not non-directive. I think that it's about as directive as you can get to
assert your opinion over theirs to the point that a person who h onestly
admits sex selection can't get the same kind of care at your center as
someone who doesn' t admit that sex selection is the intention. I ' m
part o f the minority holding this opinion. I know that some centers
have "solved" this problem by either referring such couples to a
center known to permit sex selection (or prenatal paternity testing, or
whatever the issue might be), or by doing the "okay" testing-say, for
e xample, for a maternal age-related disease-but not releasing the sex
or the paternity results until later in gestation.
It's generally accepted that termination is the primary option for
most genetic diseases found prenatally. Fetal surgery and fetal ther
apy are coming along but are still far away from the point of general
clinical applicability.93 Anytime you do surgery on the fetus, you are
also doing surgery on the mother in order to access the fetus .94 The
benefit of doing the surgery prenatally has to justify the risk to the
mother, and often it can't.93 Currently, with very few exceptions, ben93.

See supra note 56; infra note 1 1 0.

94.

"We need to guard against imposing new technologies on patients, especially

when the potential, and unproven, benefit for one (fetus or child) depends entirely on the
acceptance of risk to another (pregnant woman or living related donor)."
Michaels et al., Ethical Considerations in Listing Fetuses

as

Marian G.

Candidates for Neonatal Heart

Transplantation, 269 JAMA 401, 402 (1993). With this concern in mind, it has been pro

posed "that any attempts at therapeutic genetic intervention be carried out only a) when
there is reasonable scientific evidence that it will cure or prevent a disabling disease, and b)
with the informed, voluntary, competent, and understanding consent of the individuals in
volved." Annas & Elias, supra note 44, at 215.
95.

An observation often overlooked is that advances in gene therapy may be accom

panied by increased obligations to fetuses: "[T]he medical profession has begun to focus
on therapeutic possibilities for fetal anomalies detected during the third trimester. As a
consequence, the concept

of the third-trimester fetus as a patient has emerged."
Chervenak & McCullough, supra note 90, at 311 (footnote omitted). See also Reece &
Homke, supra note 48, at Part VI (discussing how genetic therapy capability will enhance
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efits to t h e fetus from prenatal surgery are the same as they would be
if the surgery were done after delivery.
I think termination for fetal anomaly will always have to be a n
option. I f you ban termination, what is society prepared to d o to h e l p
these kids and their families-schooling, housing, therapies, medical
expenses, and so on? Some of these kids are pretty severe ly affecte d .
One o f t h e benefits o f prenatal diagnosis has been that people w h o
wouldn't have otherwise risked having another child with a genetic
disease have been able to complete their families. Many parents say
that they could handle a child with a genetic disease, but that they will
not bring such a child into this world, a world that does not accept
such children and their needs. The problem is that, if society is never
asked to accept these children and what makes them different, it never
will rise to that occasion.
B.

A Researcher's Story96

I can only speak from a pure research perspective. The way the
Human Genome Project is set up, most laboratories involved in basic
research are working on a specific chromosome or chromosomal re
gion. Many of these researchers are particularly interested in regions
that contain genes for various human diseases. There is some overlap
in this research. We have collaborators and competitors in Germany,
Japan, and Russia; all of us are using different techniques t o map and
analyze the same chromosomal region. Personally, I am working o n
finding and characterizing the gene for a specific disease that maps t o
this region on the human chromosome-a disease that can b e severe,
but generally only causes mild deformities.
There is a patient and family whom we used in a genetic-linkage
analysis before. The mother is pregnant now, and she has asked us to
do an a nalysis on the fetal DNA to see if the child has inherited the
disease.97 In this particular family, I can tell her if the child will have
the concept of fetus as patient);
in more detail).
96.

infra note

1 10 (discussing the possibility of genetic therapy
.

The fo llowing, transcribed from audiotape and edited by the author, is a narrative

compiled from several sources and discussions that took place during the spring of 1 993.
The audiotape, although confidential, is on file with the author.
97.

When questioned about direct contact between the public and researchers, a relia

ble source who wished to remain anonymous informed me that direct contact between
researchers and the public is becoming more common-highly educated a n d motivated
patients fi n d the names of researchers through published papers and track them down. To
avoid this, some institutions preven t their laboratory researchers from talking directly to
patients and accepting samples that have not come through acceptable channels. Counsel-

1 470

HASTINGS LAW JOURNAL

[Vol.

45

the disease with a high degree of certainty. She already has one af
fected child, and she ' ll abort this fetus if it has the disease. I am hav
ing some trouble with this because I do not think that it is that bad of
a disease. I really don't see why she would want to have an abortion.
It is hard for me because I will actually perform the analysis on the
DNA.
The lab is still trying to figure out if we can or should do it. This
is the first time a patient has bypassed doctors and counselors and
come straight to us. In fact, it would be the first time that we perform
this analysis for this explicit purpose. Up to this point, we have used
patient and family DNA provided by doctors or genetic counselors to
do genetic linkage for research purposes only. Consequently, this
analysis is "underdeveloped" in that it has not been rigorously tested
for these purposes. The liability here is obvious. We have written to
the legal advisor at our university to see what we can do. We are the
only lab at this point that has the genetic markers needed to do the
analysis, which leads to an obvious dilemma: if we turn down these
people, it will make it harder to get more DNA samples from them for
research. We collect DNA from these big families, from the grandpar
ents down to the newborns. What are they getting out of providing
samples if we don't give something back? What motivation are they
going to have to let us take blood to get DNA in the future? We have
a federal grant and, to keep that grant, we have to continue to collect
patients for research; we have to please people so that they keep giv
ing us DNA to foster our research.
What we think is that, since what we are doing is research, we can
write up a consent form that says this is research ; so long as we tell
them that the information is not completely reliable, we are safe from
liability. There is no funding board I know of that has said, "Research
labs, if you mess up a single research sample relied upon by someone
in the public who is told it's research, your funds are jeopardized."
There are human subject guidelines, and they are pretty good, but
they do not expressly address this issue; we do not have guidelines
about how to treat people.98 The grant funders want results, and too
ors, hospitals, physicians, and other genetics laboratories are all generally considered to be
acceptable channels.
98. Despite the four percent of Human Genome financing devoted to the ethics of the
project, AssESSING GENETIC RISKS, supra note 9, at 460, one genetic counselor has esti
mated that it will be several years before the ethical, legal, and social issues subcommittee
of HUGO releases consensus statements on clinical utilization, privacy, and insurance as
pects of the project. The International Bioethics Committee (IBC) of the United Nations
Educational, Scientific, and Cultural Organizational (UNESCO) is working toward an eth-
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many regulations will slow down results. As soon as researchers reach
a stage with sufficient results, there is pressure to get the test out into
a commercial lab. You throw the test over as soon as you can because
you do not want to take time out from research to run these tests.
When to hand the test over is pretty much decided internally at this
point. There are some regulations from the American College of Pa
thology (commonly referred to as "CAP regs"),99 but most decisions
are the product of internal decision making and good faith.
Reputation is important. Some premature tests are being kicked
out. It is worse with other countries; we are the powerhouse in sci
ence, so we do not need results to prove ourselves as much. At the
last Human Genome conference in San Diego in '91, Dr. James Wat
son 100 was critical of Japan . 1 0 1 The Japanese walked out. He was say
ing, "You guys are saying you have stuff befo re you really have it."1 02
Generally, though, scientists are pretty good. We have to be ex
tremely ethical because it is so easy to cheat. We also have to be in
credibly careful. The social norms are that, any mistake-you just
have to publish one wrong thing-and you are out of the profession.
*

*

*

I would like it if there were regulations to require counseling for
the public. It would give us an out with the patients when they walk
up to us and ask us to run a test. B ut patient demand can provide an
ics-based international agreement concerning human genome research and its application.
But this committee, elected in 1993, is likely to produce results in accordance with its four
year term, meaning 1996. See /BC Explores Bioethics Pact, HUMAN GENOME NEws, Mar.
1994, at 4. For a discussion of domestic United States guidelines, see infra Part IV.A.1 and
2.
99. For a discussion of these regulations, see infra Part IV.A.1 (discussing these
regulations).
100. Watson, along with Frances Crick, identified the double helix structure of DNA
and won the Nobel Prize for medicine in 1962 for this discovery.
101. See Koshland, Sequences and Consequences of the Human Genome, 246 Sc1ENCE
1 89, 189 (1989); Annas, Monster Mythology, supra note 17, at 645; infra note 1 02.
102. Although there is a considerable degree of cooperation within the international
scientific community, through its open support of the Human Genome Project, the United
States has provoked what approaches constituting a cold war in genetic technology. The
fact that the United States scientific community is internationally respected for the accu
racy of its work raises an interesting question regarding the financing of the Human Gen
ome Project:
[TJhe Genome Initiative has already led to speculation about its role in interna
tional economic competition and to suggestions that the Japanese are not playing
fair and should be cut out of any international information exchange on the gen
ome. What role does, or should, international economic competition play in de
ciding how much federal funding should go to the Genome Initiative?"
Annas, Monster Mythology, supra note 17, at 645 (footnote omitted).
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incentive to move research along, both inside and outside of the lab.
If you do not have a patient saying "Do the test, do the test," will you
still have a force to push research to the commercial level? The por
tion of the Genome budget going to ethics concerns has not accom
plished anything yet. I want them to make some rulings, to say you
have to do this and that and that I have to tell patients "No." I want
to be able to say, "I can't because the NIH says 'No."'
C.

A

Parent's Story103

At the beginning of my pregnancy, my obstetrician gave me a
pamphlet that outlined some prenatal testing options. Everyone told
me, "Oh, don't take those. You get a lot of false positives." But I
decided to take an alpha-fetoprotein (AFP) test, which is just a simple
blood test. It can determine the possibility of Downs, spina bifida,1 04
and other common diseases. I had miscarried during my first preg
nancy, and I just felt the need to take it. I said, "There's not going to
be anything wrong. I don't have a family history of any of these dis
e ases. Let me just take it anyway."
103. This story is the result of an interview I conducted on July 19, 1993 in Houston,
Texas. Although "Jennifer" is not this subject's real name, the experience and words are
her own. My research method, the same method I used to gather the other stories
presented in this Article, was to conduct an interview, transcribe that interview from
audiotape, edit it into a coherent "story," and then give the subject at least one opportunity
to review it for accuracy.
104. "Spina bifida," which is Latin for "spine that is split in two," arises during the
fourth week after conception-a time when many women do not even know that they are
pregnant, and the embryo is no larger than a grain of rice. In normal embryos, a flat strip
of cells running down the center of the embryo folds in on itself and sinks into the center of
the embryo. Beginning in the middle, the outer edges of this strip of cells meet, forming a
tube. Ultimately, the upper end of this tube will become the brain and the lower end will
become the spinal cord. Spina bifida arises when the cells fail to form a tube and sink into
the embryo. The result is a jarring mass on the back and an open lesion. The higher the
location of the lesion, the more severe the disease. Treatment for a child born with spina
bifida involves (1) covering the lesion with a fold of skin to prevent infection, (2) placing a
shunt (or tube) in the child's skull and down his or her neck to drain spinal fluid, which
tends to build up in the brain, and (3) therapy and surgery to enhance functioning capabil
ity. The prognosis for severe forms of the disease generally includes no walking, no sitting
without support, problems with respiration, neurological problems, lack of mental ability
resulting from malformation of the base of the brain, no bladder function, no bowel func
tion, and many surgeries.
The preceding discussion of spina bifida has been excerpted from LISA BELKIN, FIRST,
D o No HARM 212-16, 221-30, 251-52 ( 1993) (a reporter's account of the Hermann Hospital
ethics committee). The reality of spina bifida is narrated through the story of Claire and
Kenny Sparks and their first child, Landon, who was born with a severe case of spina
bifida. It is also a story of how, because Claire and Kenny were unable to make a decision
on their own, the ethics committee at Hermann Hospital in Houston, Texas was involved in
their decision to save Landon 's life.
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So at my sixteenth week of pregnancy, I took the AFP. This was
in the fall of 1990. The results took about two-and-one-half weeks
and, during that time, I didn't think much about it. When I went in for
my regular check up, my OB came in and started measuring me . He
was a male, and he started talking to his nurse, saying, "I think it's just
that her due date is off." I had forgotten that I even took the AFP test
and that there could be a problem, so I interrupted with, "Are you
talking about me?" He sat down with me and told me that my AFP
readings came out high. He said that a high reading could mean twins,
a wrong d ue date, or spina bifida. When he strongly encouraged me
to go through genetic counseling, I started panicking. To calm me
down, he said, "Until you can get into UT [the University of Texas]
which has the high-powered, level-three ultrasound, let's j ust do an
ultrasound here in my office with the equipment I have." Throughout
the ultrasound, he did not say a whole lot. Later on, I found out that
he did see the problem in that he could tell there was only one fetus.
The only remaining possibilities were a wrong due date, false reading,
or spina bifida.
My OB referred me to UT on a Thursday, and I had an appoint
ment for genetic counseling on the following Monday. At that time,
my husband was concerned, but I think I was in total shock. It did not
even phase me. I went into the first counseling session alone and with
a very positive attitude. I kept telling myself that there was no family
history, I was a healthy person, and I felt fine. The session lasted for
about an hour, and during that time the counselors gave me statistics,
carefully explained what spina bifida is and the range of severity, and
told me what my chances were for having a baby with the disease .
They also told me that, if genetic testing detected a problem, I would
have a choice and that they would help me through that. At that
point, I still was thinking, "I don't fit into any of the high-risk groups,
and I have taken good care of myself," but I wasn't quite as sure that
there would not be a problem. The counselors definitely gave me a lot
more to think about.
I was scheduled for an amnio on the following Wednesday.105 My
husband and I went in for a second, short counseling session and then
went in to get the amnio. They had told us that first they would take a
glance with the ultrasound to see if they could spot something severe
and then do the amnio. So we went in expecting to get an ultrasound,
an amnio, and then wait about two weeks to get the result. I laid there
105. The amnio procedure is discussed supra note 48.
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as they did the ultrasound, not thinking much of it. The doctors were
taking a close look at everything, and they did not say much. It
seemed like two hours-picture after picture, after picture, and doc
tors kept coming in and out (probably discussing what they saw be
hind closed doors). When they finished, they said, "Let's take a
break." My reaction was, "What about the amnio? " but they told me
that they wanted to talk first.
When my husband and I went into the counseling room and I saw
my genetic counselor there, I knew something was wrong. I did not
expect to know right away-to know right then. They basically con
firmed that the baby had a severe case of spina bifida and, if the baby
even lived to its due date, it would be born with severe nerve damage.
That was when I fell apart. My husband and I had talked about it
before, and we had decided that our decision would be based on the
severity, on the child's potential quality of life, and on the fact that the
world we live in is hard enough without going through life with a se
vere case of spina bifida. Neither my husband nor I could watch a
child suffer through life, and we agreed 100 percent that we were go
ing to terminate the pregnancy due to the circumstances.
The procedure was scheduled for the next day. I hadn't felt any
movement throughout my pregnancy, but I felt a slight movement that
day. That was very difficult. My family, genetic counselor, and the
doctor who performed the procedure got me through it all. They were
all great. The doctor (whom I became a regular patient of) tends to be
conservative, and it is her practice to reevaluate the case before per
forming the procedure to make sure that the patient is well-informed
and certain. She told us that there was no grey area in our case, and
that put me at ease.
The actual procedure was horrible. I didn't think that it would be
that painful and last so long. They used a saline solution and induced
labor at about 1 1 o'clock that morning, and I did not start to get con
tractions until about 1 1 o'clock that night. They were mild at first, and
I even sent my husband home to get a shower. By the time he got
back, the pain was absolutely incredible, and he heard me screaming
as he came down the hall. I have never experienced pain like that; it
felt like the fetus was being pulled out of me. I just kept thinking, " I
a m going to get nothing out o f this." I n fact, I was worried that the
baby would be born alive, but I was assured that it wouldn't happen.
When the baby was delivered, they encouraged me to see it and
spend time with it to help me through the mourning process. It would
be real small but fully formed, with the exception of the effects of the
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spina bifida. But I just couldn't do it. We did hold it, but it was
wrapped. They told me that they would keep a picture on file for a
year, in case we changed our minds. We never did.
I have had a healthy child since, a little girl. She's wonderful. I
got pregnant with her unexpectedly just four months after the termi
nation. I read everything I could get my hands on that was about
spina bifida, and I decided to have an amnio at twelve weeks. That
was a tough decision. I kept thinking, "I lost one child, terminated my
second pregnancy, and now I might endanger my chance of having a
healthy child by running this test." But I wanted to know and to avoid
carrying another child late-term, only to then terminate the pregnancy
because of another bad case of spina bifida.
*

*

*

After the termination was over, I told my counselor that, if she
ever formed a support group, I wanted to be part of it. I thought that
it would be great to help others going through the experience and
feeling the loss. A support group has been formed since then, and I
am a very active member. Even with having my daughter, I don't
think that you ever completely get over something like this, and it
helps to talk.
If I could speak to the world, the one thing I would like to say is,
"Unless you have stood in my shoes, you shouldn't judge me. Every
one should have a right to choose."
D.

A

Family's Story

Bobby Lachapelle, usually called "little Bobby" because his dad
and grandfather share the same name, is ten years old. He is smart,
handsome, and likes attention-no, he demands it. Wheelchair or no
wheelchair, he has a way of always being everywhere and making his
sisters constantly call for their mother.
Bobby has spina bifida.106 In fact, he has meningomyelocele, the
most severe form of the disease. His parents, Roni and Bob, own an
106. See supra note 104 (discussing spina bifida in detail). Unlike Bobby, Landon
Sparks has not done well. Although he was a bubbly child who loved to talk, listen to
music, and play games, after nearly two years Landon developed bronchitis. As is com�on
with spina bifida children, infection set in and Landon's fever rose to 105 degree� durmg
the course of one night. Claire and Kenny awoke at 3 a.m. to find Landon in the m1�st of a
violent seizure, and he sustained severe brain damage. Landon was connected to hfe s�p
port and, this time, Claire and Kenny were able to make a decision without th� ethics
committee-they decided to tum Landon's ventilator off. But when the machme was
turned off, Landon continued to breathe. The end result is as follows:
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oil business and service station in a small New England town of four
teen thousand. Many of their neighbors are also relatives and friends.
B esides Bobby, Bob and Roni have three girls-Liz, who is twelve,
eight-year-old Jessica, and six-year-old Alison. Bobby is not treated
special; his parents expect just as much from him as they do from his
sisters, and when he misbehaves, which is pretty often, he is scolded
for it.
Because Roni already had Liz before she became pregnant with
B obby, she knew what to expect. And, when carrying Bobby, Roni
experienced nothing unusual; it was a perfectly normal pregnancy.
But the delivery did not go well-that was when the doctor knew
something was wrong. After a struggle with forceps, Bobby was deliv
ered. Almost immediately, Roni and Bob were told that their child
needed to undergo a major operation.
There was never any question about closing the lesion on B obby's
back.107 The doctors basically told Roni and Bob that their baby was
The Sparkses don't go out much. Money is tight-most of it goes to pay Landon's
medical bills-and there are few baby-sitters who want to stay with an unrespon
sive four-year-old. Landon has developed bedsores on his back, which make it
nearly impossible to put him in his car seat and take him out of the house. It has
been a long time since Claire has gone any place other than the doctor, the chil
dren's school, her local church, or the Baytown[, Texas] mall.
B ELKIN, supra note 104, at 264.
107. If the lesion on the back of a child born with spina bifida is not closed through
surgery soon after birth, infection will set in and the child will die. In many hospitals, at
least when a child is born with a severe case of spina bifida and the child's parents are
unable to reach a decision as to whether they would like to pursue treatment, an ethics
committee may become involved in the decision. See generally BELKIN, supra note 104.
The same is true when a child is born with a mild or moderate case of the disease and his or
her parents decide not to pursue treatment although, under these circumstances, the ethics
committee may make the ultimate decision-possibly deciding to treat the child despite his
or her parents' objections. Id.
Often, parents like Claire and Kenny Sparks simply cannot reach a timely decisionthe kind of decision that must be made when facing the threat of infection:
Families already feel guilty in a situation like this. They're probably imagining
everything they might have done to cause the situation in the first place. They'll
only compound that guilt more by sitting and letting a baby die. They've come
nine months through the waiting process, they've bonded to the baby even before
it's born, and then suddenly there's a calamity. It's always met with guilt. They'll
entertain the idea of withholding treatment, but in the last analysis almost all of
them change their minds.
Id. at 238.
Claire and Kenny were brought in to meet with Hermann Hospital's ethics committee,
and their experience offers insight as to the committee's decision-making process. The
committee reached the following opinion:
What needs to be considered in this opinion is whether the benefits of surgical
closure outweigh the burdens incurred by the procedure. The procedure is pallia-
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going into surgery. Roni and Bob did not even know about Bobby's
paralysis until after the lesion had been closed. It was then that they
started to get the information and to understand-that is, to under
stand the costs, having to deal with insurance companies and schools,
and developing long-term hopes. Their names were given to support
groups, and they received telephone calls from others who had al
ready gone through much of what they were being told was before
them and their son� Eventually, Roni and Bob would be able to talk
with these people, and it would help.
Beyond his spina bifida, Bobby is different. Along with the pu
rity and honesty that you generally find in children, Bobby has the
depth and awareness of his mortality that is acquired through survival.
This quality is also readily apparent in his older sister Liz, and I expect
that it is in his younger sisters as well.
Bobby and his family live with his spina bifida by accepting it and
persevering the physical, financial, and emotional challenges it
presents on a daily basis. One time, after helping Roni pack her kids
into her station wagon, I asked her how she does it as we walked
around to the driver's side and she got into the car. Bobby, out of his
wheelchair and thrilled with his enhanced mobility in the back of the
car (Bobby has incredible upper body strength) and the opportunity
to tease his sisters, was already doing so. After looking in the rear
view mirror and letting out a forceful "BOB," Roni looked up and,
without the slightest hesitation, said, "You just do what you have to."
tive and will provide comfort to this baby. Therefore, the opinion of the IEC is
that surgical closure is appropriate.
Id. at 246.
Nevertheless, although the ethics committee's opinion was delivered in a directive
manner, because Landon's condition was so serious, the ultimate decision belonged to
Claire and Kenny:
"You've already heard from three doctors that you can do one of two things," Dr.
Oelberg said, ticking off the options from pinkie to thumb as he spoke. "These
doctors aren't crazy, and they aren't incompetent. They're all very good doctors.
They're disagreeing, and doctors will always disagree. So it's not that one is right
and one is wrong. They're both right, depending upon what fits in with your
family. There are plenty of babies who come through here with a meningomy
elocele who can bring a lot of happiness to their parents. He's not going to play
football. He may h ave problems at school from a cognitive point of view. But he
may bring you just as much joy, if not more, than someone who starts out as a
perfectly normal baby."
He paused, and then gave the persuasive push he had promised the Ethics
Committee. "I would recommend that you repair it," he said. "If you feel other
wise, I'm willing to consider that, but I recommend you repair it. Otherwise I'm
afraid you'll spend your life wishing that you had."
Id. at 46.
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The Common Themes

The preceding stories are linked by common themes. The prac
tice of prenatal genetic screening is being largely left to the discretion
of the medical profession and it is being performed for prospective
parents, not for their fetuses.108 Prenatal genetic screening is about
offering prospective parents difficult choices regarding the sacrifices
they are willing to make to be parents, what mental and physical char
acteristics their children will have, and what kind of lives they want
their children to have at a time when abortion is still an option. The
assumption underlying voluntary genetic screening is that prospective
parents will be given the information obtained and be allowed to act
on that information. 1 09 The choices created through prenatal genetic
screening (whether to undergo genetic testing, which tests to run, the
option to end a pregnancy based upon a broader spectrum of test re
sults) will expand along with prenatal testing capability.
Although gene therapy will eventually create additional op
tions,1 1 0 today, only two options are given to prospective parents who
108. As explained by one observer, "[t]raditionally, the ethics of prenatal genetic coun
seling has required that prospective parents be given full information and then be allowed
to choose which, if any, genetic diagnostic tests to pursue." Nolan, First Fruits, supra note
46, at 53-54.
109. Driven by a desire to know, many parents will undergo genetic screening even if
their only option is to deliver their child:
In examining women at risk for having children with sickle cell disease, one inves
tigator who interviewed thirty women found that the majority of them would
want prenatal diagnosis even though only one quarter would abort an affected
fetus. Another group of researchers who looked not at what women said but
what they did found that of twenty-two pregnant women who were at risk for
having a child with sickle cell anemia, fourteen had amniocentesis, and of the four
fetuses found to be affected, three were aborted.
Clayton, supra note 74, at 1 1 6 (footnotes omitted).
1 10. See SoRelle, supra note 54 ("The March of Dimes believes gene therapy may soon
become the most important and powerful weapon against birth defects and disease in
human history."); Alexander Morgan Capron, Which Ills to Bear?: Reevaluating the
" Threat" of Modern Genetics, 39 EMORY L.J. 665, 674 (1990) ("In 1989, the HGTS [Human
Gene Therapy Subcommittee] and the RAC [Recumbent DNA Advisory Committee] rec
ommended, and the Director of NIH approved, the first officially sanctioned use of recom
binant DNA technology in the treatment of human beings."); see also Richard Saltus,
Doctors Try Gene Therapy on Clots, BosTON GLOBE, Sept. 17, 1994, at 29, 32 (addressing a
test for cardiovascular disease intended to provide new blood circulation in the legs of
patients with artery blockages). The Clinton Administration's removal of restrictions upon
research involving fetal tissue is likely to have a profound impact on the advancement of
this technology. See Fletcher & Wertz, supra note 23, at 755-56 (discussing how the Bush
Administration's policies regarding federal funding of research involving human embryos,
the fetus, and fetal tissue restricted this research); see also HOLDER, supra note 38, at 50-81
(discussing fetal research and relevant regulations during the mid-1980s). SCientists may
also develop the technological capability to identify and manipulate environmental factors
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rec�ive genetic scree �ing test results indicating a genetic abnormality:
. children
.
de � ivenng
with a known health impairment or propensity for
bemg unhealthy, and terminating the pregnancy. Despite our soci
ety's �eneral discomfort with late-term abortions, several states permit
abortion beyond the point of viability when a severe fetal abnormality
is detected.1 1 1 Viability is generally considered to occur at the end of
that interact with genetic abnormalities and help to determine whether those abnormalities
will cause health impairments or remain dormant. See Elsas, supra note 36, at 813.
Moreover, technological advances in testing may enable prospective parents to detect
genetic abnormalities at a much earlier stage in pregnancy, thereby eliminating the demand
for late-term abortion. For example, fetal blood aspiration from the umbilical cord has
been the subject of research involving both diagnosis and therapy. See Sachs & Korf, supra
note 1, at 460; Leon Jaroff, Brave New Babies, TIME, May 31, 1993, at 56-57 (discussing
three landmark experiments involving gene therapy to cure rare hereditary diseases
through the use of stem cells collected from umbilical-cord blood). In the future, scientists
may be able to isolate fetal cells from the maternal circulation and use them for diagnostic
purposes, thereby facilitating prenatal testing for every patient. See Sachs & Korf, supra
note 1 , at 460. Similarly, in-vitro fertilization creates the possibility of identifying genetic
abnormalities outside of the womb. See Elmer-Dewitt, Catching a Bad Gene, supra note
48. Moreover, visible deformities may be seen as early as six weeks through techniques
such as embryoscopy. See supra note 49. Despite these possibilities, however, the present
reality is that we will not be able to avoid late term abortion in the near future:
Although scientists have identified about 5,000 inherited diseases that could, in
theory, be spotted in young embryos, including Huntington's disease and sickle
cell anemia, gene screening to catch these disorders is not likely to b e widely
available anytime soon-at least in the U.S. For one thing, it requires couples to
go through in-vitro fertilization, a costly ($5,000 to $13,000) procedure with a suc
cess rate hovering around 10%. The gene-screening test adds an additional
$2,000 for each in-vitro cycle, a bill the U.S. insurance industry has already indi
cated it has little interest in footing.
Elmer-Dewitt, Catching a Bad Gene, supra note 48.
1 1 1 . See infra note 140 (citations to state statutes). Prior to Roe, many states adopted
this exception through their implementation of the Model Penal Code, which provides that
a mother may abort a severely defective fetus even in the third trimester regardless of
whether the fetus is considered viable. See Rush, supra note 55, at 122 (1983). Ironically,
Roe v. Wade, 410 U.S. 1 13 (1972), synonymous with the right of women to terminate their
pregnancies, limited this exception to the point of viability (the end of the se�ond trim�s
ter), for in Roe, the Court identified viability as the point in which preserving feta! hfe
becomes compelling. See Rush, supra note 55, at 125. Adding to this irony, tw� widely
reported episodes involving fetal abnormality that occurred in the decade proceeding Roe
are credited with turning public sentiment in favor of legalizing abortion, and thereby mak
ing Roe possible: (1) the story of Sherri Finkbine, a mother fro� �rizona who h�d ta�en
tde
thalidomide ' a sedative prescribed to ease morning sickness, while m Europe; thahdom
d
an
1950s
the
in
was discovered to cause severe birth defects m approx1mateIY 8 ,000 babies .
.1 able m
avai
still
as
but
�
1960s ' and it was removed from the United States market. in 1962,
also known
other countries until later; and (2) an outbreak of rubella .m 1962-65 ' which was t 53 at
no e
a
to cause blindness, deafness, and severe mentaI retardation. See TRIBE' supr
.
37-38.
. . . s that forb1.d doctors from performing
Many states have expressly codified proh1bitwn
NN. art. 4495b' § 4.01 1 (West
abortions on viable fetuses. See, e.g., TEX. REY. Civ. STAT. A
·

·

·

·

·

•

HASTINGS LAW JOURNAL

1480

[Vol. 45

the second trimester-that is, during the twenty-third or twenty
fourth week of pregnancy. 112
Therefore, the availability of prenatal genetic screening and the
parental choices it creates are issues that weigh heavily upon procrea
tive liberty113 and implicate abortion jurisprudence. The following is
an analysis of prenatal genetic screening in the context of each of
these more familiar and broader frameworks.

Supp. 1993). The laws of those states that have closely followed the Model Penal Code
despite Roe-Kansas, for example-thereby allowing abortions for fetal abnormality in
the third trimester may soon be changed to acknowledge the viability cut-off. Specifically,
in its recent Casey decision the Supreme Court dispensed with the trimester framework
altogether and further emphasized the importance of viability. See Planned Parenthood v.
Casey, 505 U.S.
1 12 S. Ct. 2791 (1992).
_,

1 12. See Michael J. Flower, Coming Into Being: The Prenatal Development of
Humans, in ABORTION, MEDrCINE, AND THE LAW 437-51 (J. Douglas B utler & David F.
Walbert eds., 1992). Technology is unlikely to push the point of viability-the ability to
live apart from one's mother-much earlier than the twenty-third week of pregnancy due
to the surge in fetal lung development which occurs at that time. See id; see also Charles A .
Gardner, Is a n Embryo a Person?, in ABORTION, MEDICINE, AND THE LAW, supra, at 456;
Claudia Wallis, Advancing Technology Further Complicates a National Dilemma, TIME,
July 6, 1 987, at 82 ("Even at the most sophisticated hospitals, babies born before the 24th
week of gestation or weighin g less than 500 g (1.1 lb.) have virtually no chance of sur
vival."). Nevertheless, some doctors believe that technology will shift the point of viability
well into the second trimester:
A handful of U.S. medical centers now use a constellation of devices that can
assume some heart, lung, kidney and even digestive functions for full-term babies
born with certain problems. Because the machines require the use of anticoagu
lants, they do not work for most preemies, who risk brain hemorrhages if given
such drugs. But should technology leap this hurdle, it could reduce the viability
standard to an absurdity.
Wallis, supra, at 82.
1 13. The procreative liberty issues arising from genetic screening are discussed in Robertson, supra note 36, at 697:
B ecause the genetic knowledge at issue is relevant to individual or marital choices
about reproduction, these issues may be usefully viewed through the lens of pro
creative liberty. Does a couple's right to reproduce or avoid reproduction give
them a right of access to this information? May decisions to conceive or continue
a pregnancy be made on genetic grounds? Must couples learn their carrier sta
tus? Must they act on this information?
See also John R. Harding, Jr., Note, Beyond Abortion: Human Genetics and the New
Eugenics, 18 PEPP. L. REv. 471, 504 (1991) ("Advocates of privacy rights in the use o f
genetic engineering argue that regulating positive genetic engineering may precipitate a

collision between the constitutional values of procreative liberty as well as equal opportu
nity.") (footnote omitted).
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In the Context of Abortion

Abortion provides a means to avoid the violence inflicted upon
unwanted children, 1 1 4 and it often follows the violence of nonconsen
sual intercourse.

Nevertheless, witnessing a first-trimester abortion

performed through a basic dilation and curettage• 15 is enough to es
tablish tha t abortion is a violent act. 1 16 Even many of those who do
not question the right of wome n to choose whether to carry fetuses to
term are not comfortable with late-term abortion, 1 17 which is reflected
by the fact that very few doctors are willing to perform this procedure
voluntarily. 1 1 8
1 1 4.

Although only 1 .2 percent of all abortions are per-

See generally Malinowski, supra note 73, at 209 n.101 (discussing foster care hor

ror stories).
1 1 5. This procedure, the most commonly applied, is discussed infra note 1 1 7.
1 16. Despite the fact that the majority of my students identified themselves as "pro
choice," this was their general consensus after viewing The Silent Scream, a movie pre
pared by pro-life advocates that uses ultrasound technology to show the abortion of a fetus
at 12 weeks. Class Session, Abortion, Medicine, and Social Choice, University of Houston
Law Center (Mar. 8, 1 993).
1 1 7.

The techniques available for performing late-term abortions reflect the violence

in nate to this procedure:
Dilation & Evacuation ("D &E"): The cervix is dilated, and the physician then dismembers
the fetus, crushes its skull, and vacuums it out. This is the most widely accepted and prac
ticed procedure. Although the physician must be certain that the evacuation is complete,
the procedure is relatively quick and inexpensive, and causes fewer side effects, less stress,
and less discom fort for the patient. D&E also removes any possibility that the fetus will be
born alive.
Fetal Intracardiac Potassium Injection : The fetus's heart is injected with potassium, which
causes cardiac arrest and eliminates the danger of del ivering a viable fetus. This technique
is used in conjunction with one of the other techniques.
·

Hysterotomy:

The physician performs a mini-caesarean to remove the fetus from the

uterus. This procedure involves the most invasive surgery, carries the highest risk of mor
bidity and mortality, and is the least practiced method.
Prostaglandin: The physician administers prostaglandin (a drug internationally recognized
as an accompaniment to RU486) by direct injection into the uterus, intravenous infusion ,
o r by vaginal suppositories. The prostaglandin induces contractions and other physiologi
cal activity associated with normal labor. Expulsion takes an average of 12 to 24 hours,
and the patient usually requires hospitalization. The side effects include vomiting and diar
rhea. The fetus is delivered whole, and there is a danger of it being delivered viable.
Saline Method: The physician injects hypertonic saline solution directly into the amniotic
sac, the fetus is burned by the solution , labor is induced, and the physician then delivers the
dead fetus. The entire procedure takes approximately 12 to 24 hours, and it usually re
q uires hospitalization. The side effects include vomiting and diarrhea. The fetus is deliv
ered whole, and there is a danger of it being delivered viable.
See JONATHAN B. IMBER, ABORTION AND THE PRIVATE PRACTICE OF MEDICINE 77 (1986);
John Fletcher, Fetal Intracardiac Potassium Chloride Injection to Avoid the Hopeless Resus
citation of an Abnormal Fetus: Ethical Issues, 80 OB. & GYN. 310-13 ( 1 986).
118. See Gina Kolata, In Late Abortions, Decisions are Painful and Options Few, N.Y.
TIMES, Jan. 5, 1992, at 1 ("These abortions [for cases of fetal abnormality] are legal in
about half the states, although most doctors simply refuse to do them."); see also Judith
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formed between weeks twenty-one and thirty-six of gestation, 119 the
demand for late-term abortions will be affected by the increase in the
technological capability to detect fetal abnormalities resulting from
the Human Genome Project, greater accessibility to this technology
through an increase in the availability of genetic counseling and test
ing services, and expansion of common knowledge about testing op
tions.120 Consider that, although a fetus may not be able to live apart
Gaines & Richard Saltus, Teenager Says Legal Abortion Denied, BosTON GLOBE, Jan. 16,
1994, at 29, 32 (teenager stating that she could not obtain a second-trimester abortion due
to the unwillingness of hospital staff to participate in the procedure). Hospitals creating a
demand for such services by performing genetic screening may stipulate that the doctors
working with them and referring patients to them must perform late-term abortions if a
genetic abnormality is detected in their patients. Peacock Presentation, supra note 79. Of
course, not all doctors refuse to perform late-term abortions because of ethical concerns;
many refuse to do so because of the increased risks (and liability) associated with this
procedure. Dr. Howard Praver, Class Presentation, Abortion, Law, and Social Choice,
University of Houston Law Center (Apr. 5, 1993) (a doctor with 25 years of experience
performing abortions and the director of the first Planned Parenthood clinic opened in
Texas after

Roe, who will not perform abortions on fetuses older than 14 weeks).

To fully appreciate the dearth of doctors willing to perform late-term abortions, con
sider that doctors have been pressured away from the abortion procedure in general. See
Tony Freemantle, Slaying Sparks Fear as Abortion Issue Slips on Agenda, Hou s. CttRON.,
Mar. 14, 1993, at 4A (discussing the shooting of Dr. Gunn-"the first fatality in the 20year-old war over a women's right to abortion"); Debbie Housel, Doctors Ask Judge to
Widen Protection from Protestors, Hous. PosT, June 23, 1993, at Al, AlO ("Claiming they
are tired of having their kids told that 'daddy kills babies,' tired of being called murderers,
of even being stalked, the.se doctors want a judge to give them the same protection from
anti-abortion activists that they now have at their clinics."); 60 Minutes: The Lambs of

Christ (CBS television broadcast, Aug. 23, 1 992) (discussing how the harassment o f doctors
and their families-for example, reaching doctors by subjecting their children to harass
ment at school-is pressing them away from abortion) . As a result, women are now taking
the procedure into their own hands. See 20120: Abortion Among Friends (ABC television
broadcast, June 18, 1993) (discussing the procedure for at-home abortion, the fact that
more than 2,000 women already have been trained to perform the procedure, and chroni
cling an actual at-home abortion); New Abortionist, The West (television broadcast Feb. 9,
1 992) (women training other women to perform do-it-yourself abortions) . Jn fact, during
the week of June 13-20, 1993, Planned Parenthoc;>d of New York announced that it is train
ing its own staff to perform abortions.
1 1 9. Lisa M. Koonin et al., Abortion Surveillance, United States, 1988, in ABORTION,
MEDICINE, AND THE LAW tbl. 14, at 477 (J. Douglas Butler & David F. Walbert eds., 1992).
120.

In short,

as genetic testing grows more sophisticated, the number of detectable fetal condi
tions will become larger, thus increasing the number of circumstances that could
lead to a decision to abort a pregnancy. The result may be that some couples will
abort a pregnancy not only when an untreatable disease is detected, but also
when a merely undesired condition, s uch as the "wrong" gender or eye color, is
detected. If aborting a fetus because it has Down's Syndrome is morally accepta
ble and aborting a fetus because of its gender is morally unacceptable, where is
society to place conditions such as dwarfism, myopia, or susceptibility to heart
disease?
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from i ts mother �ntil it reaches the point of viability, the fetus may
.
. .
cognitively
expenence pam as early as its twentieth week of develop
ment, for that is the point at which the rudimentary neocortex is in
place.1 21 Moreover, there is genuine concern that our control over life
at the genetic level will make life less special-that the miracle of life
will become less of a miracle when we routinely manipulate it in such
a fundamental way. 122 In the context of prenatal genetic screening,
this concern takes the form of a fear of eugenics: a fear that people
will abuse technology to have nothing less than the "perfect" baby, 1 23
and that there will be no acceptance of children like Bobby. 124 In light
Robert Wachbroit, Making the Grade: Testing for Human Genetic Disorders, 1 6 HOFSTRA
L. REv. 583, 596 ( 1988). However, as discussed supra note 1 1 0, technological advances
for example, the ability to remove fetal cells from maternal blood-may move our capabil
ity to perform genetic testing to earlier stages of pregnancy and to prevent genetic abnor
malities from resulting in genetic diseases through gene therapy and the manipulation of
environmental factors.
1 2 1 . Flower, supra note 112, at 445-46.
122. See Harding, supra note 1 13 , at 471.
1 23. "Abortion pits the rights of the mother against the rights of her child. Eugenic
genetic engineering juxtaposes our ability to be potentially free from disease, perhaps even
to reach the highest levels of human achievement, against the rights of all future genera
tions to live their lives free from genetic control." Harding, supra note 1 13, at 510; Theo
dore Friedmann, Opinion: The Human Genome Project-Some Implications of Extensive
"Reverse Genetic" Medicine, 46 AM J. Hu M. GENETICS 407, 4 1 1 (1990).
124 . Consider the words of Eileen Cronin-Noe, whose mother took thalidomide while
pregnant, causing Eileen to be born without legs:
For my parents, who did not have this knowledge, abortion was not an option
and would not have been even if they had been aware of my condition. My par
ents believe that it was God's decision, and they were content with that decision.
For this same reason, they did not pursue any legal action. For them, a lawsuit
never would have addressed the issue.
Their belief has led me to accept, even prefer, things for what they are.
Many people may find this dif?cult to be�ieve. They feel lucky ��at amnioc�ntesis
is available to screen out babies born with less severe deformities than mme.
This thought frightens me, because I know that amniocentesi� ca� ·� tell .any
parents what kind of child they will have. It can only tell what d1sab1hty might
exist in that child.
Amniocentesis could never have told my mother that I would have artistic
talent, a high intellectual capacity, a sharp wit and an outgoin� personality: The
last thing amniocentesis would tell her is that I could be physically attracti.ve.
mg to
My point is that we demean the value of an individual's worth by adher_
s
ional
profess
m�dical
worse,
is
most
a medical label such as "disabled ." What
a
-that
parents
e
to
prospectiv
convey
may
they
aren't even aware of the attitude
disabled life is not worth living.
. ed m Ho
Eileen Cronin-Noe "Thalidomide Baby" Grows Up, WASH. PosT, reprint
H
ep
st
CHRON., July 26, 1 9S7, § 7, at 5. �lso �onsider the �hysical impairments of .
0;
ca
lf
ing who, although so physically 1mpa1r�d that he 1s confine� to a wheelcha w. HA WK.
speak, has made a significant contribution to quantum physics. See STEPHEN
ING A BRIEF HISTORY OF TIME ( 1 988).
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of the option to terminate pregnancy based upon gene malfunctions
associated with health impairments, advances in the technology to di
agnose serious health impairments prenatally may retard the advance
ment of technology to treat those impairments and diminish tolerance
for biological variation. Ultimately, society may even develop a gen
eral tolerance for "characteristic shopping" on the part of prospective
parents.
Nevertheless, and especially in light of the present state of genetic
screening, valid arguments can be made to remove the viability cut-off
for legal abortions when severe fetal abnormalities are detected . 125
There are, for example,
clear examples of cases in which it is ethically justified to recom
mend alternatives to aggressive management, even when one re
gards the third-trimester fetus as a patient. Anencephaly and
triploidy are anomalies that can be detected with certainty. These
anomalies involve either immediate lethality or, in the rare cases of
short-term survival, the absence of cognitive developmental capac
ity . . . . Recommending nonaggressive management as an option is
j ustified because it does not increase the already unavoidable risk of
death . . . 1 26

It has even been suggested that, because the justification for prohibit
ing abortion at the point of viability is the state' s interest in preserving
the potential life of the fetus,127 the state's interest is lessened-and
the viability cut-off fo r abortion should be removed-when the fetus
is not healthy. 1 28 More palatable is the argument that, since the par
ents of a severely impaired newborn generally are given the option of
withholding aggressive health treatment {for example the parents of a
child born with severe spina bifida may be given the option of not
closing the child's lesion),1 29 the prospective parents of a fetus carry125. See Rush, supra note 55, at 130 ("A more fundamental question, however, is
whether, in the case of a mother seeking to abort a severely defective fetus, there should be
any viability criterion at all.").
126. Chervenak & McCullough, supra note 90, at 313 (footnotes omitted).

127. Planned Parenthood v. Casey,
Wade, 410 U.S. 113, 113 (1972) .

505

U.S.

_,

1 12 S. Ct. 2791, 2804 (1992); Roe v.

128. See Rush, supra note 55, at 119-20 (suggesting that, not only is the mother's right
to choose an abortion stronger in the case of a severely defective fetus, but also that the
state's interest in restricting such abortions is significantly weaker, so that at no point dur
ing the term of the mother's pregnancy does the state's interest become compelling enough
to allow it to prohibit such abortions.).
129. See ANSPACH, supra note 70; HOLDER, supra note 38, at 82-117; MEYERS , supra
note 70, at 105 ("Traditionally, in the United States, as in the United Kingdom, parents and
physicians have made decisions to allow seriously handicapped newborn infants to die by
not providing life-sustaining medical care. This practice has been judicially recognized.").
As explained by Meyers, courts consider a number of factors before compelling medical
treatment over the objection of parents:
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ing a genetic a?normality should not be forced to carry their fe tus to
term before bemg able to make that choice. no After all, such a child
has no chance of survival without the dedicated support, love, and
care of par�nts such as Roni and Bob Lachapelle. Such a relationship
ca �not b� tmposed through laws; properly caring fo r a seriously im
.
paired child reqmres the kind of dedication and unconditional love
that can on �y come voluntarily. The problem with this argument is
that our society has not acknowledged the fact that the choice not to
treat is already being made; these choices have been left to families
and the medical profession through widely shared but unwritten
norms. 1 31 As is discussed below, the potential for abuse of prenatal
genetic technology is simply too great for our society to avoid public
policy discussion of the issue.
B.

Beyond a Basic Exercise of Procreative Liberty

It is easy to overlook the fact that prenatal genetic screening (or
the opportunity to abort a late-term fetus based upon the presence of
a genetic abnormality) involves more than the basic exercise of proSeveral relevant factors must be taken into consideration before a state insists
upon medical treatment rejected by the parents. The state should examine the
seriousness of the harm the child is suffering or the substantial likelihood that he
will suffer serious harm; the evaluation for the treatment by the medical profes
sion; the risks involved in medically treating the child; and the expressed prefer
ences of the child. Of course, the underlying consideration is the child's welfare
and whether his best interests will be served by the medical treatment.
Id. at 104-05 (footnotes omitted).
130. The rationale undergirding this practice is that
[t]he law should not require more than reasonable conduct, for fear of discourag
ing compliance with unattainable or unfair standards of conduct. No one is better
situated than parents and physicians to act in the best interests of the infant . . . .
Fortunately, the law requires neither perfection or cure from parents or physician.
It does require that they act as reasonable persons would, in the circumstances,
act.
Id. at 109-10.
1 3 1 . See ANSPACH, supra note 70; BELKIN, supra note 104 (an "insider's" perspective
on Hermann Hospital's ethics committee); JAY KATZ, M.D., THE SILENT WoRLD OF DR.
AND PATIENT (1984); MEYERS, supra note 70, at 105-08. The Reagan A� mini�tration's
"John Doe" policy is discussed in ANSPACH, supra note 70, at 170-73. Th�s pohcy arose
after President Reagan was made aware of a case in which treatment was w1th�eld fro� a
child with Down's Syndrome ("John Doe"). The Ad�inistratio� re�ponded by mtrod �cm�
federal regulations demanding treatment for all babies born with a chance of su�vival.
These regulations were backed up with a threat that federal funding woul� be .withheld
s. No
from facilities violating them, and toll-free numbers were set up to report v10lat10�
1s
fact
the regulations The . . that
·
· 1 atmg
ever was found guilty of v10
doctor or fac1hty
·
hysicians �re
whether a baby has a chance for survival is generally a judgment call that �
e ethics
mvolv
and
nce
prude
use
able to make without being questioned so long as they
Id.
ry.
necessa
when
committees, review boards, and other physicians
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creative liberty. Prenatal genetic screening is not about the right to
choose whether or not to, have a child, nor is it necessarily about the
option of choosing whether to have an unhealthy child.132 Rather, in
most instances, the capability to detect the presence of genetic abnor
malities is well ahead of the capability to predict the actual health of a
child born with those genetic abnormalities.133 Because genetic ab
normalities may take many forms (or no form at all absent an environ
mental component134), the present state of technology is not precise,
132. The fundamental distinction is between the right to rear a family and the desire/
right to control the genetic makeup of the members of that family. See Bonnie Steinbeck,
Reproductive Rights and Responsibilities, HASTINGS CENTER REP., May/June 1994, at 1516. This distinction will have to be addressed as genetic screening capability is enhanced
and perfected.
133. See generally supra Part I.A. For example, consider that, although genetic testing
can predict whether or not a child will have Down's Syndrome, it cannot predict the sever
ity of the disease. See ABC News Special: The Perfect Baby (ABC television broadcast,
1990). The best that genetic screening can do at the present time is to inform prospective
parents about possibilities and give them a choice to abort. See supra note 110 and accom
panying text.
134. See generally supra Part IA. Many diseases only arise when a genetic abnormality
is combined with an environmental component:
Although all of us carry five to seven lethal recessive genes as well as a still unde
termined number of genes that make us susceptible to developing diseases based
on interaction with the environment (through work, diet, etc.), persons who carry
those particular genes for which screening first becomes available are in greater
danger of suffering discrimination because of their apparent singularity.
Capron, supra note 110, at 690. To better identify environmental components, more states
must establish reliable registries to track newborn and fetal abnormalities. The Texas Leg
islature, inspired by the high rate of anencephaly in southern Texas (primarily in the Rio
Grande Valley around the B rownsville area), has allocated $750,000 to establish such a
registry. See Bonnie Gangelhoff, Tragedy Spurs Mother to Back Birth Registry, Haus.
PosT, July 1 1 , 1993, at Al, A20. The United States had a similar experience with testing
newborns for sickle cell disease:
Widespread screening of children and adults for sickle cell disease was imple
mented publicly [during the 1970's] before public or private understanding was
clear on the objectives or on the use of screening results. One out of every twenty
of those screened was found to be a heterozygous carrier of the sickle gene.
Many of these asymptomatic adults were stigmatized by life insurance companies
with higher premiums and excluded from certain jobs or educational opportuni
ties. Although these screening laws of the 1970s were aimed at providing the at
risk [B)lack population with reproductive information, they were implemented
before the public was fully informed, and they did not provide for genetic coun
seling. There were no methods available for prenatal diagnosis of an affected
fetus. Thus, the only potential benefits of these early screening laws was to deter
heterozygotes from having children, an outcome that produced individual and
societal misunderstandings.
Elsas, supra note 35, at 827-28 (footnotes omitted); see infra note 219 (addressing the insur
ance implications of this mistake); see also AssESSING GENETIC RISKS, supra note 9, ch. 2,
at 8 (table listing newborn genetic screening in 1990 conducted in 53 states, common
wealths, and territories of the United States). In the context of prenatal genetic screening,
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and because research-stage testing is being made accessible for diag
.
nostic purposes, genetic screening is, to a large extent, nothing more
than an ability to make statistical predictions. ns When there is a
strong possibility that a fetus will be born with ailments so severe that
his or her parents will be given an opportunity to refuse treatment
once he or she is born, the viability cut-off for abortion (a cut-off that
such mislabeling will result in the late-term abortion of wanted pregnancies for health con
ditions that would not have arisen.
Moreover, genetic screening-whether it be on newborns or fetuses-is subject to er
ror. See infra notes 268-281 and accompanying text (quoting the findings of the Committee
on Assessing Genetic Risks). Error may arise both from testing limitations and from
human mistake:
Another set of problems arises because newborn screening, like any medical
test, is not completely accurate. Even under the most ideal testing conditions,
some children who actually have disease will be missed, and some healthy chil·
dren will inappropriately be labelled as "ill." From one perspective, "false nega
tive" tests that fail to detect affected children should not seem particularly
troubling. After all, the argument goes, the disease surely would have gone unde
tected had there been no program at all, so children are not harmed when the
program fails to work.
Things, however, are not that simple. To begin with, the existence of new
born screening programs can create a false sense of reassurance in physicians,
possibly causing them to fail to make a diagnosis as quickly as they would have
were there no screening in place once symptoms begin to appear.
The most common reason that affected children are missed, however, is not
because of the inherent inaccuracy of testing but because the tests were not prop
erly administered, if at all.
Clayton, supra note 74, at 103 (footnotes omitted).
135. See supra Part I (explaining that the presence of a genetic abnormality does not
necessarily mean that the mental and/or physical symptoms will be present, or that, if pres
ent, they will be severe); supra note 60 (explaining that genetic testing generally cannot
determine the severity of a disease and that it involves identifying the presence of abnor
malities linked to diseases-not necessarily the presence of diseases). Genetic screening
technology has been described as follows:
Today, in fact, the multiplicity of genetic variation relegates most prediction at a
molecular level to indirect linkage analysis, where the observed variation in nu
cleotide sequences by itself has no effect on the human's physiology. Thus in
most situations, the geneticist makes statistical predictions rather than exact diag
noses and has no "cure" for the diagnosis in a traditional sense.
Elsas, supra note 36, at 826. In the past, when doctors have relied upon screening technol
ogy prematurely for newborn genetic screening, the result has been mislabelling:
Inadequate medical knowledge also causes mislabelli�g. For . exa�ple, when
screening for PKU began, it was not known that some children with high I�vels .0f
,
phenylalanine did not in fact have PKU, but rather had hyperphenylalanmem1a
under
was
which does not cause significant mental retardation. Until this fact
ought to
stood, children with this later, benign condition were inappropriately t�
ally, the
Ironic
ent.
treatm
se of
be ill and subjected to the restrictions and expen
.
retartal
men
very
g
the
causin
ren,
treatment actually harmed some of these chi1d
dation that screening was supposed to avoid.
Clayton, supra note 74, at 106 (footnotes omitted).
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will force parents to make rash decisions, perhaps based upon inade
quate test results or no test results) seems destructive. However,
when the " abnormality" is mild and/or questionable (not associated
with mental and physical health impairments) and discovered on the
cusp of viability, perhaps as the result of a research-stage test, there is
justification for questioning the parental choice created through the
technology of genetic screening.136 The medical profession generally
has dealt with such decision making by establishing guidelines to de
cide both the severest and the mildest cases. For the most difficult
cases, those falling in the center of these two extremes, the medical
profession is involving ethics committees in the decision-making
process.137
As the counselor's story and the researcher's story reveal, 138 the
utilization of genetic counseling services is essentially a matter of dis
cretion on the part of hospitals, physicians, and researchers. 1 39 Gener
ally, ethics committees are not involved in the decision to abort prior
to the twenty-second week of pregnancy, and counseling may not even
take place. The understanding is that, so long as the patient is in
formed about the research-nature of a test, the unreliability of a given
test sample, the fact that the genetic abnormality may not result in a
genetic disease without environmental factors, and the uncertainty re
garding the severity of the impairments associated with the diseases at
136. Consider that we have already identified genetic abnormalities responsible for
predispositions for developing cancer and heart disease-conditions that are often treata
ble and arise later in life. See Sachs & Korf, supra note 1, at 461.
137. See generally BELKIN, supra note 104 (an account of Hermann Hospital's ethics
committee); ANSPACH, supra note 70; V1croR R. FucHs, WHo SHALL LIVE? (1983).
Although ethics committees generally work with parents, ethics committees are able to
override the decisions of parents to withhold treatment when dealing with live births:
The American courts, as we have seen, have been more willing to impose treat
ment over the wishes of the mother. This has resulted not in small part from a
strong preference for the physicians involved in many such cases to impose treat
ment, the traditional deference paid to medical views by the courts, and the fact
most such cases arise in a highly charged environment calling for immediate ac
tion where the views of the mother may often be unrepresented. Faced with sav
ing the life of an apparently salvageable fetus, the pressures on the judges
involved to order treatment are great, particularly, where medical evidence sug
gests no material harm to the mother.
David W. Meyers, Mother and Fetus: Rights in Conflict, in THE HUMAN BoDY AND THE
LAw 2, 15-16 (2d ed. 1990).
138. See supra Parts II.A. & H.B.
139. But see Elsas, supra note 36, at 816 ("It should be recognized that the practice of
medical genetics is a clinical subspecialty which is already guided and constrained by prece
dents of professional ethics and medical laws.").

August 1994]

COMING INTO BEING

1 489

issue, liability is eliminated. Moreover, under many states' laws, 1 40 a
positive test result-no matter how unreliable-and the assurance of
a physician that a genetic abnormality is present constitute adequate
grounds to terminate a pregnancy up until the point of viability. In
some states, the right to abort lasts even longer. 141
In sum, prenatal genetic screening has the potential to offer pro
spective parents an opportunity to know much about who their child
will be well before it is born. Whether the right to terminate
pregnancies based upon that knowledge will accompany the ex
panding availability of prenatal genetic testing adds a new dimension
of controversy to the abortion debate.
IV.

An Assessment and Proposal

Roni Lachapelle loves her son as much as any mother can love
her child. Nevertheless, when I asked for her opinion of the current
practice of making even research-stage testing available, she immedi
ately responded with, "Parents should know about everything." This
is also the conclusion reached by Sandra Peacock, who h as worked
with hundreds of patients such as Roni Lachapelle; her position is that
. parents should know and understand-that genetic counseling should
140. Cow. REv. STAT. § 18-6-101 (1994); FLA. STAT. ch. 390.001 (1994); KAN. STAT.
ANN. § 65-6703 (1994). States are being encouraged by the medical profession to pass

statutes respecting parental choice in the context of prenatal genetic screening. For exam
ple, the American Society of Human Genetics (ASHG) has endorsed a proposal for abor
tion bills to protect options of women at risk for bearing children with "serious" genetic or
congenital disorders. The ASHG's model statutory language provides:
Regardless of any other provision of this statute or other laws of this jurisdiction,
any pregnant female whose pregnancy has not reached the point of viability and
who has been informed by a licensed or certified health care professional that her
fetus (or fetuses) is likely to have a serious genetic or congenital disorder shall
have the right, among other options, to choose to terminate her pregnancy. This
right shall extend to situations where the female is at significantly increased risk
for bearing a child with a serious disorder for which precise prenatal diagnosis is
not available.
American Society for Human Genetics Statement on Clinical Genetics and Freedom of
Choice, 48 AM. J. HuM. GEN ET. 101 1 (1991). The ASHG also issued a suggested general
statement to accompany the model language, which provides:
In some states laws and regulations have been proposed which would, if enacted,
prohibit women from having the choice of terminating a pregnancy in which the
fetus is diagnosed with or is at significant risk of having a serious genetic or con
genital disorder. The model statutory language approved by the ASHG is its ef
fort to help elected and appointed officials to protect this option. It will be
provided by the ASHG to those jurisdictions considering legislation or regula
tions which would eliminate this option.
Id.
141. See, e.g., KAN STAT. ANN. § 65-6703.
.
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be performed by those trained in the social sciences so that they can
help patients understand the limitations of the information being
given to them , as well as the reality of raising a child with a serious
m ental and/or physical impairment. 142 Moreover, there is something
tel ling about the fact that " [g] eneticists in all nations consider it essen
tial to protect rights of parental choice."143

The technological capability to identify genetic abnormalities as
sociated with health impairments prenatally and to determine the ge
netic basis for generally shared physical and mental characteristics will
continue to expand, and policy makers simply cannot ignore this capa
bility. Restricting the practice of prenatal genetic screening means re
stricting what prospective parents will be able to learn about the
h ealth of their fetuses while there is still time to terminate their
pregnancies. At the very least, it will restrict prospective parents' op
portunities to prepare for a genetic abnormality before being con
fronted with the impairment after delivery-a time when parents are
often too e motionally charged and physically drained to understand,
despite the fact that the difficult decisions about aggressive treatment
may need to be made at that time.144 And, beyond the procreative
1 42 .

See Peacock Presentation, supra note 79 (supporting the assertion that genetic

counseling must be performed by those trained in the social sciences).
143.

Fletcher & Wertz, supra note 23, at 787.

144.

Roni described the frustration of knowing something was wrong but being too

tired to understand-the frustration of knowing decisions were being made regarding her
child, and not being able to participate. See also supra note 104 (the story of Claire,
Kenny, and Landon Sparks). For a full discussion of the emotional effects of the birth of a
health-impaired child on that child' s family, see Macintyre et al., in ABORTION, MEDICINE,
AND THE LAW, supra note 40, at 535-44. For a thorough discussion of how prenatal genetic
screening may prove beneficial even when prospective parents do not consider abortion to

be an option, see Steven L. Clark & Greggory R. DeVore, Clinical Commentary: Prenatal
Diagnosis For Couples Who Would Not Consider Abortion, 73 Os. & GYN. 1 035, 1036

(1 989) ("In all our dealings with such couples who knew in advance about their child's
handicap, we have yet to encounter one who was not grateful for the advance knowl
edge."). The reasons identified by Clark and DeVore are as follows:
1. The prospective parents may change their minds.

2. The odds favor a normal child, and, in most cases, the overall impact of prena
tal genetic screening will simply be to alleviate parental worrying and help family
relationships.
3.

The

testing may

alert

clinicians to

an

increased

risk

of pregnancy

complications.
4. The testing may allow specialized perinatal intervention which would benefit
the fetus. For example, a cesarean delivery may benefit fetuses with certain
anomalies.
5. Prospective parents are given an opportunity to make decisions regarding
medical treatment for their newborns.
6.

Parents are given an opportunity to prepare emotionally, physically, and

financially.
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liberty interests of parents, society simply cannot demand more than it
is willing to give. Although the limitations are somewhat self-imposed
and the product of choice, it is a reality that our society has limited
health care dollars.145 As reflected in the inadequate financial assist
ance given to children, such as Bobby, and their parents,146 those born
with serious impairments are often beyond the scope of the available
resources. In the absence of adequate financial assistance (one might
add acceptance and compassion), it would be nothing less than hypo
critical to restrict the late-term abortion option of prospective parents,
when genetic testing reveals that their fetuses carry genetic abnormali
ties that will result in serious impairments.147 In short, genetic screen
ing accompanied by the option to abort may allow some children to
avoid suffering and some parents to avoid the guilt and pain of not
being able to meet their child's needs. It may also enable society to
Clark & DeVore, supra at 1035-36.
145.

For a discussion of the economics of health care and the reality of rationing, see

generally HENRY J. AARON & WILLIAM B. SCHWARTZ, THE PAINFUL PRESCRIPTION: RA
TIONING HOSPITAL CARE (1984) (Brookings studies in social economics); FUCHS, supra

note 137; PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE (1982) (a
full discussion of the history behind anq business of our system of medicine). See also G.
CALABRESI, TRAGIC CHOICES (1978)

(a

law-and-economics analysis of this issue). The

higher level of rationing associated with national health care will, of course, require a com
plete change in the socialization of our medical community-a profession historically
trained to preserve life without the constraints of cost-and a public that has come to
believe that it is entitled to coverage and every opportunity to live. See The Place of Ethics
in Health Care Reform, HASTINGS CENTER REP., May/June 1994, at 7-12.
146.

The financial strain of trying to give a child with Bobby's needs an opportunity to

develop confidence-for example, trying to keep a growing child in an easily maneuvera
ble (and aesthetic) wheelchair so that he or she can keep up with his or her peers-is
virtually insurmountable for most families. This strain is heightened by the fact that, in our
society of "latch-key" children, children such as Bobby need a parent to be available at all
times, especially while they are young and undergoing surgeries.
147.

It also follows that healthy, viable fetuses have more of an existence independent

from that of their parents, because society-through adoption, for example-is able and
willing to care for them without placing any demands on their parents. However, accord
ing to Dr. Winstrom, infra note 157, there are families waiting to adopt children with seri
ous health impairments.

See Tara Bradley-Steck, In the Migliaccio Family, 25 is Not

Enough, Hous. PosT, Oct. 20, 1985, at G13 (couple that adopts youngsters "that no one

else wants"); Leslie Sowers, Adoptive Mother-Daughter Bond Thrives Despite Severe
Handicap , Hous. CHRON., Sept. 23, 1985, at 1 (discussing the adoption of a child without a
cerebral cortex by a mother with cerebral palsy; acknowledging that Spaulding for Chil
dren, a United Fund agency, specializes in such adoptions); Martha Swift, Abortion Unre
lated to Placement of Children, Haus. CHRON., May 14, 1992 (" [P]aients are also available
to adopt children with Down's syndrome, spina bifida, AIDS and various other disabili
ties."); Geoffrey Tomb, Supermom: Florida Woman Adopts 1 7' Disabled Babies, Haus.

CHRON., May 30, 1991, at D4. But see Jennifer Dixon, Thousands of Infants Left in Hospi

tals in '91 , B osToN GLOBE, Nov. 9, 1993 (discussing how thousands of unhealthy babies are
left in hospitals by their parents).
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make a substantive difference in the lives of the fewer children born
with serious health impairments.1 48
Nevertheless, the practice of prenatal genetic screening is becom
ing a standard component of prenatal care and, as such, it needs to be
questioned, debated, and subjected to some level of scrutiny in both
the medical profession and society at large. Although the recent surge
of successes in identifying genetic abnormalities linked to health im
pairments and in developing tests to detect those abnormalities have
been impressive, the presently available genetic screening technology
represents merely the beginning of an era of testing capability almost
incomprehensible just a few years ago. As recently recognized by the
Institute of Medicine,
The national investment in the Human Genome Proj ects will
greatly increase the capacity to detect genes leading to disease sus
ceptibility and the availability of genetic testing over the next 5 to
10 years, identifying the genetic basis for diseases-even some
newly discovered to be genetic-and increasing the number of tests
for detecting them. The emergence of the biotechnology industry
increases the likelihood that these findings will be rapidly translated
into widely available test kits and diagnostic products . 149

Many of these tests will be for predispositions rather than for ac
tual mental and physical impairments, for "the development of ge
netic tests for diseases that manifest in middle and late life is j ust
beginning to be explored." 1 50 Moreover, " [m]any disease genes can
b e detected in individuals befo re symptoms occur, but for many com
m on diseases with some genetic basis, such as heart disease and can
cer, the detection of genetic alterations might only indicate
148. See supra note 56. However, it is perhaps more likely that the inadequate finan
cial assistance given to such children and their families will continue because the expansion
of the practice of prenatal genetic screening is not likely to cure society of its lack of ac
ceptance and compassion for such children:
Expanding prenatal diagnostic services may circumvent but will not solve the
"problem" of birth defects; they focus on disability, not on society's discrimina
tory practices. . . . Women's desire for children without disability warrants com
plete public and private support. The question is how to provide this support in a
way that does no harm. . . . Though it is more than twenty years since the first
fetal diagnosis of Down's syndrome by amniocentesis, we do not yet know the full
impact of prenatal testing and screening on women's total health, power and so
cial standing.
Lippman, supra note 56, at 45-46 (footnotes omitted); see also Harding, supra note 1 13, at
499 ("There is also a fear that society's search for genetic perfection will serve to ostracize
other less fortunate members of society such as the mentally retarded, the infirm, the dis
abled, or the elderly.").
149. ASSESSING GENETIC RISKS, supra note 9, exec. summ. at 1.
150. Id. preface at 2.
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susceptibility, not the certainty of disease." 1 5 1 The National Institutes
of Health has acknowledged that,

[w] hile interpretation of tests for single gene disorders of late onset,
including familial cancer, is not easy, the complexities of testing and
interpretations for the gene constellations that predispose to many
common diseases such as coronary heart disease, diabetes mellitus,
hypertension and others raise new problems. These dilemmas will
become particularly thorny if testing for the yet undiscovered genes
predisposing to common psychiatric diseases such as schizophrenia
and manic depressive disorders becomes a reality. 1 52
Prospective parents are vulnerable, and many, when made aware
of genetic screening's possibilities, will seek a conclusive determina
tion as to whether they are going to have a healthy baby. They will
find themselves pursuing an answer that current technology cannot
provide or relying upon research-stage tests that may be grossly incon
clusive. Moreover in the absence of regulation, " [m]any genetic tests
will be ordered and interpreted by primary care health practitioners,
and not by geneticists or genetic counselors. "153 Similarly,
" [o]bstetricians, squeezed by legal constraints not to 'miss' a defective
fetus, will generally provide their patients with prenatal diagnosis on
demand."15 4 Accordingly, prospective parents may even be pushed to
undergo prenatal genetic testing by care-givers driven to limit their
own liability in a doctor-hostile legal system and then find themselves
confronting choices that they never wanted and are unprepared to
make. For example, such parents may be forced to decide whether to
abort their wanted pregnancy when a research-stage test indicates that
there is a forty-percent possibility the child would carry a genetic ab
normality responsible for a severe health impairment. 1 55 Further151. Id. exec. summ. at l .
152. Id. preface at 2.
153. Id. "[G)enetic testing is no longer just for specialists. Increasingly, primary care
providers will be called upon to administer tests, counsel patients, and protect their pri
vacy." Id. exec. summ. at 2.
154. Elsas, supra note 35, at 832; see also Robertson, supra note 36, at 703:
[O]bstetricians and primary care providers need assurance that they will not be
sued for failing to offer the test to persons with a negative family history for CF.
Absent this assurance, their desire to minimize malpractice exposure may lead
them to offer (in effect, order) the test on a routine basis, thus bringing about the
very situation that the experts now claim is undesirable.
155. All prospective parents who undergo prenatal genetic screening face the possibil
ity of being presented with one of the tough cases-for example, the possibility of parent
ing a child who is likely to live a short but fairly "normal" life. Consider the story of Kim
Lynch whose daughter, Catherine, has cystic fibrosis. The Perfect Child, s�p '.� note 133.
Kim again became pregnant with the knowledge that there was a strong poss1b1ht� that �er
.
second child would have cystic fibrosis and, should it be determined through genetic testing
that her child would suffer from the disease, she and her husband would face an all-or-
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more,

although

genetic

undergoing

counseling

may

release

obstetricians from liability, it may also subject prospective parents to a
loss of privacy156 and choice.157 For example, under the present insur
ance scheme, there is a possibility that genetic screening test results
nothing decision. The Lynches never had to make that decision, for the tests indicated that
the genetic abnormalities responsible for the disease were not present.
Also consider the story of a young man with cystic fibrosis who is in his twenties. See
id. He stated that, even if there is a 50

% probability that he will have a child with cystic

fibrosis, he will still have the child. In his words, "I have never met a person with cystic
fibrosis who regretted being born." But also consider the pain of losing a child one has
gotten to know and love.

Cf CHARLES STROUSE, FLOWERS FOR ALGERNON (1980);

George Miller, Lorenzo's Oil (unpublished manuscript).
156.

Clayton, supra note 74, at 108 ("Even when a condition requires no intervention,

mere entry of the diagnosis into medical records makes it available to a wide array of
people and institutions."). See also SoRelle, supra note 54 {"Of those surveyed, 98 per
cent said one has the right to know if his or her spouse carries a genetic defect. Surpris
ingly, 58 percent said the person's insurer should know and 33 percent said an employer
has the right to know."). The issue of disclosure of genetic information among family
members is discussed in Suter, supra note 6. For a broader discussion of privacy issues
arising from the practice of prenatal genetic screening, see Fletcher & Wertz, supra note
23, at 753 (" Laws against genetic discrimination are clearly necessary."); id. at 763-64 (list
ing disclosure dilemmas). Some of these issues are

(1)

whether there should be full disclo

sure of laboratory results that are conflicting, ambiguous, or simply subject to controversial
interpretations, id. at 768;

(2)

whether the p aternity of the child should be released, id. at

769; (3) whether there is a duty to disclose psychologically sensitive information that might
harm the patient, id. at 770-71; and (4) whether there is a duty to warn relatives about the
possibility that they are carriers of genetic abnormalities, id. at 770. As for this last issue, it
has been proposed that
it would be ethically acceptable to breach confidentiality and disclosure to rela
tives if three conditions are met: 1) there is a high probability of harm, 2) harm to
identifiable individuals is serious, and 3) precautions are taken to limit disclosure
to appropriate genetic information . . . . This essentially restates the "Tarasoff
rule" in the genetic counseling case, providing an exception to a general rule of
confidentiality where serious harm could accrue to an identifiable individual that
could be prevented by a disclosure.
Annas & Elias, supra note 44, at 216-17 (quoting conclusions of the Judicial Council of the
American Medical Association). But see infra note 203 (stating that the therapeutic privi
lege does not pertain to genetic counseling).
157.

According to pro-life feminist theorists, abortion removes the choices of women

by making sex available to men on demand. Dr. Margit Winstrom, Class Presentation,
Abortion, Law, and Social Choice, University of Houston Law Center (Apr. 5, 1993); see

Catharine A . MacKinnon, Reflections on Sex Equality Under Law, 100 YALE L.J. 1281,
1300 n.93 (1991) ("Juli Loesch, a self-styled 'pro-life feminist' associated with Operation
Rescue, says, 'the idea [of abortion] is that a man can use a woman, vacuum her out, and
she's ready to be used again . . . . "' (citation omitted)); cf C ATHA R INE A. MACKINNON,
TOWARD A FEMINIST THEORY OF THE STATE 190 ( 1 989) {"The availability of abortion

removes the one real consequence men could not easily ignore, the one remaining legiti
mated reason that women h ave had for refusing sex besides the headache."). Dr. Win
strom considers the fetus to be a "second patient," and although she does not dispute
abortion when the fetus is severely deformed, her philosophy is that the opportunity to
abort fetuses for all genetic abnormalities is accompanied by societal pressure to do so.
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will be treated as if the fetus has already received a diagnosis of a
preexisting condition.158 This possibility creates a strong disincentive
to undergo prenatal genetic screening and testing to determine
whether one carries a genetic abnormality unless one is willing to ab
stain from having children or undergo an abortion if the abnormality
is detected in the fetus. 1 59 Before any tests are run, prospective par
ents should be made aware of all of these dangers. They m ust also be
made aware of the importance of environmental factors in affecting
the onset and severity of many diseases linked to genetic abnormali
ties and the overall limitations of testing capability . 1 60
Finally, we must give consideration to the fact that fetuses
aborted as a result of genetic screening are often older than twenty
weeks and babies delivered as early as twenty-three weeks are being
kept alive, albeit often with severe health impairments.1 6 1 Because
our society is less intolerant of late-term abortion when a fetal abnor
mality is detected, 162 the pre-viability, late-term abortion of a fetus
based upon the result of genetic screening will not receive the same
scrutiny as the decision to refuse treatment to a seriously-impaired
newborn. 1 63 This is true even though a newborn's impairments are
158.

See Zylke supra note 51, at 1715; Vicki Quade, Protecting the Essence of Being,

BARRISTER, Summer 1993, at 9. Consider that all humans carry from four to ten ge netic
defects. Id.
1 59. Clayton, supra note 74, at 1 1 3-14 ("Even if parents want to provide economic
security for their child, receiving this sort of information may actually limit rather than
expand parents' options. Many health insurance policies do not cover preexisting con di
tions.") (footnotes omitted).
160.

See supra note 60 (addressing the importance of environmental components). The

relationship between a person's genetic makeup and production of proteins (genotype )
and a person's observable traits (phenotype) is fully discussed in Suter, supra note 6, at
1856-59.
161.

Although many state's abortion laws still reflect the trimester framework erected

in Roe v. Wade, 410 U.S. 1 13 (1973), according to the Supreme Court's recent decision in
Planned Parenthood v. Casey, 112 S. Ct. 2791 ( 1 992), women have a right to choose abor
tion up to the point of viability. See supra note 127. Accord ing to a recent study reported
in the New England Journal of Medicine, doctors "should aggressively try to save prema
ture babies born at 25 weeks gestation but not those born before 22 weeks." Study Details
Critical Time for Preemies, WORCESTER TELEGRAM & GAZETTE, Nov. 25, 1 993. at A3 1 .
According t o this study, "[o)nly 2 percent of those born at 23 weeks escaped severe abnor
malities, compared with 21 percent born at 24 weeks and 69 percent at 25 weeks." Id.
162.

See supra notes 129-130 and accompanying text.

163.

Even the scrutiny given to decisions to withhold treatment from seriously i m 
paired newborns may b e nonexistent. See ANSPACH, supra note 70; see also Martha A .
Field, Killing "The Handicapped "-Before and After Birth, 16 HARV. WOMEN'S L.J. 79, 79
(1993) (a constitutional law treatment of the issue that discusses, among other things, how
"support of a 'right to life' for newborns with handicaps is consistent with belief in a broad
right to choose abortion").
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certain and defined, while the genetic screening test results that create
an opportunity to abort a pregnancy late-term may be far from con
clusive and may detect nothing more than the propensity for develop
ing a treatable condition. What is most disturbing is the fact that,
because the technology u nderlying prenatal genetic screening is in its
infancy and a great deal of genetic screening is being conducted by
research laboratories that are not being properly regulated

(or

rele

vant regulations are not being enforced) ,164 it is subject to a level of
error not acceptable for diagnostic purposes. As acknowledged by the
Committee on Assessing Genetic Risks, errors in genetic testing per
formance are likely to continue for . the following reasons:
•Many clinical laboratories are unfamiliar with the recombinant
DNA techniques used in most new genetic tests;
•The use of very small samples with PCR increases the chance o f
contamination with foreign DNA;
•The large volume of tests increases the chance of unintentional
switching of samples;
•The vast majority of results will be in the normal range, a tendency
that reduces the vigilance of those performing the test;
•The nature of genetic disorders increases the chance of errors in
interpretation;
•Tests at the DNA level may not detect all disease-causing or sus
ceptibility-conferring mutations, resulting in false negative results;
and
•A positive test result cannot always predict disease severity and, in
some instances, may falsely predict the future occurrence of disease
particularly in tests for predispositions to multifactorial disorders
and disorders of variable expressivity.165

We must confront the fact that such errors often will result in the late
term abortion of wanted pregnancies. Accordingly, rather than ac
cepting the reliance upon unspoken norms associated with the deci
sion making surrounding seriously impaired newborns, 166 we should
"codify the substance of widely shared but unwritten moral agree
ments found in the practice of medical genetics."167 At the very least,
Part V.C.

164.

This is discussed

165.

ASSESSING GENETIC RISKS, supra note 9, ch. 3, at l.

1 66.

See

167.

Fletcher & Wertz,

supra note

infra

129.

supra

note 23, at 760; id. at 785 (" [T]his study supports the

claims made above for this Article's fourth premise that strong agreements are present
world-wide on some crucial approaches to several of the major ethical problems in the old
and new genetics."). However, survey studies, such as the study completed by Fletcher and
Wertz, have been criticized on the grounds that
[ s]uch questionnaires, in which physicians are asked to comment on hypothetical
dilemmas, evoke responses that are suggestive, but not indicative, of decisions in
actual practice. Case records, the second source of data, are retrospective ac
counts of decisions, often written with an eye to the hospital administration and
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in light of its social implications, we should erect some legal restric
tions around the practice of prenatal genetic scree ning (or at least ap
ply the existing restrictions imposed on commercial laboratories, as
discussed in Part IV.C. of this Article) to ensure that our society's
level of reliance

upon the

underlying technology

to

terminate

pregnancies is the product of debate and conscious choice, and subject
to at least a minimum level of public scrutiny.
The following is an assessment of the prese nt status of regulation
of the practice of prenatal genetic screening in the United States. As
is set forth below, in the absence of efforts to control it and through
the unlimited access to nascen t technology made possible by research
laboratories, the practice of prenatal genetic screening is currently be
ing expanded by: the influence of legal liability; the insurance indus
try's drive to minimize risk; market pressures on laboratories and
hospitals; and the emergence of a powerful biotechnology industry.
A.

The Absence of Minimum Bioethical Standards

The definitive evaluation of the state of prenatal genetic screen
ing in the United States at the presen t time is a report recently issued
by the Committee on Assessing Genetic Risks, Division of Health Sci
ences Policy, of the Institute of Medicine . 1 68 The Commi ttee con
cluded that,
[w]hile existing standards may have been adequate for the past, new
standards must be developed in response to rapid developments in
genetic testing methods that are now experimental. In particular,
additional standards are needed for prenatal diagnosis, predisposi
tional testing, and multiplex testing. Research and policy analysis is
needed in prenatal genetic diagnosis to address problems such as:
the complexities of fetal identification of cells in maternal blood,
maternal serum alpha-fetoprotein screening, notions of "perfectibil
ity," use of prenatal diagnosis and selective abortion to choose the
sex of the fetus, the special impact of prenatal diagnosis on women,
and carrier detection in pregnancy rather than prior to conception
. . . . Standards are also needed for genetic testing for predisposition
to late-onset disorders. There is an important "window of opportu
nity" for considering these issues now, before predispositional ge
netic testing becomes widespread.169

The Committee also acknowledged that,

�

�

�

the law. Parti �u arly in view o the ighly charged legal climate surrounding Jife
and-death dec1s1ons, the relat10nsh1p between resolving hypothetical dilemmas
and making actual decisions is an open question.

ANSPACH, supra note 70, at 42.
168. See AssESSING GENETIC R 1 s Ks supra note 9.
,

169.

Id. exec. summ. at 2 2 (citations omitted).

1498

HASTINGS LAW JOURNAL

[Vol. 45

[i]n its efforts to complete a comprehensive overview of issues in
genetic testing and screening, the [Committee] identified significant
gaps in data, research, and policy analysis that impede informed pol
i cy making for the future . Surprisingly few data exist on the extent of

genetic testing and screening today, for example, and no system is in
place to gather data or to assess practices in relation to the commit
tee's principles and recommendations for the future.170

The George Washington University's recent announcement that
its researchers171 successfully cloned human embryos drew interna
tional attention to the fact that there are no national bioethical re
straints on the human genome-related research of private institutions
in this country-the most powerful, advanced, and capable collection
of such institutions in the world. Specifically, "the only checks on
such research are a patchwork of guidelines, state laws, advisory com
mittees and recommendations by professional associations." 172 In
fact, although the fetal cloning experiment did immediately generate
the circulation of a report from the Congressional Office of Technol
ogy Assessment critical of Congress's silence regarding biomedical ad
vances,173 currently there is not even so much as a movement to enact
a federal privacy law related to genetic screening.174 This regulatory
vacuum reflects the fact that "the U.S. government has no official
body to make policy on dilemmas raised by biomedical advances. "175
Over the past few decades, commissions have been formed to address
specific biomedical issues-one such commission, the National Com
mission for the Protection of Human Subjects of Biomedical and Be
havioral Research (National Commission) , is responsible for the ban
170. Id. exec. summ. at 20 (emphasis added).
171. This research was done by a team headed by Dr. Jerry Hall.
172. Richard Saltus, Embryo Duplication Brings Calls for a Guiding Policy, B osTON
G LOBE, Oct. 26, 1993, at Al, 1 0 [hereinafter Saltus, Embryo Duplication]; see infra Part
IVA.(2), (4) (discussing various guidelines and recommendations).
173. See O FFICE OF TECHNOLOGY ASSESSMENT, B10MEDICAL ETHICS IN U.S PUBLIC
Poucv-BACKGROUND PAPER, OTA - BP-BBS-1-5 (U.S. Gov't Prtg. Office 1993). In this
report, the Office of Technology Assessment (OTA) stated that it is ill-equipped to address
many of the quandaries arising from advances in biology and medicine, and it urged Con
gress to take an active role in deciding public policy related to bioethics. Id. See also
George J. Annas, Will the Real Bioethics Commission Pleo,se Stand Up?, HASTINGS
CENTER REP., Jan./Feb. 1994, at 19 [hereinafter Annas, Real Bioethics Commission]; Rich
ard Saltus, France Weighs Restrictive Biomedical Science Law, BosTON GLOBE, Oct. 23,
1993, at A6 [hereinafter Saltus, France]. The OTA also stated in its report that, at present,
the federal government analyzes implications of novel research on an ad hoc basis and
added that this is "the least desirable mechanism to address bioethical dilemmas." OFFICE
OF TECHNOLOGY ASSESSMENT,

supra.

174. Saltus, France, supra note 173, at A6.
175. Saltus, Embryo Duplication, supra note 172, at Al.
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on human experimentation without the subject's consent.1 76 These
commissions generally have been quickly disbanded, the last such e f
fort being the Biomedical Ethics Advisory Committee that was al
lowed to expire four years ago before it reached any conclusions
about biomedical research.177 In contrast, at least twenty-seven other
countries have set up national commissions to debate issue s such as
genetic privacy and reproductive technology.17 8
The public's reaction to the George Washington University's feta]
cloning experiment as reported by the media has been much of specu 
lation about the social implications arising from the everyday applica
tion of such technology.179 As has been emphasized throughout this
Article, the United States has not had the same level of head-on con
frontation with prenatal genetic screening. It is ironic that, while the
nation speculates about the social implications of human cloning, the
practical significance of which is perhaps a decade once removed, hun
dreds of woman are undergoing prenatal genetic screening on a daily
basis.1 80
176. See also Annas, Real Bioethics Commission, supra note 173, at 19-21 . The four
predominant efforts concentrated on in the OTA report are: the National Commission for
the Protection of Human Subjects of Biomedical and Behavioral Research (in existence
1974-1987); the Presidential Commission for the Study of Ethical Problems in Medicine
and Biomedical and Behavioral Research (in existence 1979-1983); the Biomedical Ethics
Advisory Committee (in existence 1988-1989); and the Ethics Advisory Board (in existence
1977-1980).
177. The Biomedical Ethics Advisory Committee was "a victim of the abortion contro
versy . . . . " Editorial, An Embryonic Debate, BosTON GLOBE, Oct. 31, 1993, at 86.
178. Id. at Al; see generally, OFFICE OF TECHNOLOGY ASSESSMENT, supra note 173, at
43-68. For example, in 1990 the United Kingdom enacted such legislation as a result of
work done from 1982 through 1984 by the Warn�c� Commission. Id. a t p. 51-52.

"[C]areful study and debate [generated by the Comm1ss1on] produced a national consen
sus." Id.
179. See, e.g., An Embryonic Debate, B osTON GLOBE, supra note 177, at 87 ("Gui
dance by the federal government is needed now if cloning is to be brought under the con
trol of the broader society."); Ellen Goodman, The Embryo Imbroglio, BOSTON GLOBE
Oct. 31, 1993 ("But you don't have to believe in Frankenstein to worry about the effect of
having a clone of your own in the freezer."); 3 of 4 Polled Say Cloning is Wrong, B osToN
GLOBE, O ct 31, 1993 (a poll, based upon a survey of 500 people, revea led that
58 % of
those questioned believe it is morally wrong to clone a human being); see a lso Reader
'
Feedback: Should Legal Limits be Set on Scientists Genetic Tinkering with Hu m ans ? B os
TON G LOBE, Oct. 28, 1993, at 52 (stating that, of 306 callers who resp onded, 222 � d tha t
s i
"there should be legal limits on the genetic manipulation of huma ns") .
180. If there �re approximately 500 genetic counselors and each sees approximately
_
five hundred patients per year, about 250,000 women are undergoing
prenatal geneti c
counseling on an annual basis. See supra Part II.A. (estimating th at, in the summer of
199� , there were approximately 450 genetic counselors, each seeing between 200 and l ,000
patients annually}.
.
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The legal forces in this country do, in fact, directly influence the
practice of prenatal genetic screening. However, their effect is not to
ensure any level of public debate, conscious policy making by those
accountable to the public, or a minimum level of accountability on the
part of the institutions and individuals making this technology avail
able to the public. Thus, while there are law-based regulatory forces
influencing the practice of prenatal genetic screening, their ability to
impose control is trailing far behind the reality of the technology. 18 1
In fact, the practice of prenatal genetic screening has not been directly
addressed by our public policy makers and, as is explained below, the
overall influence of the existing regulatory forces is to expand the
practice of prenatal genetic screening at the expense of caution.
(1)

Self-Regulation by the Medical & Genetic Professions

"[T]he United States is the only developed country in the world
without a social insurance or statutory system to cover basic expenses
181. The first priority has been developing the technology, and the ethical issues are
arising out of its application:
Since there have been large-scale genetic screening and counseling programs for
such diseases as Tay-Sachs, sickle cell disease, PKU, and neural tube defects, it
might be supposed that the major social policy issues raised by such screening
have been solved. This supposition would be incorrect. This in part results from
the fact that each genetic disease has unique characteristics and thus poses unique
issues. For example, some diseases occur most frequently in specific racial or
ethnic groups, raising potential issues of discrimination and stigmatization. Other
screening tests, such as those for neural tube defects, can be done only on preg
nant women, and abortion is the only " treatment." Still others can be performed
only on newborns, and screening for conditions such as PKU that require imme
diate treatment to prevent harm has been made mandatory by almost all states.
Annas, Monster Mythology, supra note 17, at 641 (footnotes omitted). The technology is
advancing, and perhaps the most that can be done is to put more effort into addressing the
ethical problems it is creating:
(T]here are some who argue that without first addressing the ethical challenges
that would result from advances in genetic research, it is inappropriate to perform
the research. Some criticisms directed at the Human Genome Project are appro
priate, but whether we like it or not, the project has begun and is being carried
out in many parts of the world.
Sachs & Korf, supra note 1, at 460. The groups of societal issues arising from the Genome
Project have been identified as follows:
In the Human Genome Initiative there are three major societal issues: popula
tion-based genetic screening, resource allocation and commercialization, and
eugenics. More specifically, the questions raised by the project are to what uses
its fruits should be put to screen groups of people, such as applicants for the
military, government workers, immigrants, etc.; what priority should the genome
project have for federal funding and what role should patenting laws play; and
finally, should we attempt to use the new genetics to improve our citizens, either
by trying to eliminate specific genetic diseases or by enhancing desirable traits.
Annas, Monster Mythology, supra note 17, at 639 (footnote omitted).
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for medical services for most of its population, " 182 and the medical
profession within the United States enjoys an incredible amount of
autonomy. On the other hand, peer pressure within the medical pro
fession is a powerful regulatory force, and it works on the local, re
gional, national, and international183 levels-often simultaneously. At
the present time, there are no less than "eleven active gene therapy
protocols worldwide; nine more have been approved and many more
are in various stages of organization."184 Moreover, various organiza
tions within the medical community are publishing statements on is
sues relating to prenatal genetic screening.185 The American Society
of Human Genetics (ASHG) has issued some guidelines in recent
years,186 and because the ASHG is democratic in nature, these guide
lines are likely to be taken seriously. Unfortunately, many of the
medical profession's ethical norms have not been formally recognized
and codified into regulations.187 And, finally, some genetic testing
quality assurance is being provided by the Council of Regional Net182.

AssESSING GENETIC RISKS, supra note 9, exec. summ. at 17.

183. Fletcher & Wertz, supra note 23, at 753 ("Because the genome mapping project is
international in scope, ethical issues in human genetics must be addressed by national and
international societies of geneticists and colleagues in allied fields."); id. at 744 (presenting
a list of the 10 major ethical issues identified through an international study performed on
medical geneticists).
184. Sachs & Korf, supra note 1, at 460. See also supra note 98 (addressing IBC/
UNESCO efforts to establish on international agreement); AssESSING GENETIC R1sKs,
supra note 9.
185.

See NATIONAL SocIETY OF GENETIC CouNSELORS (NSGC), STATEMENT OF

G UIDING PRINCIPLES ON CONFIDENTIALITY OF TEST RESULTS (1991); American Society of
Human Genetics Statement on Clinical Genetics and Freedom of Choice, 48 AM. J. HuM.
GENET. 1011 (1991); Kenneth J. Ryan, Transactions of the Tenth Annual Meeting of the
American Gynecological and Obstetrical Society, 166 AM. J. Os. GYN. 1029 (1992); see also
Richard Saltus, Scientist Opposes Potential 'Gay Gene' Abortions, BosTON GLOBE, Feb. 22,
1994. In its recent report, the Committee on Assessing Genetic Risks acknowledged that
[a)I though the American Society of Human Genetics, National Society of Genetic
Counselors, American Academy of Pediatrics, American College of Obstetricians
and Gynecologists, and other professional organizations have developed policy
statements on key policy issues in genetic testing, genetic testing has moved be
yond the domain of genetics specialists alone.
ASSESSING GENETIC R1sKs, supra note 9, exec. summ. at 21.
186. See ASHGA Ao Hoc COMMITTEE ON IDENTIFICATION BY DNA ANALYSIS, PRIN
CIPLES ON THE PROTECTION OF DNA DATE AND DNA DATA BANKING (1990); see also
supra note 140 (proposed language issued in 1990).
187. See generally ASSESSING GENETIC R1sKs, supra note 9. 1\vo scholars have con
ducted an international survey to compile geneticists' reactions to difficult genetic screen
ing case scenarios. See Fletcher & Wertz, supra note 23. The result of their effort is the
discovery of consensus and shared ethical norms, but that "geneticists persist with an oral
tradition in ethics to the detriment of their specialty." Id. at 760; see also supra note 9
(identifying a weakness in this study).
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works of Genetic Services (CORN), the College of American Pathol
ogists (CAP), and the Centers for Disease Control (CDC), all of
which have helped to develop specific genetic tests or tests for specific
disorders.188
(2)

Federal Regulation

Perhaps the greatest social danger arising out of the Human Gen
ome Project comes from a lack of regulation enforcement regarding
researchers who may not be conscious of the social impact of their
work.189 Although it would be natural for the Food and Drug Admin
istration (FDA) to regulate researchers running genetic tests and de
veloping test kits, relevant regulations have not been implemented
and regulations carefully and directly tailored to prenatal genetic
screening have not been drafted.190 The Committee on Assessing Ge
netic Risks of the Institute of Medicine found that, "although ade
quate legislative authority exists to oversee the quality of genetic
testing, this authority is not in fact being implemented for genetic test
ing."191 The Committee also acknowledged that
[t]he emergence of the biotechnology industry increases the likeli
hood that [genetic screening] findings will be rapidly translated into
widely available test kits and diagnostic products. Entrepreneurial
pressure may also lead to the development of commercial and aca
demic 'genetic testing services' that would not be regulated under
current FDA procedures . 192

Another source of federal regulation over prenatal genetic
screening is the NIH, which has had a profound influence over re
searchers through regulations accompanying NIH grants, 1 93 including,
for example, guidelines for research involving recombinant DNA mol188. AssESSING GENETIC RrsKs, supra note 9, ch. 3, at 5.
189. See id.
190. See infra Part IV.C. (addressing existing regulations that could be implemented to
enforce caution).
191. Id. at 9.
192. Id. exec. summ. at 1.
193. National Institutes of Health Workshop Statement: Reproductive Genetic Testing:
Impact on Women, 51 AM. J. HuM. GENET. 1161 (1992). The NIH has acknowledged that,
although reproductive genetic testing, counseling, and other services have the potential to
(1) increase the knowledge of pregnancy outcomes; (2) provide reassurance during preg
nancy; (3) allow women the opportunity to choose whether to continue their pregnancies;
and (4) facilitate prenatal or early infant therapy, they also carry the potential to (1) in
crease anxiety and place excessive responsibility, blame, and guilt on women for the health
?f their newborns and general pregnancy outcomes; (2) interfere with mother-infant bond
mg; and (3) disrupt relationships between a woman, her family members, and her commu
nity Id. at 1 161. The NIH has also recognized that "[t]he value that women and their
:.
fam1hes place on these services depends heavily on a mixture of psychological and ethno-
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� cules. The NIH has a�so f�rmed subcommittees to address specific
issues. One such committee is the Human Gene Therapy Subcommit
tee (HGTS) , a committee created to provide the NIH with an addi
tional, specialized review of all research in which recombinant DNA
would be used to insert a "foreign" gene into a human being. More
over, " [r]ecognizing the enormity of the ethical and social questions
presented by the genetic research, the NIH and the Department of
Energy have established [ELSI]."194
Finally, it is worth acknowledging that, in the event that the exec
utive branch of our government is returned to an anti-choice adminis
tration, it is likely that prenatal genetic screening-as its presence
becomes more widely recognized-will be affected by abortion recultural influences, religious and moral values, and legal and economic constraints that are
unique to each woman." Id. Finally, the NIH has reached the following conclusions:
1 . Services should not be used to pursue "eugenic" goals. Id. at 1161 ("The ideals of
self-determination in family matters and respect for individual differences . . . are jeopard
ized whenever the primary goal of these services becomes the prevention of the birth of
individuals with a disorder or a disability.").
2. The primary goal should be to enhance personal reproductive decisions. Id. at
1 1 62.
3 . The services should be value sensitive:
Training of professionals who will provide these services should include special
emphasis on influences of psychological, sociodemographic, religious and moral
values, and ethno-cultural diversity in women's needs and interests regarding re
productive genetic testing services. The true impact that the providers' gender,
race, ethnicity, class, and educational discipline have on how services are pro
vided must be evaluated.
Id. at 1 162.
4. The standards of care for reproductive genetic services should emphasize genetic
information, e ducation, and counseling rather than testing procedures alone.
5. Social, legal, and economic constraints on reproductive genetic services should be
removed.
6. It must be recognized that genetic screening services may further sti��atize in�i
viduals affected by a particular disorder or disability. Id. at 1 162-63 ("Jnd1v1duals with
disabilities, who have a variety of information, experiences, and views to share, must �e
_ out m
involved in the development and implementation of further research to be earned
this area."). See also Capron, supra note 1 10, at 670; Elsas, supra note 36, at 830-31 (footnotes omitted):
Any proposed investigation which involves recombinant DNA and apprie_s �or
nt
National Institute of Health (NIH) funds is reviewed by the NIH Recombina
e
e
and its working group on Human .Ge? :11 rD NA Advisory Committee (RAC)
.
by mst1tut1ona1
apy. At the local level, recombinant DNA research is revie. wed
.
.
(FDA) or
ation
rmstr
rood and Drug Adm
b1osafety committees Similar1y, th e c
ene therg
all
ew
!
rev
will
)
the Department of H�man and Health Services (HHS
.
.
s. Now,
d
boar
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revie
onal
tituti
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ms
1
I
l bY oca
apy projects and reqmre pnor approva
.
.
.
arc
rese h acfiv
layers of review advice and reguI ation °f non-therapeutic genetic
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ity in huma ns a;e generally applied to proposals for federally
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lated restrictions, such as the Reagan-Bush era restrictions on fetal
tissue research.19s So long as abortion is the only feasible option other
than giving birth to a child with a genetic abnormality, a reinstatement
of conservative abortion policy-or expansion of the Hyde Amend
ment196_could limit the availability of prenatal genetic services at in
stitutions receiving federal funds.
(3)

Legal Liability

Legal liability is presently the most profo und force working to
transform advanced prenatal genetic screening technology into a stan
dard component of prenatal care . 197 The medical profession has rec
ognized the liability (actual and potential) arising from the practice of
prenatal genetic screening. For example, this liability was the inspira
tion for the American College of Obstetricians and Gynecologists'
first professional liability alert, which was issued in 1 985 .198
The increasing liability imposed on obstetricians is arising out of
the judiciary's greater recognition of wrongful birth and wrongful life
actions and state legislatures' passage of statutes authorizing such ac
tions. Both causes of action stem from the right of patients to make
choices. In the context of prenatal genetic screening, the issue is the
right of parents to choose what is best for themselves and for their
195. Fletcher & Wertz, supra note 23, at 755-56 (footnote omitted); see Paul Recer,
U.S. Funds Fetal Tissue Research, BOSTON GLOBE, Jan. 5, 1994, at 3 (with the caption "Ac
tion is first since ban lifted"). However, conservative politics in the United States aside, it
is important to recognize that reservations regarding fetal tissue research also have been
shared by many throughout the world. See Elsas, supra note 36, at 836 ("In fact, the moral
objectives of preserving human dignity, combined with the variety of conflicting definitions
of when life begins, have forced a moratorium on fetal research throughout the world.
This moratorium is currently under reconsideration.").
196. See B.J. George, Jr., State Legislatures Versus the Supreme Court: Abortion Legis
lation into the 1990s, in ABORTION, MEDICINE, AND THE LAw 67-69 (J. Douglas Butler &
David F. Walbert eds., 1992). The Hyde Amendment banned the use of federal Medicaid
funding for nontherapeutic abortions or therapeutic abortions other than for certain re
stricted reasons. Id.
197. Annas & Elias, supra note 44, at 215 ("[P]hysicians now face numerous ethical
dilemmas with uncertainty and confusion while practicing in a climate in which m alpractice
suits threaten even the most competent and conscientious practitioner.").
198. See Aubrey Milunsky, Screening for Birth Defects: A Professional Liability Alert,
LAW, MED. & HEALTH CARE, Sept. 1985, at 142 ("An obstetrician who elects not to screen
all patients in routine pregnancy or who fails to offer and discuss this screening test invites
a malpractice action should a patient deliver a child with a neural tube defect or Down's
Syndrome."). It should be noted that the testing which generated this warning was di
rected at a noninvasive blood draw rather than at invasive blood draw associated with
amnio and CVS that is necessary for much of the genetic testing that is the subject of the
article. See supra note 48.
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prospective children.199 Wrongful birth actions are premised upon the
right of parents to choose to terminate a pregnancy due to a genetic
abnormality ;200 wrongful life actions20!-are premised upon the right of
children not to have been born.202 In states recognizing such actions,
parents are likely to be told increasingly about even the most remote
possibility of a genetic abnormality as prenatal genetic counseling
bridges the gap between medicine and counseling, for there is no ther
apeutic privilege-the privilege to withhold information for the bene
fit of patients-in counseling.203 Although only three states have fully
199. Specifically,
[a]ny woman who employs a physician for prenatal care should have the right to
have the physician fully inform her of any reason the physician has to believe that
her fetus might be handicapped . . . . [I]t is entirely reasonable for the pregnant
woman to expect her physician to apprise her of any relevant information regard
ing her fetus, and options she might have, so that she and the child's father can
determine what action to take . . . .
Annas & Elias, supra note 44, at 216 (citation omitted); see also infra notes 205-209.
200. These cases are brought "for failure to counsel about existing technology where
the lack of knowledge results in a couple having a genetically handicapped child they
would not otherwise have had . . . . " Annas, Monster Mythology, supra note 17, at 658.
201. These suits, brought on behalf of the child, allege "that the child would have been
better off not having been born, and would not have been born if the physician had prop
erly counseled its parents or properly performed agreed upon screening tests." Id. at 658.
202. See Robertson, supra note 36, at 707; Timothy J. Dawe, Note, Wrongful Life:
Time of a "Day in Court, " 51 OHIO ST. L.J. 473 (1990) (addressing the elements for these
causes of action, how they apply, relevant state statutes, and providing case citations). As
for distinguishing these two causes of action,
It is important to note that wrongful life suits are brought by or on behalf of the
impaired infant himself. This distinguishes claims for wrongful life from those for
"wrongful birth," which are brought instead by the parents of the impaired child
for the emotional and financial damages that they have suffered as a result of
birth.
Dawe, supra at 476 (footnote omitted). Wrongful life actions are more controversial:
[t]he wrongful life plaintiff must then show a trier of fact that his life was truly
wrongful to him-that is, the burdens of his life outweigh the benefits he has
received. This formula approach derives from the ,"benefit rule" doctrine of tort
law, which states that "when the defendant's tortious conduct has caused harm to
the plaintiff . . . and . . . has conferred a special benefit to the interest of the
plaintiff that was harmed, the value of the benefit that was conferred is consid
ered in mitigation of damages, to the extent that this is equitable.
Id. at 497. These actions present difficult damages issues:
The courts have had significant problems when considering the issue of damages
in wrongful life suits. These problems basically exist on two levels: first, the great
difficulty courts face in ascertaining and measuring what damages are due the
defective plaintiff; and second, the bigger question of whether any damages can
logically and legally have been suffered at all by the plaintiff because of his
birth-in other words, another manifestation of the "sanctity of life" argument.
Id. at 490 (footnote omitted).
203. The therapeutic privilege is routinely exercised by health care professionals:
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recognized causes of action for wrongful life at the present time and
some states have expressly rejected such causes of action,204 most
states fall somewhere in between.
Moreover, obstetricians are finding themselves subjected to gen
eral malpractice liability for: failing to suggest genetic counseling
when there is even the slightest indication that it might prove help
ful;205 failing to fully inform prospective parents about the tests that
are available; failing to explain the risks of testing;206 failing to choose
responsible laboratories to run tests; and failing to monitor the quality
of test samples .207 Liability may even arise from informing or failing
Normally, a physician may assert a therapeutic privilege and not fully inform the
patient of all the material facts if in the physician's judgment the information
would do the patient more harm than good. However, for several reasons, the
therapeutic privilege is not applicable when the issue is the disclosure of test re
sults from genetic counseling.
Carolyn Lee Brown, Note, Genetic Malpractice: Avoiding Liability, 54 U. CrN. L. REV.
857, 874-75 {1 986) (citation omitted). The reasons why the therapeutic privilege does not
apply to the practice of prenatal genetic screening have been summarized as follows: ( 1 )
t h e concept o f informed consent mandates disclosure; (2) genetic screening generally does
not mandate immediate decision making-"immediate" meaning that a decision must be
made within 24 hours; (3) recognition ofprocreative liberty and the privacy of family life;
and (4) the fact that the basic purpose of undergoing genetic counseling is to obtain the
very information that the therapeutic privilege would withhold. Id. But see supra note 157.
204.

The states barring such actions generally do so out of the belief that they en

courage abortion and result in non-appreciation for fetal life. See Dawe, supra note 202, at
474 n.6. This same fear has resulted in states such as Louisiana, Missouri, Minnesota, and
Illinois passing laws prohibiting the discarding of embryos. See Robertson, supra note 36,
at 707 (citation omitted). In addition, Pennsylvania has expressly banned wrongful birth
and wrongful life actions. ACTIONS 'FOR WRONGFUL B IRT H & WRONGFUL LIFE, PA. CoNs.

STAT. ANN. § 8305 {1994)
205.

The Council on Scientific Affairs, a division of the American Medical Association,

has summarized the indications for genetic counseling as follows: "birth defects in one or
more family members, behavioral problems or mental retardation in a child previously
born, advanced age of the mother, certain ethnic backgrounds, drug use by parent, expo
sure to mutagens by parent, three or more spontaneous abortions, or infertility." Brown,
supra note 203, at 865.
206.

Id. at 870 (" Regardless of which standard is adopted, the physician has a duty to

inform the patient of the risks involved in amniocentesis so that the patient can decide
intelligently whether or not to undergo the procedure."); see Kimble, supra note 43; see
also Keel v. B anach, 624 So. 2d 1022 (Ala. 1993).
207.

See Brown, supra note 202, at 870. In sum,

[g]enetic counseling actually consists of three stages: the patient-counselee must
directly approach or be referred to the genetic counselor; the genetic counselor
must obtain all necessary information to allow for a proper diagnosis; and, ulti
mately, the genetic counselor must communicate his diagnosis to the patient
counselee. At each step, the potential for genetic malpractice exists.
Id. at 859.
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to inform other family members when a mutant gene is discovered.20s
Moreover, this liability has been enhanced by the recognition of pre
natal genetic counseling as a medical subspecialty,209 and it will ex
pand as additional prenatal genetic screening tests are made available.
In sum, obstetricians are facing a growing legal duty to refer pa
tients to genetic counselors,210 and they are beginning to make refer
rals to counselors when there is even the slightest indication that
counseling might prove helpful for " [t]he legal guidelines for doctors
in the field of genetic counseling are few and unclear."21 1 Moreover,
it is expected that, in the near future, "[m]any genetic tests will be
ordered and interpreted by primary care health practitioners, [rather
than] only by geneticists or genetic counselors . "212
(4)

State Laws

Although "[a]t present, only 1 0 states have some form of specific
requirements for the licensing of clinical laboratories providing ge
netic tests[,]"213 state law directly affects prenatal genetic screening
through abortion statutes. As discussed above, many states have codi
fied exceptions to restrictions on late-term abortion when fetal abnor
malities are present. The applicability of these exceptions to genetic
testing results is currently a matter of discretion on the part of the
medical community. As state legislatures become aware of the reli208. Id. at 878 ("The best answer is for the physician to have the counselee sign a n
advance statement allowing the physician to disclose necessary information t o necessary
relatives.").
209. As discussed in Brown:
It is the generally accepted rule that a physician who holds himself out as a spe
cialist is held to a higher standard of knowledge and skill than a general practi
ticner. Therefore, an obstetrician usually will be held to a higher standard than a
general practitioner and a genetic counselor will be held to a higher standard than
an obstetrician.
Brown, supra note 202; see also supra note 77 and accompanying text (discussing recogni
tion of genetic counseling as a medical subspecialty).
210. Id. at 863.
211. Id. at 858. Wrongful birth suits are discussed in Annas & Elias, supra note 44 , at

216:
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ance on genetic testing for determining the presence of fetal abnor
m alities and the limitations of the underlying technology, it is likely
that at least some state legislatures will impose restrictions-for exam
ple, requiring that genetic testing meet the international research
" true-positive" standard of reliability before being relied upon as an
indicator of fetal abnormality.214 Specifically, state legislatures may
require that the genetic testing being relied upon (a) indicate that an
identified abnormality is present, (b) be specific for the given disease,
and (c) be capable of detecting the abnormality in ninety to 100 per
cent of population samples. To enforce such standards, especially in
states such as Louisiana and Pennsylvania that heavily regulate and
restrict abortion within their borders, state legislatures may also re
quire post-mortem genetic analysis on the fetuses aborted (which
would raise the costs of these abortions) and require health profes
sionals to report their prenatal genetic screening related activities.
(5)

Insurance Law

The role of the insurance industry in the practice of prenatal ge
netic screening is yet to be defined, and its potential role raises a
number of difficult issues. Among these are the possibility of
mandatory testing,21 5 the confidentiality of testing results,21 6 coverage
issues regarding the costs of testing,217 coverage issues regarding the
cost of care when parents choose not to abort despite prenatally diag
nosed conditions,218 the insurance impact of being identified as a car214. See generally ROBERT J. LEVINE, ETHICS AND REGULATION OF CLINICAL RE
(2d ed. 1988) (discussing the use of human subjects-including fetuses and chil
dren-in medical and scientific research).
215. See Suter, supra note 6, at 1887-1905.
2 16. See id. See also ELSI Working Group Explores Privacy Issue, HUMAN GENOME
N Ews July 1 994, at 10; Richard Saltus, Fear of Insurers Leading to Gene Testing in Secret,
BosTON G LOBE , Sept. 12, 1 994, at 1, 10.
217. See Sachs & Korf, supra note 1, at 831 ("Most insurance companies now consider
prenatal diagnosis to be a generally acceptable practice and will pay for these medical
services.").
218. I spoke with several members of the Houston-area medical community regarding
insurance coverage for genetic screening, and they independently identified several com
mon stories and issues, some of which I have been able to confirm through research. For
example, a genetic counselor and insurance administrator both mentioned an instance in
San Francisco where a fetus was diagnosed prenatally as having cystic fibrosis, its parents
refused to terminate, and their HMO refused to cover the child's health costs on the
ground that the cystic fibrosis was a preexisting condition. According to both accounts and
the discussion of the case in the media, enough controversy was raised to make the health
maintenance organization (HMO) agree to provide coverage for the child. See Beth
Healy, Genetic Testing Has Attention of Insurers, BosTON Bus. J., Oct. 11, 1994, at 4; see
also Zylke, supra note 51, at 1715 (addressing this case). Another common concern is that
SEARCH

,
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rier of a genet�c �bnormality,219 the availability of testing services,220
and the potential impact of a movement toward a nationalized health
care syst :m on the decision to undergo genetic screening and abort
preg�anc1es when the genetic abnormalities responsible for serious
impairments are detected.221 Although the Clinton Administration's
proposed health care reform package may address some of the diffi
cult insurance industry issues regarding prenatal genetic screening,
currently these issues either are not being addressed or are being ad
dressed at the state level.222 Assuming that the Clinton Administra
tion is successful in at least initiating some reforms in the direction of
a nationalized health care system, one difficult issue likely to be ad
dressed, given the expense of assisting a seriously impaired child, is
coverage will be denied to prospective parents who undergo testing which determines that
the prospective parents are carriers for genetic abnormalities, even though carrier status
does not create any risk to their own health nor does it necessarily mean that the trait they
carry will arise in their offspring. Cf Quade, supra note 158, at 9 (profile of a lawyer who
was deprived of insurance coverage at the age of 28 because her father was incorrectly
diagnosed with Huntington's disease).
219. For example, testing programs for sickle cell anemia in the 1970s were carried out
with a misunderstanding about the difference between carriers of the disease and those
who actually had the disease. As a result, many carriers suffered from insurance and em
ployment discrimination as well as unfounded fear about their own health. See Leslie Rob
erts, One Worked: The Other Didn't, 247 SCIENCE 18 (1990). Carriers of genetic
abnormalities linked to cystic fibrosis may now be subjected to these same problems. See
Benjamin S. Wilfond & Norman Fost, The Cystic Fibrosis Gene: Medical and Social Impli
cations for Heterozygote Detection, 263 JAMA 2777, 2778 (1990).
220. "Women who receive prenatal diagnosis are disproportionately white, well-edu
cated, and financially secure" and "unequal access or no access to services is the most
widespread ethical problem in human genetics." Fletcher & Wertz, supra note 23, at 756,
761-62 (proposing that genetic services be included in the "floor of services" made avail
able through a nationalized health care system); see also Harding, supra note 113, at 487
("Women in higher economic strata, for example, have greater access to amniocentesis.");
U.S. DEP'T OF HEALTH AND HuMAN SERVS., HEALTH, UNITED STATES 1989, at 31 (1990)
("An estimated 24% of all new mothers annually receive no prenatal care in the first tri
mester of pregnancy.").
221. See AssESSING GENETIC RISKS, supra note 9, exec. summ. at 17; ch. 7, at 1-10; see
alw Case Study, HASTINGS CENTER REP., July/Aug. 1992, (Special Supplement), at S18-S20
(with commentaries by Paul Billings, Mark A. Rothstein, and Abby Lippman).
222. Consider California's effort to provide regulation in this area:
A provision [of the California State Civil Rights Act] (which will remain in effect
until January 1, 2000) prohibits health insurers from either not enrolling or
overcharging individuals carrying disease genes. Similarly, firms that write life
and disability insurance cannot refuse an application for insurance based on a
person's genetic characteristics. . . . Although a gene may indicate that an individ
ual is at risk, the person may not develop the disease if the condition results from
an interaction between the environment and the gene. . . . It is hoped that the
Ethical, Legal, and Social Issues Joint Working Group will recommend model
laws that can be enacted by states to prevent insurance discrimination.
Sachs & Korf, supra note 1, at 460-61.
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the accessibility of prenatal genetic screening and late-term abortion
services in the event that genetic abnormalities are detected. 223
(6)

Intellectual Property Law

Patent protection offers the ability to protect investment and dis
covery in the area of prenatal genetic screening. 224 In fact, "private
parties have quietly been obtaining patents on bits and pieces of the
human genome from the Patent and Trademark Office (PT0 ) . "225
Moreover, trade secret battles already are being waged over such
information. 226
It is generally recognized that to put this new technology-ge
netic screening and splicing techniques, for example-to practical use,
either private business must be allowed to "own" and profit from it as
223. See Fletcher & Wertz, supra note 23, at 756. Despite procreative liberty concerns
and the cost of caring for seriously impaired children, it is unlikely that testing under such a
system would be made completely accessible. For example, "[i]t has been estimated that if
a national screening program were introduced, it would cost $2.2 million for each case of
cystic fibrosis avoided." Sachs & Korf, supra note 1, at 459. See Medicaid Abortion Rule
Seen as Peril, BosToN GLOBE, Jan. 6, 1994 (discussing new federal rule requiring states to
pay for abortions for poor women who are impregnated through rape and incest). Should
the Clinton Administration succeed in introducing a national health care system, " [m]uch
can be learned in the United States about the role of genetic services in the total health
care systems of other nations, which is now well-described in eighteen other nations."
Fletcher & Wertz, supra note 23, at 758.
224. Applying patent law to this technology involves a new application of the products
of nature doctrine recognized in patent law. See Rebecca S. Eisenberg, Patenting the
Human Genome, 39 EMORY L.J. 721, 723 (1990). "[T]he cases suggest that the patentabil
ity of such inventions turns on whether the claimed invention is a new product or process
resulting from human intervention and, if so, whether the intervention is obvious in light of
the prior art, including previously available natural products." Id. at 725. Applying estab
lished patent law principles to human DNA sequences,
[o]ne could argue that a newly cloned human gene that previously existed within
the chromosomes of human cells is analogous to a newly isolated or purified
chemical that previously existed in impure form. . . . Moreover, a cloned gene
provides a means of producing its corresponding protein in larger quantities and
in a more pure form than may be obtained conveniently from human cells. The
cloned gene thus has distinct advantages over the gene as it exists naturally in the
chromosomes of human cells, just as purified vitamin B12 has distinct advantages
over impure vitamin Bl 2 as it exists in cow liver.
Id. at 729. However, because the DNA sequences themselves are not original, the best that
patent law may be able to do is protect the only known means of detecting a particular
sequence. Id. at 734. "[A]s a practical matter a patent on the only known means of mak
ing an unpatented product may be effective only for as long as it takes someone to develop
another means of making the same thing, which may be far less time than the duration of
the patent term." Id. at 736.
225. Id. at 721 & n.4 (listing patent citations).
226. See Victoria Slind-Fiol, Biotech Firms in Fight Over House Patent, B usINESs
WATCH, Mar. 25, 1994, § B.
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an investment, or the federal government must directly underwrite in
vestment cost, as is being done through the Human Genome Pro
ject.227 Given these options, it is important to recognize that, although
the federal government is investing some $200 million per year in the
Human Genome Project, this amount is trivial in comparison to pri
vate investment in biotechnology research and development, which,
for example, is estimated to have reached $1.5 to $2 billion in 1987 .22s
The potential regulatory force of patent law includes its ability to en
courage putting the research accomplishments resulting from the
Human Genome Project to practical use.229 However, before intro
ducing patent law into the scientific community for genetic screening
227. See Eisenberg, supra note 224, at 721 .
228. Id. at 737-38 (footnote omitted). The following are American companies and or
ganizations working to turn Human Genome Project-related knowledge into marketable
drugs and therapies:
Location
Company
Seattle, WA
Darwin Molecular Technologies
St. Louis, MO
Genome Systems Inc.
San Francisco, CA
Genomyx
Cambridge, MA
Genzyme
Rockville, MD
Human Genome Sciences
Palo
Alto, CA
Incyte Pharmaceuticals
Rockville, MD
Institute for Genomic Research
Menlo
Park, CA
Mercator Genetics
Cambridge, MA
Millennium Pharmaceuticals
Salt Lake City, UT
Myriad Genetics
San Diego, CA
Nanotronics
Princeton, NJ
SEQ Limited
Sequana Therapeutics
La Jolla, CA
Pro
ts
and
Ethics
Lawrence M. Fisher,
fi
Clash in Research on Genetic Coding, N.Y. TIMES,
Jan. 30, 1994, at 1, 1 8. All but three of these companies were founded in the last two years.
Id. at 18. See also Richard Saltus, Latecomer Boston Labs Eyeing Gene Therapy, BOSTON
G LOBE, Feb. 22 1993, at Cl, C4 (listing companies); Ronald Rosenberg, Biotech Thrives on
Hot Idea, BosTON GLOBE, Apr. 10, 1 994, at A77, A80 (discussing the efforts of Millenium
Pharmaceuticals and the gene testing industry).
229. "[E]ven if public funding were sufficient to generate the sequence information
itself, the lack of intellectual property rights in DNA sequences might undermine incen
tives for the private sector to support subsequent research to put this information to practi
cal use. Since 1980, federal law has promoted private exploitation of patent rights in
inventions emanating from federally-sponsored research as a means of promoting the de
velopment of these inventions." Eisenberg, supra note 224, at 744. However, Senator
Hatfield has introduced a bill, entitled the "Life Patent Moratorium Act," which would
result in patents on DNA sequences being withheld for two years while Congress addresses
ethical implications. The research and development community has responded to this bill
by arguing that the resulting lack of patent protection will remove incentives for genetic
research.
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purposes, the overall impact of patent law on the dissemination of in
formation must be evaluated.230 This process is currently under
way. 231
(7)

Summation

In the absence of enforceable regulations establishing minimum
standards for genetic screening and ensuring that the technology is
applied with caution, the practice of prenatal genetic screening is cur
rently being expanded by the effects of legal liability, the insurance
industry's drive to minimize risk, national and international market
pressures on laboratories and hospitals providing research and genetic
screening services, and the emergence of a powerful commercial bio
technology industry. Prenatal genetic screening technology is being
applied, for the most part, by the medical profession in conjunction
with research laboratories and essentially without reservation-that is,
without public scrutiny and legal restraint. In fact, it is now used as a
means to avoid legal liability. This is occurring even though research
stage genetic screening technology, which is nascent technology com
ing into being, is increasingly being relied upon as the basis for making
choices to terminate wanted pregnancies. As recognized by the Com
mittee on Assessing Genetic Risks, "the misinterpretation of test re
sults is more likely in genetic tests than in many other areas of clinical
230. "Although both the patent law and the scientific community reward priority of
invention and thus place a premium on prompt disclosure of new discoveries, patent appli
cants are likely to publish their discoveries later than scientists who are indifferent to intel
lectual property rights." Id. at 741. In other words, a scientist is likely to publish her
findings as soon as they are reliable so as to claim her victory, while an inventor seeking
patent protection may delay disclosure to protect her investment. Introducing patent pro
tection into the scientific community may skew the scientific community's norms, for
" [p)atent protection may also impede scientific progress even after disclosure occurs if it
gives patent holders the power to stop others from using their discoveries in subsequent
research." Id. at 742 (footnote omitted).
The difficulty of estimating the potential impact of patent protection on genetic testing
technology is somewhat enhanced by the fact that our patent system may soon change. A
bill was introduced in Congress in 1993 to change the United States' patent system from
awarding patents to the "first to invent" to awarding them to the "first to file." See
Thomas Smith, Debate Heats Up Over First-to-file Patent System, NAT. L.J., Aug. 8, 1 994, at
C7, ClO. The quid pro quo for obtaining a patent is disclosing how an invention works, and
the "first to file" theorists argue that this change in the patent system will result i n earlier
disclosure of inventions, thereby fostering increased communication of scientific advances.
This proposed "first to file" system would bring the United States in line with most other
countries. See id.
231. See Conference Examines DNA Patenting, Tech Tranfer Issue, HUMAN GENOME
NEws Mar. 1994, at 6; Staking a Claim on Biotechnology, HUMAN GENOME NEWS, Mar.
1994, at 6.
·

,
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testing, and misinterpretation may have more serious consequences
particularly in fetal diagnosis. "232 These consequences and the poten
tial implications for individuals and society-such as a loss of privacy
and even less tolerance for children who deviate from perfection-are
as unnoticed as the diagnostic applications of research-stage genetic
testing technology that are presently being conducted and relied upon
by prospective parents .233
B.

A Legislative Paradigm: The Efforts of France to Identify and Codify
its Minimum Societal Standards

In contrast with our country's failure to directly address the im
plications of prenatal genetic screening at a national, public policy
level, France is in the process of enacting sweeping legislation that will
confront prenatal genetic screening and other biomedical advances.
The articulated purpose of this legislation is to ensure that public pol
icy decisions resulting from the rapid advances of biomedical science
and the emergence of a powerful biotechnology industry are made by
France's chosen public policy makers-and thereby subject to public
scrutiny-rather than by its individual doctors on a case-by-case
basis . 234
Specifically, three proposed statutes have been drafted by
France's Constitutional Counsel (the equivalent of our Supreme
Court) and approved by the French National Assembly.235 This proAssESSING GENETIC RISKS, supra note 9, ch. 3. at 10.
233. See supra Part V.A. (quoting findings of the Committee on Assessing Genetic

232.

Risks that existing standards are outdated and adequate data regarding prenatal genetic
screening is nonexistent); see also infra note 286.
234. See Richard Saltus, La w on the Biomedical Frontier, B osTON GLOBE, Oct. 22,
1 993, at 18; Saltus, France, supra note 173. France's proposed legislation was discussed at a
symposium conducted on October 22-23, 1 993 in Boston, Massachusetts. The symposium,
which was organized by Suffolk U niversity Law School and the University of Massach�
setts Medical Center, addressed the legal, ethical, and public policy ramifications o� bi
omedical advances. See id. Justice Noelle Lenoir of France's Constitutional Council, a
coauthor of the proposed legislation, spoke at this symposium. (Justice Lenoir is also presi
men:i
dent of a UNESCO advisory committee on bioethics, discussed supra note 98, and a
cono
European
the
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posed legislation has received an abundance of public support, and it
is expected to be approved, in some version, by France 's Senate. The
purpose of the proposed legislation is set out in Title One of bill
number sixty-six, which provides that: "The primacy of the person is
the foundation of society. The law ensures that this principle is recon
ciled with the legitimate requirements fo r the progress of scientific
knowledge and for safeguarding the public health. It guarantees re
spect fo r every human being as soon as life begins." 236 Bill number
sixty-six also provides that the proposed legislation: (1) "guarantees
the dignity of the human body"; (2) "ensures the inviolability and ina
lienability of the human body " ; and (3) "protects the integrity of the
human species."237 Moreover, it states that:
•"Only therapeutic necessity or the law may authorize interference
with the integrity of the human body." 238
•"The intervention may not have as its effect to interfere with the
health of others or with that of future generations." 239
•"No one may interfere with the integrity of the human species." 2 40
•"Any eugenic practice tending toward the selection of the genes,
the sex or the physical or racial traits of human beings is
prohibited . "24 1
•"No change may be made in the genome or in the human cells of a
person for the purpose of alte ring his/her offspring. "242
•"The organs, tissues, cells, genomes and products of the human
body as such cannot be the object of a patent. " 243
•"[T]he study of the traits of a person by genetic examination may
be undertaken only for medical or scientific research purposes, and
in the cases provided for by law." 244

To accomplish these broad public policy objectives, the proposed
legislation calls for the creation of a National Consultative Commis
sion on Ethics for Life Sciences and Medicine. This Commission will
render advice and publish recommendations regarding ethical
problems raised by research and practice in the fields of biology,
the National Consultation Commission on Ethics for Life Sciences and Health"); DRAFT
LAW ADOPTED BY THE NATIONAL ASSEMBLY ON PROCESSING PERSONAL INFORMATION
FOR THE PURPOSE OF SEEKING TO PROTECT OR IMPROVE HEALTH, No. 68, 1st Reg. Sess.
(1992-93).
236. No. 66, supra note 235, art. lA.
237. Id. art. 2.
238. Id. art. 19.
239. Id.
240. Id. art. 20.
241. Id.
242. Id.
243. Id. art. 21.
244. Id. ch. III, art. 25.
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medi �ine ' a �d he alth.245 Although the Consultative Commission may
. .
.
exer�1se 1 unsd1ct1on over any question relevant to its competence and
pubhsh recommendations, it is also intended to be the recipient of
matters referred to it by the President of the National Assembly, the
.
Pres1d �nt of the Senate, the Prime Minister, any institution of higher
education, and any public institution or recognized foundation of pub
lic utility, the principal activity of which is technological research and
development.246 One of the Commission's primary missions is to keep
the public informed about biomedical research and advances.247
The proposed legislation also provides for the creation of a Na
tional Commission of Medicine and Biology of Reproduction and Pre
natal Diagnostics, which will be composed of "practitioners
designated by proposals of their representative organizations; person
alities selected by reason of their competence in the fields of procrea
tion, prenatal diagnostics, genetic counseling and the right of filiation;
and representatives of the involved governmental agencies as well as a
representative of family associations."248 This National Commission
will be "in charge of giving an opinion on the requests for authoriza
tion to exercise medically assisted procreation activities and prenatal
diagnostics as well as approval requests from multidisciplinary centers
of prenatal diagnostics." It will also be responsible for conducting fol
low-up procedures and evaluating the operations of these facilities.249
Along with genetic privacy, in-vitro fertilization, and other issues
related to biomedical science, the proposed legislation regulates
"medically assisted procreation, " which it defines as "medical and bio
logical techniques permitting procreation beyond natural
processes. "250 The legislation also identifies the purpose of medicallY
.
assisted procreation as being "to alleviate an infertility of a pathologi
cal character that has been medically determined or to prevent the

transmission of a particularly serious and incurable disease to the
child. "25 1
The proposed legislation permits medically ass�st·e·d procreatio?

procedures only when "performed under the respons1b1hty ?f a practi
or
tioner specifically approved for such purpose in each estabhshment
245.

246.
247.
248.
249.
250.
251 .
added).

No. 67, supra note 235, art.

IA.

Id.
Id.
de, tit. II' ch 3 ' art L 673-3).
Id. art. 10 (to be codified at VI Pub H. Co
Id.
L. 671 -1).
at VI p b H Code art.
Id. art. 8, tit. II, ch. 1 (to be codified
L. 671-2) (emphasis
art.
1
c
u
II.
'
.
tit.
Code,
Id. (to be codi fied at VI Pub H.
.
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laboratory authorized to practice them."252

All establishments and

laboratories authorized to practice prenatal diagnostics "must present
to the minister in charge of health, an annual report of activities. "253
The legislation also directly addresses prenatal diagnostics

( pre

natal genetic screening and therapy), the purpose of which is a " diag
nostic or therapeutic intervention on the embryo or the fetus. "254
Specifically, the bill provides that:
•The goal of prenatal diagnostics "can only be to anticipate or to
treat an ailment of a particular gravity in the interest of the child to
be born";255
•"Genetic counseling as well as analyses of molecular and chromo
somal genetics in view of establishing a prenatal diagnostic can be
practiced only in health establishments and in medical biology anal
ysis laboratories [expressly] authorized [to do so . ] "; 256
•"When any prenatal diagnostic leads to envision a voluntary inter
ruption of pregnancy for a therapeutic motive, it must be confirmed
by two authorized physicians, one of which must exercise his activity
in a multidisciplinary prenatal diagnostics center . " ;257 and
•"Registers shall be established and kept by the multidisciplinary
prenatal diagnostics centers, and shall indicate the causes of the
therapeutic pregnancy interruption and shall permit verifying the
authenticity of the anomaly detected by the prenatal diagnostic . "25 8

To ensure compliance, the proposed legislation also includes penal
and administrative sanctions.

For example, one provision provides

that " ( a] ny violation noted in the establishment or the laboratory and

h e nce of the legislative and regulatory requirements applicable to
medically assisted procreation or to prenatal diagnostics leads to the
temporary or definitive revocation of the authorizations

[to

provide

medically assisted procreation activities ] . "259 Another provides,

[t]he persons found guilty of one of the offenses provided in the
present chapter are also liable to a complementary penalty of prohi
bition, for a duration of not more than ten years, to practice the
professional or social activity in the exercise of which or at the occa
sion of which the infraction was committed . 260

In sum, the legislation proposed in France demonstrates a n effort
to address the public policy concerns of prenatal genetic screening at a
252.
253.
254.
255.
256.
257.
258.
259.
260.

Id. (to be codified at VI Pub. H. Code, tit: II, ch. 1, art. L. 671-3).
Id. Art. 10 (to be codified at VI Pub. H. Code, tit. II, ch. 3, art. L.

Id. art.

10 (bis) (to be codified at

Id. (emphasis added).

VI Pub. H. Code, tit. II (bis), art.

673-2).
673-6).

Id.
Id.
Id.
Id. art. 13 (to be codified at VI Pub. H. Code, tit. III, ch. 2, art. L.
Id. (to be codified at VI Pub. H. Code tit. III, ch. 2, art. L. 682-9).

682-1).
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societal level before the impending capability of prenatal genetic
screening is fully realized and before the existing. capability is intro
duced to the public. Serving as a point of comparison, it also high
lights the obvious failure of the United States to address the issue .
C.

A Proposal for Regulation Within the United States

It would be naive to suggest that the United States simply follow
the precedent for genetic technology regulation set by European na
tiorn� because of both the differences in our health care system, which
reflects a high level of deference and autonomy to the medical profes
sion, and our chronic struggle with the issue of abortion-an issue
over which the populous of France and England reached societal reso
lutions long ago .261 Nevertheless, due to our culture, the United
States may be even more in need of such legislation. The availability
of prenatal genetic screening technology is likely to reinforce insecuri
ties arising from our survival-of-the-fittest norms,262 and those same
norms may compel prospective parents to act on their insecurity.263

261. See Meyers, supra note 137, at 4-8 (England). The British are currently publicly
debating advances in fertility treatments. See William Miller, A Charge of 'Designer Ba
bies, ' BosToN GLOBE, Jan. 4, 1994, at 1, 5 (addressing how fertility treatments are
"throw[ing] Europe into debate over medical, social ethics"); William Miller, British De
bate: Does Fertility Science Break "Natural Law"?, BosToN GLOBE, Jan. 9, 1994; William
Miller, Poll Says Most Britons Oppose Using Eggs of Fetuses, BosTON GLOBE, Jan. 10,
1994, at 7.
262. These same norms are epitomized in the premium we place upon "Jeffersonian
pluralism,'; and they result in our relatively fractious society that resists national regulation
and compromise. See generally ARTHUR M. SCHLESINGER, JR., THE DISUNITING OF
AMERICA (1992); see also Annas, The Real Bioethics Commission, supra note 173, at 20-21
("Because of how America is constituted and because of our Constitution, no government
commission can define 'American Bioethics,'"). As explained above, especially where is
sues are innately personal, subjective, and ethics-oriented, our pluralistic nature makes it
relatively difficult for us to find shared norms to codify. See generally supra Part II (ad
dressing the relationship between law, ethics, and shared norms).
263. Our reaction to health impairments is, at least to some extent, cultural:
For example, the fact that doctors perform amniocentesis most frequently in this
country to afford women an opportunity to abort fetuses that have Down's syn
drome, a condition leading to mental retardation among other things, demon
strates that many upper-class whites view the birth of such a child as a result that
they should avoid. . . . Other cultures may view the burden of retardation as less
onerous. One recent study cited the statement of a Haitian man in New York
who said that there was no reason to diagnose Down's Syndrome
prenatally. . . . Indeed, there is no word for Down's syndrome in the Haitian
language even though the incidence of this syndrome around the world varies
only with the age at which women have children. This investigator also noted that
people in other cultures view conditions leading to physical defects as more hand
icapping than mental retardation.
Clayton, supra note 74, at 115 n.130.
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Although the medical profession should be involved in all genetic
screening regulatory efforts, we need to enact legislation around the
practice of prenatal genetic screening to control the breadth of its ap
plication and make it the subject of public scrutiny.264 This could be
accomplished by directly addressing the practice of prenatal genetic
screening through existing regulatory bodies and coordinating these
efforts through a national, nonpartisan, multidisciplinary commission
similar to the commissions that will be created in France under tha�
country's proposed legislation.265 The primary missions of this com
mission should be to (1) keep the public informed as to biomedical
research efforts and advances, thereby generating national and state
level debate on important issues related to prenatal genetic screening
and (2) make published recommendations (regarding everything from
counseling guidelines and informed consent requirements to insurance
regulations and patent law) to the medical profession, state legisla
tures, the FDA, PTO, other administrative agencies, and Congress.
264. The federal government's potential regulatory role regarding prenatal genetic
screening has been addressed by others, and one scholar has summarized it as follows:
The government's regulatory role is to protect consumers of genetic information
by assuring that genetic information is accurately provided by competent profes
sionals. It achieves that goal by licensure and certification, or by after-the-fact
accountability for deviations from appropriate standards of care.
A second governmental role would be to provide access to genetic services to
those who lack the resources or knowledge to obtain them on their own.
As genetic knowledge increases, however, proposals to mandate certain
kinds of reproductive behavior to prevent genetically handicapped offspring will
undoubtedly arise. Some persons will clamor loudly that individuals have a moral
obligation to learn their carrier status and to avoid reproduction when there is a
high risk that their offspring will have serious genetic disease.
Debate on these issues will be improved if two key distinctions that often are
missed in discussions of reproductive responsibility are made. The first distinc
tion is in the locus of harm from the alleged irresponsible reproductive behavior.
Is the alleged harm visited upon the offspring or on others? This distinction is
important, because negligently or even intentionally bringing a genetically handi
capped child into the world cannot really be considered a wrong to offspring. The
"responsible" reproductive behavior urged as the preferable alternative would
have prevented birth altogether, hardly a gain for the offspring being protected.
Robertson, supra note 36, at 715-17 (footnote omitted). Some localities, dissatisfied with
federal regulations, have generated their own. Perhaps the most noted example of this is
Cambridge, Massachusetts-the home of Harvard University and the Massachusetts Insti
tute of Technology. See Annas, Monster Mythology, supra note 17, at 653. As early as
1976, Cambridge developed regulations calling for laboratory inspections by a publicly
appointed committee. Id.
265. See Nolan, First Fruits, supra note 46, at S4 (s.uggesting that a pragmatic solution
to difficult genetic screening ethics issues might be found through decision making by inter
disciplinary organizations and citing the American Academy of Pediatrics "Red Book
Committee" as an example).
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There is precedent within the United States for the creation of
such a commission, a committee that blends the concerns of scientists
government officials, and ethicists, to deal with difficult legal-ethicalmedical issues, both at the national and local level.266 An example of
the latter are the hundreds, if not thousands, of ethics committees that
have been formed at hospitals across the United States over the past
decade to resolve difficult ethical questions regarding whether aggres
sive treatment is appropriate-questions usually generated by the ca
pability to sustain life created through advanced medical
technology.267 These committees are essentially "reasonable person"
constructs, which is reflected by the fact that they are being formed
both to resolve difficult ethical questions and to avoid legal liability
for withholding treatment.
'

An example of such a committee at the national level is the Com
mittee on Assessing Genetic Risks created by the Institute of
Medicine, the multidisciplinary committee that recently issued the re
port on genetic screening (the definitive statement on the practice of
prenatal genetic screening within the United States at the present
time) which has been cited throughout this Article. Among the con
clusions reached and suggestions made by this multidisciplinary com
mittee are the following:
•"Informed consent should be an essential element of all screening .
These principles and procedures described above should apply to
genetic testing regardless of the setting . . . . "268
•"Anyone considering prenatal diagnosis must be fully informed
about the risks and benefits of both the testing procedure and the
possible outcomes, as well as alternative options that might be avail
able[;] " 269 " [o]btaining informed consent should be the method of
ensuring that genetic testing is voluntary . " 270
• "Genetic professionals and all others offering or referring for ge
netic testing should be trained in the ethical, legal, and social issues
surrounding genetic diagnosis, testing, and screening[;] " 271 [a ]nyone
who is offering (or referring for) genetic testing must provide (or

266. As evidenced by the media, there is at least some popular support for the creation
of such a committee. See Editorial, A n Embryonic Debate, supra note 177, at 86 ("The
problems and opportunities of genetic research could best be put in an American context
by a committee that blends the concerns of scientists, government officials, ethicists and
religious leaders.").
267. See BELKIN, supra note 104, at 246.
268. ASSESSING GENETIC RISKS, supra note 9, exec. summ. at 3.
269. Id. exec. summ. at 6.
270. Id. exec. summ. at 18.
271. Id. exec. summ. at 16.
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refer for) appropriate genetic counseling and education prior to
testing. "272
• "Standards of care for prenatal screening and diagnosis should also
include education and counseling before and after the test, either
directly or by referral, and ongoing counseling should also be avail
able following termination of pregnancies."27 3
• " [P]renatal diagnosis should only be offered for the diagnosis of
genetic disorders and birth defects . . . . Reproductive genetic serv
ices should not be used to pursue eugenic goals, but should be
aimed at increasing individual control over reproductive op
tions[;] "274 "[t]he goal of reducing the incidence of genetic condi
tions is not acceptable, since this aim is explicitly eugenic . . . . "275
• " [P]opulation screening for late-onset diseases should only be con
sidered for treatable or preventable conditions of relatively high fre
quency and only after appro riate, reliable, sensitive, and specific
tests become available . . . . " 76
• "The safety and effectiveness of genetic tests should be established
b efore they are used routinely and, even when that comes to pass,
great care should be taken in performing the tests and interpreting
the results . . . . [T]he committee believes the nature of genetic tests
and their interpretation and the magnitude of the personal and
clinical decisions which may be made based on those results-in
cluding the abortion o f affected fetuses-warrant a standard with
close to "zero-error" chance of error for such tests. "277
•"Legislation should be adopted to prevent medical risks, including
genetic risks, from being taken into account in decisions on whethe r
to issue o r how to price health care insurance[;] "278 "[t]he commit
tee recommends that insurance reform preclude the use of genetic
information in establishing eligibility for health insurance[;) "279 and
" [i]n order to develop appropriate financing for genetic testing and
counseling services, private and public health plans, and geneticists
and consumers should work together to develop guidelines for the
reimbursement of genetic services. " 280
•"For effective overall and continuing policy oversight, the majority
of the committee recommends the creation of a broadly representative National Advisory Committee and Working Group on Genetic
Testing to oversee professional practices and determine when new
genetic tests are ready for wide-scale use in medical practice. "28 1

f

Whether or not such a national commission is created, legal
boundaries must be erected around the practice of prenatal genetic
272.
273.
274.
275.
276.
277.
278.
279.
280.
281 .

Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.
Id.

exec. summ.

at 12.
at 6.
exec. sumr·' . at 6-7.
exec. summ. at 12.
exec. summ. at 8, 22.
exec. summ. at 9.
exec. summ. at 19.
exec. summ. at 20.
exec. summ. at 17.
exec. summ. at 21.
exec. summ.
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screening. Steps have to be taken to prevent the practice of prenatal
genetic screening from degenerating into eugenics.282 Specifically,
prenatal genetic screening technology should be questioned at the na
tional, public policy level2 83 before being handed over to the public.2s4
At the very least, legislation should be enacted to ensure that (1) pre
natal genetic screening is not performed without genetic counseling;2ss
282. One of the most recognized eugenics concerns is that genetic screening will be
used for sex selection. See Fletcher & Wertz, supra note 23, at 788 ("An exception to this
duty should be made in decisions that involve information about the gender of the fetus,
unrelated to genetic diseases, that may lead to abortion.").
283. Consider how leaving genetic testing programs for newborns to state discretion
has resulted in a great deal of variance:
These state-run newborn screening programs differ from one another in the
source of their authority. In some states, the legislature specifies the tests to be
performed. In others, the legislature delegates the authority to develop screening
programs to other institutions, most frequently departments of public health.
Even when the legislature takes a direct role, the statutes are usually quite simple
in structure, occupying at most a few sections. Some states conduct screening
programs even though they have no enabling legislation.
The states also vary in whether they allow parents to opt out of screening,
and if so, what reasons suffice. In some states, parents can refuse testing only for
religious reasons; in others, any reason for objecting will do. Almost no state
legislatures require parents to provide their informed consent to screening, de
spite the formal recognition that screening receives in other medical settings.
Clayton, supra note 74, at 98-99 (footnotes omitted).
284. Consider the following suggestion:
Although none of the major issues raised by past genetic screening and counsel
ing cases have been solved, the major factors to be considered before initiating a
screening program have been identified: (1) the frequency and severity of the
condition; (2) the availability of treatment of documented efficacy; (3) the extent
to which detection by screening improves the outcome; (4) the validity and safety
of the screening tests; (5) the adequacy of resources to assure effective screening
and counseling follow-up; (6) the costs of the program; and (7) the acceptance of
the screening program by the community, including physicians and the public.
Annas, Monster Mythology, supra note 17, at 641 (footnote omitted).
285. See Conrad, Genetic Counseling, supra note 39, at 41 (addressing the impending
explosion of knowledge in human genetics and concluding that "[g)iven our current medi
cal division of labor, genetic counselors are the obvious candidates for the job"). Genetic
counselors, who deal with testing laboratories and patients' needs on a daily basis, are most
capable of informing patients as to what testing is available and its reliability, where the
testing is done, and whether the patient's own test sample is reliable. They also are capable
of monitoring research laboratories, ensuring both speed and accuracy, and putting pa
tients in contact with those who have faced similar choices.
To ensure counselor involvement in genetic testing, NIH grants should be accompa
nied by prohibitions forbidding research laboratories from running their tests for anyone
who is not a recognized genetic counselor, geneticist, or physician associated with an estab
lished health care facility. See supra note 193 (addressing present NIH guidelines). More
over, the medical facilities that make genetic counseling services available s�ould be
expressly forbidden from running research-stage tests that have not reached an mdustry
accepted level of accuracy. Such restrictions are justified by the fact that
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(2) the genetic counseling is given by those trained in the social sci
ences;286 (3) those giving the counseling satisfy specific informed-con
sent requirements;287 and (4) the information presented to satisfy
[b]iotechnology companies have economic incentives to sell their diagnostic prod
ucts, but proficiency testing and quality control for laboratories performing DNA
analysis remain limited. Given good, well-controlled DNA linkage studies or
even direct gene analysis, there are few controlled clinical research studies to con
firm the benefit generated by early diagnosis of heritable diseases for which no
cure exists.
Elsas, supra note 36, at 827 (footnotes omitted).
286. See supra Parts II.A. & 11.B. Who performs the genetic counseling is perhaps as
important as whether there is counseling: "Even who does the counseling associated with
prenatal diagnosis can influence what a woman does after learning of a fetal chromosome
abnormality; rates of induced abortion are higher when obstetricians relate the results of
testing than when geneticists do." Lippman, supra note 56, at 36 (footnotes omitted). The
role of genetic counselors is to help patients make choices. "Medical geneticists are
mediators between other fields in medicine with experience in dealing with ethical
problems in human genetics." Fletcher & Wertz, supra note 23, at 748. In contrast, con
sider scientists' approach to morality:
Scientists, on the other hand, (with the possible exception of some involved in the
Human Genome Initiative), tend to think of social policy and ethics as fields that
"lag behind" science and cannot "keep up with" scientific progress and advance
ment. It is almost as if they believe that morality is a field of knowledge "in the
charge of unidentified, but presumably rather incompetent experts." Experts in
both fields have little experience with each other, and generally only meet in the
courtroom or in the congressional hearing room. Scientists often then revert to
the old slogan, "What is good for General Motors is good for the country," or
more precisely, as James Watson has put it, "Science is good for society."
Annas, Monster Mythology, supra note 17, at 651 (footnotes omitted); see also Capron,
supra note 110, at 665 ("I don't think these scientists are thinking about mankind at all. I
think that they're getting the thrills and the excitement and the passion to dig in and keep
digging to see what the hell they can do." (quoting Alfred E. Vellucci, Mayor of Cam
bridge, Mass.)); Cassell, supra note 51, at 37 ("Doctors who have mastered a technology
tend to use it as often as possible-not necessarily for reasons of profit, but because they
love their skills and technologies."); cf. MICHAEL CRICIITON, JURASSIC PARK (1990) (imag
ining a future in which scientists extract dinosaur genes from a preserved insect that dined
on dinosaur blood, clone dinosaurs, and unleash havoc).
As discussed supra note 139 and the accompanying text, medical doctors who are free
to diagnose conditions, which may mean "counseling" patients to the point of pushing
them towards a given result, may remove choice from parental decision making. See
Gangelhoff, supra note 134, at Al (A mother who decided to deliver a child who would die
of anencephaly describes how doctors pressured her when the condition was discovered
prenatally: "They said her baby would have more in common with a fish than a human.
They said to expect the girl to be about as smart as a baboon."); cf Leslie Loddike, Men's
Attitudes Toward Poor Wanes During Medical School, Hous. PoST, May 19, 1993, at A6
(discussing the "Male View" towards moral problems as analyzing them in terms of rights
and rules).
287. The intent of true informed-consent requirements is to provide the patient with
enough information so that he or she, rather than his or her physician, is able to determine
what treatment is best for him or her, and this is the responsibility of genetic counselors.
See supra notes 268-281 and accompanying text. Standardized informed-consent require-
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these informed-consent requirements reflects the proven impact of
the identified genetic abnormality on the health of children born with
that abnormality. Some genetic testing-for example, testing for sex
selection, treatable conditions such as hypertension and diabetes, and
character traits such as sexual orientation-should be flatly banned on
the ground that it is eugenic in nature. In addition, individuals with
disabilities should be included in decision making regarding prenatal
genetic testing.
Because the practice of prenatal genetic screening presently is
highly dependent upon research laboratories and medical tests that
are diagnostic in nature, immediate steps can, and should, be taken.
Specifically, the Clinical Laboratory Improvement Amendments of
ments could help insure that this responsibility is met. The Committee on Assessing Ge
netic Risks has made the following recommendations:
Principles of disclosure for informed consent, whether for routine or experimen
tal prenatal screening or diagnosis, should include (1) fair and balanced explana
tion of the procedures and their safety; (2) a description of the risks and benefits;
(3) consideration of all possible outcomes, including the possibility that one op
tion might be termination of the pregnancy; (4) knowledge of the potential need
for and availability of psychosocial counseling; (5) documentation of consent; and
(6) full information concerning the spectrum of severity of the genetic disorders
for which prenatal diagnosis is being offered . . . .
ASSESSING GENETIC RISKS, supra note 9, ch. 2, at 35-36
Many states have imposed similar informed-consent requirements on women who
choose to exercise their constitutional right to abort their fetuses. See C. Elaine Howard,
Autonomy versus Automaton, Abortion and the Law, University of Houston Law Center,
May 1993 (unpublished manuscript on file with author). Specifically, 18 states regulate
informed consent for abortion. See IDAHO CoDE § 18-609 (1983); KY. REv. STAT. ANN.
§ 311.720 (Michie/Bobbs-Merrile 1992); LA. REv. STAT. ANN. § 1299.35.6 (West 1992); ME.
REV. STAT. ANN. tit. 22, § 1599 (West 1992); MASS. GEN. L. ch. 1 12, § 12s (1992); Mrss.
CoDE ANN. § 41-41-33 (1991); Mo. REV. STAT. § 188.039 (1983); MONT. CoDE ANN. § 5020-104 (1991); NEB. REV. STAT. § 28-326 (1992); NEV. REV. STAT. § 442.252 (1991); N.D.
CENT. CoDE § 14-02.1-02 (1992); 18 PA. CoNs. STAT. § 3205 (1992); R.I. GEN. LAWS § 234.7-1 (1992); S.D. CoDIFIED LAWS ANN. § 34-23A-10.1 (1992); TENN. CODE ANN. § 39-15202 (1992); UTAH CODE ANN. § 76-7-305 (1992); VA. CooE ANN. § 18.2-76 (Michie 1992);
Wis. STAT. § 1 46.78 (1992). Although most of these statutes are consistent with the physi
cian's informed-consent obligation under common law, Ohio's informed consent abortion
statute requires that materials be made available to a woman seeking an abortion that
describe the characteristics of the fetus at two-week intervals from the fourth week of
development through the twenty-fourth week of development. This material is accompa
nied by photographs and includes information about physical characteristics, brain and
heart functions, and the presence of internal organs. Also, many are accompanied by wait
ing periods that vary from two hours to three days before the abortion procedure can be
carried out. See, e.g, KY. REV. STAT. ANN. § 311.726 (Michie/Bobbs-Merrill 1992) (requir
ing that the woman obtain the information at least two hours before the procedure); TENN.
CoDE ANN. § 39-15-202 (1992) (requiring that at least two days elapse after the day the
woman is given the information; she may return on the third day following her initial visit).
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1 988 ( CLIA88)288 and the medical devices legislation under which the
FDA regulates testing products such as kits, probes, and reagents289
are means of providing some immediate control.290 The following
measures, all of which have been suggested in some form and to some
degree by the Committee on Assessing Genetic Risks,291 should be
carried out under this legislative authority:
•Most genetic tests should be classified as "high complexity" and
governed by CLIA88 to assure the highest level of federal oversight
of laboratories performing genetic tests;292
See 57 Fed. Reg. 7137 (1992) (codified at 42 C.F.R.

288.

§ 493.1). The CLIA88 pro

vides regulations for laboratories performing an "examination of materials derived from
the human body for the purpose of providing information for the diagnosis, prevention, or
treatment of any disease or impairment of, or the assessment of the health of, human be
ings . . . . " See id. CUA standards vary according to whether the tests performed are of
"moderate" or "high" complexity, and the factors influencing which standards apply in
clude: the knowledge needed to perform the test, the characteristics of the operational
steps, the judgment required, and interpretation of the results. AssESSING GENETIC R1sKs,
sup ra note 9, ch. 3, at 9. The Committee found that:
Few laboratories performing genetic tests as their sole or principal activity are yet
complying with the CLIA88 regulations. Based on the committee's workshops
and other information, it appears that few genetics laboratories have applied for
certification from HCFA [Health Care Financing Administration] even though
they provide genetic test information for clinical use. Committee staff also sur
veyed the directors of 12 genetics laboratories in academic centers to ask if their
laboratory had applied for certification, and only 1 laboratory indicated that it
had.
Id. ch 3, at 10. The fact that the CLIA88 is not being implemented to regulate prenatal

genetic screening is significant, for the Committee on Assessing Genetic Risks found that
" [a]n increasing number of tests are being marketed as laboratory services by commercial
laboratories and a few academic laboratories." Id. ch. 3, at 2.
289. lnvestigational Device Exemptions, 21 C.F.R. § 812 (1993); Medical Devices Act
of 1976 and Safe Medical Device Amendments of 1990, 21 C.F.R. § 201(h) (1993). Many
genetic tests are being made available as kits, and "[b]efore a medical device can be legally
marketed for invitro diagnostic use, its sponsor (manufacturer, university, or individual
scientist) must obtain premarket approval (PMA)." A ssESSING GENETIC RISKS, supra
note 9, ch. 3, at 12. Nevertheless, "[o]nly a small proportion of genetic tests in widespread
use have been reviewed by FDA . . . . " Id. ch. 3, at 1 1 . Moreover, "FDA is aware of the
problem of the use of medical devices that it has not reviewed for marketing and that are
not in compliance with its regulations regarding investigational devices." Id. ch. 3, at 15
(citing the MSAFP test as an example).
290.

The Committee on Assessing Genetic Risk has expressly acknowledged that fed

eral legislative authority is not being implemented to oversee the quality of genetic testing.

ASSESSING GENETIC RrsKs, sup ra note 9, exec. summ. at 9; see also id. ch. 3. This is true
despite the fact that, in July 1 992, congressional hearings were held to highlight unresolved
laboratory issues in human genetics. See id. ch 3, at 3 (discussing these hearings).
291 . See id. ch. 3.
292. As suggested by the Committee on Assessing Genetic Risks, to satisfy FDA data
requirements for safety and effectiveness,
[f]or rare diseases, the FDA could grant the applicant "provisional premarket ap
proval," a designation under which the test could be made more widely available
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•All research laboratories-whether they be situated in academic
health centers or elsewhere-that conduct research but perform ge
netic tests as a service also should be governed by CLIA88 and be
subjected to the same criteria, standards{and regulation as commer
cial genetic testing laboratories;
•Prenatal genetic testing should be banned unless it is performed
with the involvement of a qualified genetic counselor;
•All genetic tests 'should either be designated as investigational de
vices-thereby subject to institutional review board approval and
FDA regulation-or be submitted to the FDA for full premarket
approval;
•Similarly, the manufacturers and users of new genetic screening
tests, including state laboratories and health departments, should be
made to comply with the FDA's regulations for investigational
devices;
•Because of the nature of genetic tests and the fact that people may
rely upon them to the extent of aborting wanted pregnancies, they
should be subject to a standard of close to zero chance of error;
•To ensure quality and testing proficiency, testing for rare diseases
should be centralized in a few laboratories that would accept speci
men referrals; and
•All laboratories performing genetic screening should be compelled
to report their activities.293

Conclusively, subjecting the practice of prenatal genetic screen
ing, which presently is being carried out to a large extent through re
search laboratories, to existing FDA regulations and CLIA88 would at
least ensure some minimum level of public accountability. In light of
the impact of prenatal genetic screening technology on parental
choice and the societal importance of these choices, we should accept
nothing less.
Conclusion

Before the end of this decade, extensive prenatal genetic screen
ing will be a standard component of prenatal health care. The technowhile making the manufacturer responsible for obtaining additional postmarket
data until sufficient data are available to warrant full "premarket" approval.
Id. exec. summ. at 11.
293. In fact, ultimately, we should encourage the commercialization of the prenatal
genetic screening tests that prospective parents will rely upon in order to ensure the ac
countability and the level of reliability that can be achieved through centralization of test
ing. Unfortunately, it appears that such a movement is currently being discouraged. See
Richard Saltus, Plan to Market Tests for Cancer Gene Is Hit, BosTON GLOBE, Mar. 10,
1994, at 3 (reporting a warning issued as a statement by the Nati�nal Institutes Advisory
Council for Human Genome Research that "it is premature to offer DNA testing or
screening for cancer predisposition outside a carefully monitored research environment")
(this statement is also published in the March issue of the Journal of the American Medical
Association).
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logical capability to detect genetic abnormalities that have been
identified as causative of hundreds of health impairments is already
here, and it is being expanded dramatically even as this Article goes
into print. More importantly, the technology is being relied upon by
prospective parents, many of whom will undergo late-term abortions
of their wanted pregnancies based upon the information prenatal ge
netic screening offers.
With the technological capability to know information about the
health of fetuses before viability comes an obligation-whether aris
ing from procreative liberty, legal liability, or society's failure to ac
cept children with serious

health

impairments

and

offer them

adequate assistance-to let prospective parents know about the health
of their fetuses. However, because genetic screening creates the op
tion of late-term abortion, and because presently this is generally the
only option other than delivery for prospective parents whose fetuses
are found to carry genetic abnormalities, policy makers must ensure
that it is practiced with caution.

Prospective parents who undergo

prenatal genetic testing must understand the limitations of the tech
nology, and an effort must be made to ensure that the late-term abor
tion option created through genetic screening is not abused.
Although extensive prenatal genetic screening is already a reality,
important policy choices have not been made. This Article has identi
fied many of those choices. Its message is theoretically simple:

In

light of the fact that prospective parents are a vulnerable group living
within a competitive society that places an extraordinary value o n
"perfection," w e are i n danger of allowing a n incredible opportunity
to expand parental choice to degenerate into a eugenic nightmare.
This danger is captured in

The Twilight of the Golds,

a play writ

ten by Jonathan Tollins that ran on Broadway during the fall of
1993 .294 It is the story of a family thrown into turmoil when genetic

testing of a woman's fetus reveals that her child will most likely be
gay. The social danger of such genetic testing capability is captured in
the words of the characte r David Gold, who says, "Every human be
ing is a tapestry. You pull one thread, one undesirable color, and the
art unravels.

You end up staring at the walls."

Prenatal genetic

screening enables us to identify these "colors." Although the wonders
of prenatal genetic screening should be welcomed, they should also be
subj ected to public scrutiny and approached with caution, lest the tap
estry of future generations be unravelled.

294.

J. Tollins, The Twilight of the Golds (unpublished manuscript).

